
CEPIVA
in
CEPLJENJE
Ali so strahovi upravičeni?
ALEŠ PRAPROTNIK

CEPIVA *in* CEPLJENJE

Ali so strahovi upravičeni?

ALEŠ PRAPROTNIK

Aleš Praprotnik

CEPIVA in CEPLJENJE

Ali so strahovi upravičeni?

© Aleš Praprotnik, 2025

Vse pravice pridržane.

Slika na naslovnici:
Aktivirani makrofag, slikan z elektronskim mikroskopom (vir: Steve Gschmeissner/Science Photo Library/Alamy Stock Photo)

Slika na zadnji strani:
zgoraj: limfociti T, slikani z elektronskim mikroskopom (vir: ameriški Nacionalni inštitut za alergije in nalezljive bolezni; NIAID/Flickr)
spodaj: virusi influence A, slikani z elektronskim mikroskopom (vir: ameriški Nacionalni inštituti za zdravje; NIH/Flickr)

Strokovna recenzija:
dr. Teja Čelhar, mag. farm.
izr. prof. dr. Nataša Karas Kuželički, mag. farm.
izr. prof. dr. Janja Zupan, mag. farm.
prof. dr. Tomaž Bratkovič, mag. farm.
izr. prof. dr. Martina Gobec, mag. farm.
dr. Veronika Učakar, dr. med., specialistka epidemiologije
doc. dr. Nina Graselli Kmet, dr. med., specialistka infektologije in intenzivne medicine
doc. dr. Alenka Šmid, mag. farm.
asist. dr. Jasna Omersel, mag. farm.

Lektura: Mojca Blažej Cirej

Oblikovanje: Tanja Kaštrun

Izdala in založila: POST PRODUKCIJA, Mirjana Radičanin s.p.

Tisk: Didigatni tisk Primus

Naklada: 300 izvodov

Ljubljana 2025

CIP - Kataložni zapis o publikaciji
Narodna in univerzitetna knjižnica, Ljubljana
614.47
615.371.065
PRAPROTNIK, Aleš, 1979-
Cepiva in cepljenje : ali so strahovi upravičeni? / Aleš Praprotnik. - Ljubljana : Post produkcija, 2025
ISBN 978-961-96954-0-1
COBISS.SI-ID 229373187

7

Literatura

[1] P. E. Tressoldi, "Extraordinary Claims Require Extraordinary Evidence: The Case of Non-Local Perception, a Classical and Bayesian Review of Evidences," *Front. Psychol.*, vol. 2, p. 117, Jun. 2011, doi: 10.3389/fpsyg.2011.00117.

[2] BBC, "Alex Jones to pay extra $473m damages over 'fake Sandy Hook' claim," *BBC News*, Nov. 10, 2022. Accessed: Jan. 17, 2023. [Online]. Available: https://www.bbc.com/news/world-us-canada-63592386

[3] BBC, "David Icke: Conspiracy theorist banned from Netherlands," *BBC News*, Nov. 04, 2022. Accessed: Jan. 17, 2023. [Online]. Available: https://www.bbc.com/news/world-europe-63511142

[4] M. Pokorn, "»Sem od mame in očija, ne od države«*," Delo. Accessed: Jul. 05, 2018. [Online]. Available: https://www.delo.si/mnenja/gostujoce-pero/sem-od-mame-in--ocija-ne-od-drzave-46012.html

[5] S. Pluviano, C. Watt, and S. D. Sala, "Misinformation lingers in memory: Failure of three pro-vaccination strategies," *PLOS ONE*, vol. 12, no. 7, p. e0181640, Jul. 2017, doi: 10.1371/journal.pone.0181640.

2

Literatura

[1] L. Sompayrac, *How the immune system works*, 5th ed. Wiley Blackwell, 2016.

[2] J. Omersel *et al.*, *Imunski sistem - Ključni obrambni sistem človeškega organizma*. Ljubljana: Univerza v Ljubljani, Fakulteta za farmacijo, 2017.

[3] S. Weller *et al.*, "T-independent responses to polysaccharides in humans mobilize marginal zone B cells prediversified against gut bacterial antigens," *Sci. Immunol.*, vol. 8, no. 79, p. eade1413, Jan. 2023, doi: 10.1126/sciimmunol.ade1413.

[4] E. C. Semmes, J.-L. Chen, R. Goswami, T. D. Burt, S. R. Permar, and G. G. Fouda, "Understanding Early-Life Adaptive Immunity to Guide Interventions for Pediatric Health," *Front. Immunol.*, vol. 11, Jan. 2021, doi: 10.3389/fimmu.2020.595297.

[5] J. Charles A Janeway, P. Travers, M. Walport, and M. J. Shlomchik, "The course of the adaptive response to infection," in *Immunobiology: The Immune System in Health and Disease. 5th edition*, Garland Science, 2001. Accessed: Oct. 04, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK27125/

[6] S. Crotty, "T follicular helper cell differentiation, function, and roles in disease," *Immunity*, vol. 41, no. 4, pp. 529–542, Oct. 2014, doi: 10.1016/j.immuni.2014.10.004.

[7] A. K. Simon, G. A. Hollander, and A. McMichael, "Evolution of the immune system in humans from infancy to old age," *Proc R Soc B*, vol. 282, no. 1821, p. 20143085, Dec. 2015, doi: 10.1098/rspb.2014.3085.

3

Literatura

[1] L. Sompayrac, *How the immune system works*, 5th ed. Wiley Blackwell, 2016.

[2] K. Yusuf, V. Sampath, and S. Umar, "Bacterial Infections and Cancer: Exploring This Association And Its Implications for Cancer Patients," *Int. J. Mol. Sci.*, vol. 24, no. 4, p. 3110, Feb. 2023, doi: 10.3390/ijms24043110.

[3] J. T. Schiller and D. R. Lowy, "An Introduction to Virus Infections and Human Cancer," *Recent Results Cancer Res. Fortschritte Krebsforsch. Progres Dans Rech. Sur Cancer*, vol. 217, pp. 1–11, 2021, doi: 10.1007/978-3-030-57362-1_1.

[4] J. Charles A Janeway, P. Travers, M. Walport, and M. J. Shlomchik, "The course of the adaptive response to infection," in *Immunobiology: The Immune System in Health and Disease. 5th edition*, Garland Science, 2001. Accessed: Oct. 04, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK27125/

[5] A. Kraigher, A. Ihan, and T. Avčin, *Cepljenje in cepiva - dobre prakse varnega cepljenja: univerzitetni učbenik za študente medicinske in zdravstvene fakultete*. Ljubljana: Sekcija za preventivno medicino SZD : Sekcija za klinično mikrobiologijo in bolnišnične okužbe SZD : Inštitut za varovanje zdravja RS, 2011.

[6] K. K. Dewan, B. Linz, S. E. DeRocco, and E. T. Harvill, "Acellular Pertussis Vaccine Components: Today and Tomorrow," *Vaccines*, vol. 8, no. 2, Art. no. 2, Jun. 2020, doi: 10.3390/vaccines8020217.

[7] U.S. Department of Health and Human Services, Office of Infectious Disease and HIV/AIDS Policy, "Vaccine Types." Accessed: Oct. 29, 2024. [Online]. Available: https://www.hhs.gov/immunization/basics/types/index.html

[8] National Institutes of Health, National Institute of Allergy and Infectious Diseases, "Vaccine Types." Accessed: Oct. 29, 2024. [Online]. Available: https://www.niaid.nih.gov/research/vaccine-types

[9] The College of Physicians of Philadelphia, "Different Types of Vaccines." Accessed: Jul. 19, 2018. [Online]. Available: https://www.historyofvaccines.org/content/articles/different-types-vaccines

[10] Slovensko zdravniško društvo, Združenje za pediatrijo, "Oslovski kašelj." Accessed: Feb. 12, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje/oslovski-kaselj

[11] G. Sundeen and J. T. Barbieri, "Vaccines against Botulism," *Toxins*, vol. 9, no. 9, p. 268, Sep. 2017, doi: 10.3390/toxins9090268.

[12] CDC, "Notice of CDC's Discontinuation of Investigational Pentavalent (ABCDE) Botulinum Toxoid Vaccine for Workers at Risk for Occupational Exposure to Botulinum Toxins." Accessed: Nov. 07, 2024. [Online]. Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6042a3.htm

4

Literatura

[1] S. A. Plotkin, P. A. Offit, W. A. Orenstein, and K. M. Edwards, *Plotkin's vaccines*. Elsevier, 2018.

[2] Centers for Disease Control and Prevention, "History of Smallpox." Accessed: Jan. 18, 2023. [Online]. Available: https://www.cdc.gov/smallpox/history/history.html

[3] J.-M. Cavaillon and S. Legout, "Louis Pasteur: Between Myth and Reality," *Biomolecules*, vol. 12, no. 4, p. 596, Apr. 2022, doi: 10.3390/biom12040596.

[4] J. V. Ashurst, J. Truong, and B. Woodbury, "Typhoid Fever (Salmonella Typhi) (Archived)," in *StatPearls*, Treasure Island (FL): StatPearls Publishing, 2023. Accessed: Oct. 30, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK519002/

[5] E. Hall, P. Wodi A., J. Hamborsky, V. Morelli, and S. Schillie, *Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases*, 14th ed. Washington: Public Health Foundation, 2021. Accessed: Mar. 15, 2021. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html

[6] I. Barberis, N. L. Bragazzi, L. Galluzzo, and M. Martini, "The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus," *J. Prev. Med. Hyg.*, vol. 58, no. 1, pp. E9–E12, Mar. 2017.

[7] M. Likar, *Cepiva danes in jutri*. Arkadija, 2004.

[8] World Health Organization, "A Brief History of Vaccination." Accessed: Jan. 18, 2023. [Online]. Available: https://www.who.int/news-room/spotlight/history-of-vaccination/a-brief-history-of-vaccination

[9] Public Health Agency of Canada, "Basic immunology and vaccinology: Canadian Immunization Guide." Accessed: Oct. 31, 2024. [Online]. Available: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-14-basic-immunology-vaccinology.html

[10] M. Michalik, B. Djahanshiri, J. C. Leo, and D. Linke, "Reverse Vaccinology: The Pathway from Genomes and Epitope Predictions to Tailored Recombinant Vaccines," *Methods Mol. Biol. Clifton NJ*, vol. 1403, pp. 87–106, 2016, doi: 10.1007/978-1-4939-3387-7_4.

[11] A. A. El-Moamly and M. A. El-Sweify, "Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects," *Trop. Med. Health*, vol. 51, no. 1, p. 29, May 2023, doi: 10.1186/s41182-023-00516-w.

[12] S. Sato, "Plasmodium—a brief introduction to the parasites causing human malaria and their basic biology," *J. Physiol. Anthropol.*, vol. 40, p. 1, Jan. 2021, doi: 10.1186/s40101-020-00251-9.

[13] Centers for Disease Control and Prevention, "Malaria Vaccines." Accessed: Nov. 01,

2024. [Online]. Available: https://www.cdc.gov/malaria/php/public-health-strategy/malaria-vaccines.html

[14] E. M. Anderson and B.-A. G. Coller, "Translational success of fundamental virology: a VSV-vectored Ebola vaccine," *J. Virol.*, vol. 98, no. 3, p. e01627, Feb. 2024, doi: 10.1128/jvi.01627-23.

[15] X. Topalidou, A. M. Kalergis, and G. Papazisis, "Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines," *Pathogens*, vol. 12, no. 10, p. 1259, Oct. 2023, doi: 10.3390/pathogens12101259.

[16] B. S. Graham, "Biological Challenges and Technological Opportunities for Respiratory Syncytial Virus Vaccine Development," *Immunol. Rev.*, vol. 239, no. 1, pp. 149–166, 2011, doi: 10.1111/j.1600-065X.2010.00972.x.

[17] Centers for Disease Control and Prevention, "Healthcare Providers: RSV Vaccination for Adults 60 Years of Age and Over." Accessed: Nov. 01, 2024. [Online]. Available: https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html

[18] European Medicines Agency, "Arexvy." Accessed: Nov. 01, 2024. [Online]. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy

[19] European Medicines Agency, "Abrysvo." Accessed: Nov. 01, 2024. [Online]. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo

[20] European Medicines Agency, "mResvia." Accessed: Nov. 01, 2024. [Online]. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/mresvia

[21] J. Omersel and N. Karas Kuželički, "Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines," *J. Clin. Med.*, vol. 9, no. 11, Art. no. 11, Nov. 2020, doi: 10.3390/jcm9113561.

[22] The College of Physicians of Philadelphia, "The Scientific Method in Vaccine History." Accessed: Jan. 18, 2023. [Online]. Available: https://cpp-hov.netlify.app//vaccines-101/how-are-vaccines-made/scientific-method-vaccine-history

[23] S. Y. Tan and Y. Tatsumura, "Alexander Fleming (1881–1955): Discoverer of penicillin," *Singapore Med. J.*, vol. 56, no. 7, p. 366, Jul. 2015, doi: 10.11622/smedj.2015105.

[24] R. Gaynes, "The Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Use," *Emerg. Infect. Dis.*, vol. 23, no. 5, p. 849, May 2017, doi: 10.3201/eid2305.161556.

5

Literatura

[1] G. D. Chloros, A. D. Prodromidis, and P. V. Giannoudis, "Has anything changed in Evidence-Based Medicine?," *Injury*, vol. 54, pp. S20–S25, May 2023, doi: 10.1016/j.injury.2022.04.012.

[2] A. Čuk, "Na izsledkih temelječa medicina - I. splošna načela," *Zdrav. Vestn.*, no. 72, pp. 695–9, 2003.

[3] T. Greenhalgh, *How to read a paper, the basics of evidence-based medicine*, 5th ed. Wiley Blackwell, 2014.

[4] K. G. Falavarjani, M. B. Kashkouli, and H. Chams, "Letter to Editor, a scientific forum for discussion," *J. Curr. Ophthalmol.*, vol. 28, no. 1, pp. 1–2, Mar. 2016, doi: 10.1016/j.joco.2016.01.006.

[5] Z. Munn, C. Stern, E. Aromataris, C. Lockwood, and Z. Jordan, "What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences," *BMC Med. Res. Methodol.*, vol. 18, no. 1, p. 5, Jan. 2018, doi: 10.1186/s12874-017-0468-4.

[6] M. Burton, "Expert opinion is not always right," Evidently Cochrane. Accessed: Mar. 16, 2024. [Online]. Available: https://www.evidentlycochrane.net/expert-opinion-not-always-right/

[7] F. Man, "The hierarchy of evidence: Is the study's design robust?," The Logic of Science. Accessed: Mar. 14, 2019. [Online]. Available: https://thelogicofscience.com/2016/01/12/the-hierarchy-of-evidence-is-the-studys-design-robust/

[8] National Cancer Institute, "Definition of case report." Accessed: Aug. 01, 2022. [Online]. Available: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/case-report

[9] Care Development Group, "The Importance of Case Reports," CARE Case Report Guidelines. Accessed: Aug. 01, 2022. [Online]. Available: https://www.care-statement.org/case-reports

[10] M. S. Setia, "Methodology Series Module 3: Cross-sectional Studies," *Indian J. Dermatol.*, vol. 61, no. 3, pp. 261–264, 2016, doi: 10.4103/0019-5154.182410.

[11] S. Lewallen and P. Courtright, "Epidemiology in Practice: Case-Control Studies," *Community Eye Health*, vol. 11, no. 28, pp. 57–58, 1998.

[12] M. S. Setia, "Methodology Series Module 1: Cohort Studies," *Indian J. Dermatol.*, vol. 61, no. 1, pp. 21–25, 2016, doi: 10.4103/0019-5154.174011.

[13] E. Hariton and J. J. Locascio, "Randomised controlled trials—the gold standard for effectiveness research," *BJOG Int. J. Obstet. Gynaecol.*, vol. 125, no. 13, p. 1716, Dec. 2018, doi: 10.1111/1471-0528.15199.

[14] D. Coggon, G. Rose, and D. Barker, "Experimental studies," in *Epidemiology for the uninitiated*, London: BMJ Publishing Group, 2020. Accessed: Aug. 25, 2022.

[Online]. Available: https://www.bmj.com/about-bmj/resources-readers/publications/epidemiology-uninitiated/9-experimental-studies

[15] D. Hallas, R. Spratling, and J. Fletcher, "Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines," *J. Pediatr. Health Care*, vol. 35, no. 4, pp. 443–448, 2021, doi: 10.1016/j.pedhc.2021.04.001.

[16] The Cochrane Collaboration, "Cochrane and systematic reviews." Accessed: Aug. 25, 2022. [Online]. Available: https://consumers.cochrane.org/cochrane-and-systematic-reviews

[17] L. Uttley *et al.*, "The problems with systematic reviews: a living systematic review," *J. Clin. Epidemiol.*, vol. 156, pp. 30–41, Apr. 2023, doi: 10.1016/j.jclinepi.2023.01.011.

[18] S. Prasad *et al.*, "Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy," *Nat. Commun.*, vol. 13, no. 1, Art. no. 1, May 2022, doi: 10.1038/s41467-022-30052-w.

[19] Institute for Quality and Efficiency in Health Care (IQWiG), "What are clinical practice guidelines?," in *Informed Health Online*, Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG), 2016. Accessed: Mar. 22, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK390308/

[20] A. Taddio *et al.*, "Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline," *CMAJ*, vol. 182, no. 18, pp. E843–E855, Dec. 2010, doi: 10.1503/cmaj.101720.

[21] K. A. Papp *et al.*, "Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies," *J. Cutan. Med. Surg.*, vol. 23, no. 1, pp. 50–74, Jan. 2019, doi: 10.1177/1203475418811335.

[22] G. E. Gross *et al.*, "German evidence and consensus-based (S3) guideline: Vaccination recommendations for the prevention of HPV-associated lesions," *JDDG J. Dtsch. Dermatol. Ges.*, vol. 19, no. 3, pp. 479–494, 2021, doi: 10.1111/ddg.14438.

[23] I. Chalmers, "The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care," *Ann. N. Y. Acad. Sci.*, vol. 703, pp. 156–163; discussion 163-165, Dec. 1993.

[24] The Cochrane Collaboration, "Cochrane Diversity and Inclusion." Accessed: Aug. 27, 2022. [Online]. Available: https://www.cochrane.org/about-us/cochrane-diversity-and-inclusion

[25] The Cochrane Collaboration, "Review Groups." Accessed: Aug. 27, 2022. [Online]. Available: https://www.cochrane.org/about-us/our-global-community/review-groups

[26] E. A. Ochodo *et al.*, "Molnupiravir for treating COVID-19," *Cochrane Database Syst. Rev.*, no. 8, 2022, doi: 10.1002/14651858.CD015381.

[27] S. Tort and A. Ciapponi, "For adults with mild or moderate to severe symptomatic COVID-19, what are the effects of ivermectin?," *Cochrane Clin. Answ.*, 2022, doi: 10.1002/cca.4030.

[28] The Cochrane Collaboration, "Our funders and partners." Accessed: Aug. 27, 2022. [Online]. Available: https://www.cochrane.org/about-us/our-funders-and-partners

6

Literatura

[1] Age of Autism, "The Vaccine Autism Link." Accessed: Feb. 09, 2019. [Online]. Available: https://www.ageofautism.com/the-vaccine-autism-link.html

[2] RTV Slovenija, "Zdravniška etika," RTVSLO. Accessed: Feb. 09, 2019. [Online]. Available: https://4d.rtvslo.si/arhiv/akcent/174560320

[3] A. J. Wakefield *et al.*, "RETRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children," *The Lancet*, vol. 351, no. 9103, pp. 637–641, Feb. 1998, doi: 10.1016/S0140-6736(97)11096-0.

[4] Elsevier, "What is a corresponding author?," Elsevier Author Services. Accessed: Nov. 29, 2022. [Online]. Available: https://scientific-publishing.webshop.elsevier.com/publication-recognition/what-corresponding-author/

[5] B. Deer, "Royal Free MMR video news release, 1998." Accessed: Jul. 05, 2018. [Online]. Available: http://briandeer.com/wakefield/royal-video.htm

[6] R. Greenslade, "The story behind the MMR scare," *The Guardian*, Apr. 24, 2013. Accessed: May 31, 2019. [Online]. Available: https://www.theguardian.com/society/2013/apr/25/mmr-scare-analysis

[7] G. Millward, "MMR," in *Vaccinating Britain: Mass vaccination and the public since the Second World War*, Manchester University Press, 2019. Accessed: Jun. 05, 2022. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK545996/

[8] B. Deer, "BMJ – Secrets of the MMR scare – part 3." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/solved/bmj-wakefield-3-1.htm

[9] General Medical Council, "Our role and the Medical Act 1983." Accessed: Feb. 25, 2023. [Online]. Available: https://www.gmc-uk.org/about/what-we-do-and-why/our-mandate

[10] B. Deer, "Andrew Wakefield struck off as doctor." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/solved/st-january-31-2010.htm

[11] General Medical Council, "Fitness to practise panel hearing 28 January 2010." 2010. Accessed: Jun. 08, 2018. [Online]. Available: https://cdn.factcheck.org/UploadedFiles/gmc-charge-sheet.pdf

[12] General Medical Council, "Determination on Serious Professional Misconduct (SPM) and sanction." Accessed: Nov. 09, 2018. [Online]. Available: https://briandeer.com/solved/gmc-wakefield-sentence.pdf

[13] M. Carey, "Andrew Wakefield sets out his talking points in a new book," Left Brain Right Brain. Accessed: Nov. 12, 2018. [Online]. Available: https://leftbrainrightbrain.co.uk/2010/05/27/andrew-wakefield-sets-out-his-talking-points-in-a-new-book/

[14] C. Tidy, "Childhood Disintegrative Disorder (Heller's Syndrome)." Accessed: Jun. 06, 2022. [Online]. Available: https://patient.info/doctor/childhood-disintegrative-disorder-hellers-syndrome

[15] B. Deer, "Some of Deer's Wakefield stories." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/mmr/st-mmr-reports.htm
[16] B. Deer, "BMJ – Secrets of the MMR scare – part 2." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/solved/bmj-wakefield-2-1.htm
[17] B. Deer, "Andrew Wakefield – the fraud investigation." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/mmr/lancet-summary.htm
[18] B. Deer, "How the case against the MMR vaccine was fixed," *BMJ*, vol. 342, Jan. 2011, doi: 10.1136/bmj.c5347.
[19] B. Deer, "Andrew Wakefield: a cheat exposed." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/mmr-lancet.htm
[20] B. Deer, "Timeline of Wakefield MMR scandal, 2011." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/solved/bmj-wakefield-timeline.htm
[21] G. Taylor, "Senior Author of MMR Paper, John Walker-Smith, Wins Appeal," Canary Party. Accessed: Nov. 14, 2018. [Online]. Available: http://canaryparty.org/commentary/senior-author-of-mmr-paper-john-walker-smith-wins-appeal/
[22] Age of Autism, "Quashing of GMC Findings Against Prof Walker-Smith." Accessed: Nov. 14, 2018. [Online]. Available: https://www.ageofautism.com/2012/03/quashing-of-gmc-findings-against-prof-walker-smith.html
[23] MR JUSTICE MITTING, *Walker-Smith v General Medical Council [2012] EWHC 503 (Admin)*. 2012. Accessed: Nov. 14, 2018. [Online]. Available: http://www.bailii.org/ew/cases/EWHC/Admin/2012/503.html
[24] D. R. Reiss, "Andrew Wakefield is innocent – another vaccine denier trope and myth." Accessed: Nov. 14, 2020. [Online]. Available: https://www.skepticalraptor.com/skepticalraptorblog.php/andrew-wakefield-is-innocent-vaccine-denier-trope-myth/
[25] S. A. Grando and J. D. Bernhard, "'First Author, Second Author, et Int, and Last Author': A Proposed Citation System for Biomedical Papers," *Sci. Ed.*, vol. 26, no. 4, 2003.
[26] B. Deer, "John Walker-Smith switches MMR story." Accessed: Nov. 14, 2018. [Online]. Available: https://briandeer.com/solved/john-walker-smith.htm
[27] S. Murch, "Simon Murch on his MMR research." Accessed: Nov. 14, 2018. [Online]. Available: https://briandeer.com/mmr/lancet-murch.htm
[28] "Top 10 most highly cited retracted papers," Retraction Watch. Accessed: Nov. 06, 2024. [Online]. Available: https://retractionwatch.com/the-retraction-watch-leaderboard/top-10-most-highly-cited-retracted-papers/
[29] B. Goldacre, *Bad Science*. Harper Perennial, 2009.
[30] S. Thompson, J. C. Meyer, R. J. Burnett, and S. M. Campbell, "Mitigating Vaccine Hesitancy and Building Trust to Prevent Future Measles Outbreaks in England," *Vaccines*, vol. 11, no. 2, Art. no. 2, Feb. 2023, doi: 10.3390/vaccines11020288.
[31] A. Hannaford, "Andrew Wakefield: autism inc," *The Guardian*, Apr. 06, 2013. Accessed: Nov. 15, 2018. [Online]. Available: https://www.theguardian.com/society/2013/apr/06/what-happened-man-mmr-panic

[32] D. Gorski, "Andrew Wakefield: Pushed out by the board of directors at Thoughtful House?" Accessed: Nov. 17, 2018. [Online]. Available: https://scienceblogs.com/insolence/2010/02/18/andrew-wakefield-pushed-out-by-the-board

[33] M. Carey, "Thoughtful House changes name and focus." Accessed: Jul. 06, 2018. [Online]. Available: https://leftbrainrightbrain.co.uk/2011/07/21/thoughtful-house-changes-name-focus/

[34] B. Deer, "Andrew Wakefield pays for libel failure." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/wakefield/wakefield-cheque.htm

[35] THE HON. MR JUSTICE EADY, *Andrew Wakefield v Channel Fout Television Corporation, Twenty Twenty Productions Ltd, Brian Deer*. 2005. Accessed: Jul. 06, 2018. [Online]. Available: http://www.5rb.com/wp-content/uploads/2013/10/Wakefield--v-Channel-4-QBD-4-Nov-2005.pdf

[36] B. Deer, "BMJ series on the Wakefield fraud." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/solved/bmj-secrets-series.htm

[37] C. McRoberts, "Andrew Wakefield loses again in court; what happened?" Accessed: Jul. 06, 2018. [Online]. Available: https://violentmetaphors.com/2014/09/20/andrew-wakefield-loses-again-in-court-what-happened/

[38] HONORABLE AMY CLARK MEACHUM, *Dr. Andrew J. Wakefield v. The British Medical Journal Publishing Group, Ltd.; Brian Deer; and Dr. Fiona Godlee*. 2014, p. 24. Accessed: Oct. 12, 2019. [Online]. Available: http://www.search.txcourts.gov/SearchMedia.aspx?MediaVersionID=656035a1-e049-4673-9a68-90368bb677da&MediaID=97a330b3-84bc-4e8c-a3bf-f6a7cea00623&coa=%22%20+%20this.CurrentWebState.CurrentCourt%20+%20@%22&DT=Opinion

[39] H. L. Sun and A. Brittain, "Meet the New York couple donating millions to the anti--vax movement," *Washington Post*, 2019. Accessed: Jun. 22, 2022. [Online]. Available: https://www.washingtonpost.com/national/health-science/meet-the-new--york-couple-donating-millions-to-the-anti-vax-movement/2019/06/18/9d791bcc-8e28-11e9-b08e-cfd89bd36d4e_story.html

[40] Reuben, "Andrew Jeremy Wakefield, Litigious Bully," The Poxes Blog. Accessed: Nov. 15, 2018. [Online]. Available: https://thepoxesblog.wordpress.com/2014/05/02/andrew-jeremy-wakefield-litigious-bully/

[41] Realtor.com, "Check out the home I found in Austin." Accessed: Nov. 15, 2018. [Online]. Available: https://www.realtor.com/realestateandhomes-detail/802-Crystal-Creek-Dr_Austin_TX_78746_M75291-16929

[42] S. Dominus, "The Crash and Burn of an Autism Guru," *The New York Times*, Apr. 20, 2011. Accessed: Nov. 15, 2018. [Online]. Available: https://www.nytimes.com/2011/04/24/magazine/mag-24Autism-t.html

[43] E. Szeto, K. Pedersen, and A. Tomlinson, "Hidden cameras capture misinformation, fundraising tactics used by anti-vaxx movement," CBC. Accessed: Jan. 20, 2020. [Online]. Available: https://www.cbc.ca/news/health/marketplace-anti-vaccination-hidden-camera-washington-1.5429805

7

Literatura

[1] Centers for Disease Control and Prevention, "About CDC." Accessed: Jul. 12, 2024. [Online]. Available: https://www.cdc.gov/about/cdc/index.html

[2] F. DeStefano, T. K. Bhasin, W. W. Thompson, M. Yeargin-Allsopp, and C. Boyle, "Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan atlanta," *Pediatrics*, vol. 113, no. 2, pp. 259–266, Feb. 2004, doi: 10.1542/peds.113.2.259.

[3] Centers for Disease Control and Prevention, "Autism and Vaccines." Accessed: Aug. 01, 2024. [Online]. Available: https://www.cdc.gov/vaccine-safety/about/autism.html?CDC_AAref_Val=https://www.cdc.gov/vaccinesafety/concerns/autism/cdc2004pediatrics.html#cdc_vaccine_special_topics_recommendations-cdc-statement-2004-mmr-and-autism-study

[4] A. Wakefield, *Vaxxed: From Cover-Up to Catastrophe*, (2017). Accessed: Jul. 06, 2018. [Online Video]. Available: http://www.imdb.com/title/tt5562652/

[5] M. J. Maenner, "Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020," *MMWR Surveill. Summ.*, vol. 72, 2023, doi: 10.15585/mmwr.ss7202a1.

[6] L. Wiederlight, "Face it, There IS an Autism Epidemic," SafeMinds. Accessed: Jul. 06, 2018. [Online]. Available: https://safeminds.org/home/face-it-there-is-an-autism-epidemic/

[7] D. Gutierrez, "When will Congress finally address the autism epidemic in America?," NaturalNews. Accessed: Jul. 12, 2022. [Online]. Available: https://www.naturalnews.com/055628_autism_Congress_vaccines.html

[8] National Institutes of Health, "What is Prevalence?," National Institute of Mental Health (NIMH). Accessed: Jul. 12, 2022. [Online]. Available: https://www.nimh.nih.gov/health/statistics/what-is-prevalence

[9] Centers for Disease Control and Prevention, "Facts about CDC's Autism and Developmental Disabilities Monitoring (ADDM) Network." Accessed: Mar. 19, 2024. [Online]. Available: https://www.cdc.gov/autism/communication-resources/addm-network-factsheet.html?CDC_AAref_Val=https://www.cdc.gov/ncbddd/autism/materials/addm-factsheet.html

[10] M. A. Gernsbacher, M. Dawson, and H. H. Goldsmith, "Three Reasons Not to Believe in an Autism Epidemic," *Curr. Dir. Psychol. Sci.*, vol. 14, no. 2, pp. 55–58, Apr. 2005, doi: 10.1111/j.0963-7214.2005.00334.x.

[11] Centers for Disease Control and Prevention, "Autism Spectrum Disorder (ASD)." Accessed: Mar. 19, 2023. [Online]. Available: https://www.cdc.gov/autism/?CDC_AAref_Val=https://www.cdc.gov/ncbddd/autism/hcp-dsm.html

[12] M. J. Maenner *et al.*, "Potential Impact of DSM-5 Criteria on Autism Spectrum Disorder Prevalence Estimates," *JAMA Psychiatry*, vol. 71, no. 3, p. 292, Mar. 2014, doi: 10.1001/jamapsychiatry.2013.3893.

[13] S. Lundström, A. Reichenberg, H. Anckarsäter, P. Lichtenstein, and C. Gillberg, "Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general population samples," *BMJ*, vol. 350, p. h1961, Apr. 2015, doi: 10.1136/bmj.h1961.

[14] S. N. Hansen, D. E. Schendel, and E. T. Parner, "Explaining the Increase in the Prevalence of Autism Spectrum Disorders: The Proportion Attributable to Changes in Reporting Practices," *JAMA Pediatr.*, vol. 169, no. 1, pp. 56–62, Jan. 2015, doi: 10.1001/jamapediatrics.2014.1893.

[15] H. Coo, H. Ouellette-Kuntz, J. E. V. Lloyd, L. Kasmara, J. J. A. Holden, and M. E. S. Lewis, "Trends in autism prevalence: diagnostic substitution revisited," *J. Autism Dev. Disord.*, vol. 38, no. 6, pp. 1036–1046, Jul. 2008, doi: 10.1007/s10803-007-0478-x.

[16] P. T. Shattuck, "The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education," *Pediatrics*, vol. 117, no. 4, pp. 1028–1037, Apr. 2006, doi: 10.1542/peds.2005-1516.

[17] D. V. M. Bishop, A. J. O. Whitehouse, H. J. Watt, and E. A. Line, "Autism and diagnostic substitution: evidence from a study of adults with a history of developmental language disorder," *Dev. Med. Child Neurol.*, vol. 50, no. 5, pp. 341–345, 2008, doi: 10.1111/j.1469-8749.2008.02057.x.

[18] K.-Y. Liu, M. King, and P. S. Bearman, "Social influence and the autism epidemic," *AJS*, vol. 115, no. 5, pp. 1387–1434, Mar. 2010, doi: 10.1086/651448.

[19] B. A. Virnig, T. M. Tuttle, T. Shamliyan, and R. L. Kane, "Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes," *JNCI J. Natl. Cancer Inst.*, vol. 102, no. 3, pp. 170–178, Feb. 2010, doi: 10.1093/jnci/djp482.

[20] W. C. Black and H. G. Welch, "Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of Therapy," *N. Engl. J. Med.*, vol. 328, no. 17, pp. 1237–1243, Apr. 1993, doi: 10.1056/NEJM199304293281706.

[21] A. Mosterd *et al.*, "Trends in the Prevalence of Hypertension, Antihypertensive Therapy, and Left Ventricular Hypertrophy from 1950 to 1989," *N. Engl. J. Med.*, vol. 340, no. 16, pp. 1221–1227, Apr. 1999, doi: 10.1056/NEJM199904223401601.

[22] F. DeStefano, T. K. Bhasin, W. W. Thompson, M. Yeargin-Allsopp, and C. Boyle, "Autism and Childhood MMR Vaccine Draft of Analysis Plan." 2001. Accessed: Nov. 09, 2022. [Online]. Available: https://lbrbblog.files.wordpress.com/2014/10/mmr_analysis_plan_final.pdf

[23] D. Gorski, "Did a high ranking whistleblower really reveal that the CDC covered up proof that vaccines cause autism in African-American boys?," Science-Based Medicine. Accessed: Jul. 06, 2018. [Online]. Available: https://sciencebasedmedicine.org/did-a-high-ranking-whistleblower-really-reveal-that-the-cdc-covered-up-proof-that-vaccines-cause-autism-in-african-american-boys/

[24] M. Carey, "The William Thompson Documents. There's no whistle to blow.," Left Brain Right Brain. Accessed: Jul. 06, 2018. [Online]. Available: https://leftbrainrightbrain.co.uk/2016/01/04/the-william-thompson-documents-theres-no-whistle-to-blow/

[25] M. Carey, "A new Autism Media Channel video. A chance to watch some sleight of hand," Left Brain Right Brain. Accessed: Jul. 06, 2018. [Online]. Available: https://leftbrainrightbrain.co.uk/2014/10/17/a-new-autism-media-channel-video-a-chance-to-watch-some-sleight-of-hand/

[26] D. Gorski, "The 'CDC whistleblower saga': Updates, backlash, and (I hope) a wrap-up," Science-Based Medicine. Accessed: Jul. 06, 2018. [Online]. Available: https://sciencebasedmedicine.org/the-cdc-whistleblower-saga-updates-backlash-and-i-hope-a-wrap-up/

[27] M. Carey, "Andrew Wakefield releases the trailer for his William Thompson video. Slick production and dishonesty." Accessed: Jul. 06, 2018. [Online]. Available: https://leftbrainrightbrain.co.uk/2016/03/22/andrew-wakefield-releases-the-trailer-for-his-william-thompson-video-slick-production-and-dishonesty/

[28] Minitab Blog Editor, "Analysis and Reanalysis: The Controversy Behind MMR Vaccinations and Autism, part 2." Accessed: Nov. 22, 2024. [Online]. Available: https://blog.minitab.com/en/adventures-in-statistics-2/analysis-and-reanalysis3a-the-controversy-behind-mmr-vaccinations-and-autism2c-part-2

[29] Translational Neurodegeneration, "Retraction Note: Measles-mumps-rubella vaccination timing and autism among young African American boys: a reanalysis of CDC data," *Transl. Neurodegener.*, vol. 3, no. 1, p. 22, Oct. 2014, doi: 10.1186/2047-9158-3-22.

[30] A. Park, "Whistleblower Claims CDC Covered Up Data Showing Vaccine-Autism Link," Time. Accessed: Nov. 30, 2024. [Online]. Available: https://time.com/3208886/whistleblower-claims-cdc-covered-up-data-showing-vaccine-autism-link/

[31] B. Deer, "Timeline of Wakefield MMR scandal, 2011." Accessed: Jul. 06, 2018. [Online]. Available: http://briandeer.com/solved/bmj-wakefield-timeline.htm

[32] S. Dominus, "The Crash and Burn of an Autism Guru," *The New York Times*, Apr. 20, 2011. Accessed: Nov. 15, 2018. [Online]. Available: https://www.nytimes.com/2011/04/24/magazine/mag-24Autism-t.html

[33] DocBastard, "124 (now 144) (now now 157) papers that DO NOT prove vaccines cause autism." Accessed: Sep. 05, 2021. [Online]. Available: http://www.docbastard.net/2016/05/124-papers-that-do-not-prove-vaccines.html?m=1

[34] F. Man, "Vaccines and autism: A thorough review of the evidence (2019 update)." Accessed: Sep. 05, 2021. [Online]. Available: https://thelogicofscience.com/2019/03/12/vaccines-and-autism-a-thorough-review-of-the-evidence-2019-update/#jump

[35] G. Delong, "A positive association found between autism prevalence and childhood vaccination uptake across the U.S. population," *J. Toxicol. Environ. Health A*, vol. 74, no. 14, pp. 903–916, 2011, doi: 10.1080/15287394.2011.573736.

[36] S. Seneff, R. M. Davidson, and J. Liu, "Empirical Data Confirm Autism Symptoms

Related to Aluminum and Acetaminophen Exposure," *Entropy*, vol. 14, no. 11, Art. no. 11, Nov. 2012, doi: 10.3390/e14112227.

[37] T. Deisher, V. D. Ngoc, O. Angelica, K. Kumiko, and B. Sarah, "Impact of environmental factors on the prevalence of autistic disorder after 1979," *J. Public Health Epidemiol.*, vol. 6, no. 9, pp. 271–286, Sep. 2014, doi: 10.5897/JPHE2014.0649.

[38] C. D. Nevison, "A comparison of temporal trends in United States autism prevalence to trends in suspected environmental factors," *Environ. Health*, vol. 13, p. 73, Sep. 2014, doi: 10.1186/1476-069X-13-73.

[39] A. Suresh, "Autism increase mystery solved? No, it's not vaccines, GMOs, glyphosate—or organic foods." Accessed: Jul. 26, 2018. [Online]. Available: https://geneticliteracyproject.org/2016/09/22/autism-increase-mystery-solved-no-its-not-vaccines-gmos-glyphosate-or-organic-foods/

[40] L. Tomljenovic and C. A. Shaw, "Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?," *J. Inorg. Biochem.*, vol. 105, no. 11, pp. 1489–1499, Nov. 2011, doi: 10.1016/j.jinorgbio.2011.08.008.

[41] C. Gallagher and M. Goodman, "Hepatitis B triple series vaccine and developmental disability in US children aged 1–9 years," *Toxicol. Environ. Chem.*, vol. 90, no. 5, pp. 997–1008, Sep. 2008, doi: 10.1080/02772240701806501.

[42] C. M. Gallagher and M. S. Goodman, "Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997-2002," *J. Toxicol. Environ. Health A*, vol. 73, no. 24, pp. 1665–1677, 2010, doi: 10.1080/15287394.2010.519317.

[43] V. K. Singh, S. X. Lin, and V. C. Yang, "Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism," *Clin. Immunol. Immunopathol.*, vol. 89, no. 1, pp. 105–108, Oct. 1998, doi: 10.1006/clin.1998.4588.

[44] V. K. Singh, S. X. Lin, E. Newell, and C. Nelson, "Abnormal measles-mumps-rubella antibodies and CNS autoimmunity in children with autism," *J. Biomed. Sci.*, vol. 9, no. 4, pp. 359–364, Aug. 2002, doi: 10.1007/BF02256592.

[45] M. I. S. Kawashti, O. R. Amin, and N. G. Rowehy, "Possible immunological disorders in autism: concomitant autoimmunity and immune tolerance," *Egypt. J. Immunol.*, vol. 13, no. 1, pp. 99–104, 2006.

[46] A. R Mawson, B. D Ray, A. R Bhuiyan, and B. Jacob, "Pilot comparative study on the health of vaccinated and unvaccinated 6- to 12- year old U.S. children," *J. Transl. Sci.*, vol. 3, no. 3, 2017, doi: 10.15761/JTS.1000186.

[47] A. R. Mawson, A. Bhuiyan, B. Jacob, and B. D. Ray, "Preterm birth, vaccination and neurodevelopmental disorders: a cross-sectional study of 6- to 12-year-old vaccinated and unvaccinated children," *Open Access Text*, 2017, doi: 10.15761/JTS.1000187.

[48] A. Kasprak, "'First Ever' Study Comparing Vaccinated and Unvaccinated Children Shows Harm from Vaccines?," Snopes.com. Accessed: Jul. 13, 2018. [Online]. Available: https://www.snopes.com/news/2017/05/17/vaccine-study-autism/

[49] M. D. Elizabeth Mumper, "Can Awareness of Medical Pathophysiology in Autism Lead to Primary Care Autism Prevention Strategies?," *North Am. J. Med. Sci.*, vol. 6, no. 3, Art. no. 3, Jul. 2013.

[50] H. Kawashima, T. Mori, Y. Kashiwagi, K. Takekuma, A. Hoshika, and A. Wakefield, "Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism," *Dig. Dis. Sci.*, vol. 45, no. 4, pp. 723–729, Apr. 2000, doi: 10.1023/a:1005443726670.

[51] K. M. Madsen *et al.*, "A population-based study of measles, mumps, and rubella vaccination and autism," *N. Engl. J. Med.*, vol. 347, no. 19, pp. 1477–1482, Nov. 2002, doi: 10.1056/NEJMoa021134.

[52] L. Smeeth *et al.*, "MMR vaccination and pervasive developmental disorders: a case--control study," *The Lancet*, vol. 364, no. 9438, pp. 963–969, Sep. 2004, doi: 10.1016/S0140-6736(04)17020-7.

[53] Y. D'Souza, E. Fombonne, and B. J. Ward, "No Evidence of Persisting Measles Virus in Peripheral Blood Mononuclear Cells From Children With Autism Spectrum Disorder," *Pediatrics*, vol. 118, no. 4, pp. 1664–1675, Oct. 2006, doi: 10.1542/peds.2006-1262.

[54] F. DeStefano, C. S. Price, and E. S. Weintraub, "Increasing Exposure to Antibody-Stimulating Proteins and Polysaccharides in Vaccines Is Not Associated with Risk of Autism," *J. Pediatr.*, vol. 163, no. 2, pp. 561–567, Aug. 2013, doi: 10.1016/j.jpeds.2013.02.001.

[55] L. E. Taylor, A. L. Swerdfeger, and G. D. Eslick, "Vaccines are not associated with autism: An evidence-based meta-analysis of case-control and cohort studies," *Vaccine*, vol. 32, no. 29, pp. 3623–3629, Jun. 2014, doi: 10.1016/j.vaccine.2014.04.085.

[56] A. Jain, J. Marshall, A. Buikema, T. Bancroft, J. P. Kelly, and C. J. Newschaffer, "Autism Occurrence by MMR Vaccine Status Among US Children With Older Siblings With and Without Autism," *JAMA*, vol. 313, no. 15, pp. 1534–1540, Apr. 2015, doi: 10.1001/jama.2015.3077.

[57] A. Hviid, J. V. Hansen, M. Frisch, and M. Melbye, "Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study," *Ann. Intern. Med.*, Mar. 2019, doi: 10.7326/M18-2101.

[58] A. Grignolio, *Kdo se boji cepiv?*, 1st ed. *cf, 2018.

[59] J. Davis, "Anti-Vaxxers Fund Study That Finds Zero Link Between Vaccinations And Autism," IFLScience. Accessed: Jul. 06, 2018. [Online]. Available: http://www.iflscience.com/health-and-medicine/anti-vaxxers-fund-study-finds-zero-link-between-vaccinations-and-autism/

[60] I. B, "Pomagajte štiriletnemu Inayu: Rodil se je zdrav, zdaj je avtist," Vestnik. Accessed: Feb. 09, 2019. [Online]. Available: https://www.vestnik.si/pomagajte-stiriletnemu-inayu-rodil-se-je-zdrav-zdaj-je-avtist-6648871?fb_comment_id=2296177043767919_2298267300225560

[61] L. Herlihy, K. Knoch, B. Vibert, and D. Fein, "Parents' first concerns about toddlers with autism spectrum disorder: Effect of sibling status," *Autism Int. J. Res. Pract.*, vol. 19, no. 1, pp. 20–28, Jan. 2015, doi: 10.1177/1362361313509731.

[62] H. Waddington, E. Macaskill, A. J. O. Whitehouse, W. Billingham, and G. A. Alvares, "Parent-reported atypical development in the first year of life and age of autism diagnosis," *J. Autism Dev. Disord.*, Apr. 2022, doi: 10.1007/s10803-022-05506-1.

[63] P. Hotez, *Vaccines did not cause Rachel's autism*, 1st ed. Johns Hopkins University Press, 2018.

[64] E. Courchesne, R. Carper, and N. Akshoomoff, "Evidence of Brain Overgrowth in the First Year of Life in Autism," *JAMA*, vol. 290, no. 3, pp. 337–344, Jul. 2003, doi: 10.1001/jama.290.3.337.

[65] H. C. Hazlett *et al.*, "Early brain development in infants at high risk for autism spectrum disorder," *Nature*, vol. 542, no. 7641, pp. 348–351, Feb. 2017, doi: 10.1038/nature21369.

[66] R. W. Emerson *et al.*, "Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age," *Sci. Transl. Med.*, vol. 9, no. 393, p. eaag2882, Jun. 2017, doi: 10.1126/scitranslmed.aag2882.

[67] R. Stoner *et al.*, "Patches of disorganization in the neocortex of children with autism," *N. Engl. J. Med.*, vol. 370, no. 13, pp. 1209–1219, Mar. 2014, doi: 10.1056/NEJMoa1307491.

[68] B. Weinhold, "Epigenetics: The Science of Change," *Environ. Health Perspect.*, vol. 114, no. 3, pp. A160–A167, Mar. 2006.

[69] M. H. Pesch *et al.*, "Autism Spectrum Disorder Diagnoses and Congenital Cytomegalovirus," *Pediatrics*, vol. 153, no. 6, p. e2023064081, Jun. 2024, doi: 10.1542/peds.2023-064081.

[70] D. Christensen and J. Zubler, "From the CDC: Understanding Autism Spectrum Disorder," *Am. J. Nurs.*, vol. 120, no. 10, pp. 30–37, Oct. 2020, doi: 10.1097/01.NAJ.0000718628.09065.1b.

[71] P. Offit, *Bad advice: or why celebrities, politicians and activists aren't your best source of health information*. Columbia University Press, 2018.

[72] N. B. Chief Special Master Dorsey, *J.M. and V.M., in their Own Right and as Best Friends of their Son, V.J.M., v. Secretary of Health and Human Services*. 2018. Accessed: Jul. 13, 2018. [Online]. Available: https://www.skepticalraptor.com/blog/wp-content/uploads/2018/03/JM-Mini-OMnibus-NVICP.pdf

8

Literatura

[1] M. Černič, "Ideološki konstrukti cepljenja: doktorska disertacija," Fakulteta za uporabne družbene študije, Nova Gorica, 2014.

[2] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[3] World Health Organization, "Global vaccine market report 2023," Geneva, 2024. Accessed: Jun. 13, 2024. [Online]. Available: https://iris.who.int/bitstream/handle/10665/376909/B09022-eng.pdf?sequence=1

[4] GlaxoSmithKline, "Full year and fourth quarter 2017," London, 2018. Accessed: Jul. 16, 2018. [Online]. Available: https://www.gsk.com/media/4629/fy-2017-results--announcement.pdf

[5] GlaxoSmithKline, "Full year and fourth quarter 2021," London, 2022. Accessed: Jun. 13, 2024. [Online]. Available: https://www.gsk.com/media/7377/fy-2021-results-announcement.pdf

[6] GlaxoSmithKline, "Full year and fourth quarter 2022," London, 2023. Accessed: Jun. 16, 2024. [Online]. Available: https://www.gsk.com/media/9847/fy-2022-results-announcement.pdf

[7] Merck Sharp & Dohme (MSD), "Company fact sheet." Accessed: Jun. 14, 2024. [Online]. Available: https://www.msd.com/media/company-fact-sheet/

[8] Merck & Co., "Form 10-K Annual report 2017," Washington, 2018. Accessed: Jun. 14, 2024. [Online]. Available: https://s21.q4cdn.com/488056881/files/doc_financials/2017/2017-Form-10-K_FINAL-wo-Exhibits_Filed-022718.pdf

[9] Merck & Co., "Form 10-K Annual report 2022," Washington, 2023. Accessed: Jun. 14, 2024. [Online]. Available: https://s21.q4cdn.com/488056881/files/doc_financials/2022/ar/b390be48-92bf-4595-96da-ac5cd7c3d92e-(1).pdf

[10] Sanofi, "Form 20-F Annual report 2017," Washington, 2018. Accessed: Jun. 16, 2024. [Online]. Available: https://www.annualreports.com/HostedData/AnnualReportArchive/s/NYSE_SNY_2017.pdf

[11] Sanofi, "Form 20-F Annual report 2022," Washington, 2023. Accessed: Jun. 16, 2024. [Online]. Available: https://www.sanofi.com/assets/dotcom/content-app/publications/annual-report-on-form-20-f/2022-01-01-form-20-f-2022-en.pdf

[12] Pfizer, "2017 Financial Report," 2018. Accessed: Jun. 16, 2024. [Online]. Available: https://s28.q4cdn.com/781576035/files/doc_financials/2017/AR/Financial-Report-2017.pdf

[13] Pfizer, "Form 10-K Annual report 2022," Washington, 2023. Accessed: Jun. 16, 2024. [Online]. Available: https://s28.q4cdn.com/781576035/files/doc_financials/2022/ar/PFE-2022-Form-10K-FINAL-(without-Exhibits).pdf

[14] P. A. Offit, "Why are pharmaceutical companies gradually abandoning vaccines?," *Health Aff. (Millwood)*, vol. 24, no. 3, pp. 622–630, 2005, doi: 10.1377/hlthaff.24.3.622.

[15] J. Smith, M. Lipsitch, and J. W. Almond, "Vaccine production, distribution, access and uptake," *Lancet*, vol. 378, no. 9789, pp. 428–438, Jul. 2011, doi: 10.1016/S0140-6736(11)60478-9.

[16] A. Waye, P. Jacobs, and A. B. Schryvers, "Vaccine development costs: a review," *Expert Rev. Vaccines*, vol. 12, no. 12, pp. 1495–1501, Dec. 2013, doi: 10.1586/14760584.2013.850035.

[17] A. Chit, J. Parker, S. A. Halperin, M. Papadimitropoulos, M. Krahn, and P. Grootendorst, "Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines," *Vaccine*, vol. 32, no. 26, pp. 3336–3340, May 2014, doi: 10.1016/j.vaccine.2013.06.055.

[18] D. W. Light, J. K. Andrus, and R. N. Warburton, "Estimated research and development costs of rotavirus vaccines," *Vaccine*, vol. 27, no. 47, pp. 6627–6633, Nov. 2009, doi: 10.1016/j.vaccine.2009.07.077.

[19] M. Herper, "The Truly Staggering Cost Of Inventing New Drugs," Forbes. Accessed: Jul. 16, 2018. [Online]. Available: https://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/#23d4999f4a94

[20] Finance, "Top izvozniki." Accessed: Oct. 24, 2022. [Online]. Available: https://izvozniki.finance.si/file/brosura2021

[21] Krka, "Annual Report 2021." 2021. Accessed: Apr. 22, 2022. [Online]. Available: https://www.krka.biz/media/doc/en/for_investors/2022/KRKA%202021%20Annual%20Report.pdf

[22] S. Plotkin, J. M. Robinson, G. Cunningham, R. Iqbal, and S. Larsen, "The complexity and cost of vaccine manufacturing – An overview," *Vaccine*, vol. 35, no. 33, pp. 4064–4071, Jul. 2017, doi: 10.1016/j.vaccine.2017.06.003.

[23] C. M. C. Rodrigues and S. A. Plotkin, "Impact of Vaccines; Health, Economic and Social Perspectives," *Front. Microbiol.*, vol. 11, p. 1526, Jul. 2020, doi: 10.3389/fmicb.2020.01526.

9

Literatura

[1] S. Lyman, "Pharma's tarnished reputation helps fuel the anti-vaccine movement." Accessed: Jan. 14, 2020. [Online]. Available: https://www.statnews.com/2019/02/26/anti-vaccine-movement-pharma-tarnished-reputation/

[2] T. Carr, "Anti-Vaxxers Lack Trust. Here's Why.," Undark Magazine. Accessed: Jan. 14, 2020. [Online]. Available: https://undark.org/2019/04/24/anti-vaxxers-vaccines-trust-big-pharma/

[3] R. Blaskiewicz, "The Big Pharma conspiracy theory," *Med. Writ.*, vol. 22, no. 4, pp. 259–261, Dec. 2013, doi: 10.1179/2047480613Z.000000000142.

[4] V. Iannelli, "What Happened to Kennedy's Vaccination Safety Committee?" Accessed: Apr. 04, 2019. [Online]. Available: https://vaxopedia.org/2018/06/02/what-happened-to-kennedys-vaccination-safety-committee/

[5] V. Iannelli, "Robert F. Kennedy, Jr. on Vaccines." Accessed: Apr. 04, 2019. [Online]. Available: https://vaxopedia.org/2016/10/07/robert-f-kennedy-jr-on-vaccines/

[6] C. Lee, "Public Health Experts Alarmed at Trump's Pick of RFK Jr. to Lead HHS," *Time*, Nov. 15, 2024. Accessed: Jan. 03, 2025. [Online]. Available: https://time.com/7177027/rfk-jr-hhs-secretary-trump-public-health/

[7] M. B. Moran, M. Lucas, K. Everhart, A. Morgan, and E. Prickett, "What makes anti-vaccine websites persuasive? A content analysis of techniques used by anti-vaccine websites to engender anti-vaccine sentiment," *J. Commun. Healthc.*, vol. 9, no. 3, pp. 151–163, Jul. 2016, doi: 10.1080/17538068.2016.1235531.

[8] D. R. Grimes, "On the Viability of Conspiratorial Beliefs," *PLOS ONE*, vol. 11, no. 1, p. e0147905, Jan. 2016, doi: 10.1371/journal.pone.0147905.

[9] Datapharm Ltd., "About emc." Accessed: Jul. 16, 2024. [Online]. Available: https://www.medicines.org.uk/emc/about-the-emc

[10] Republika Slovenija, Ministrstvo za zdravje, Javna agencija Republike Slovenije za zdravila in medicinske pripomočke, Zavod za zdravstveno zavarovanje Slovenije, and Nacionalni inštitut za javno zdravje, "Centralna baza zdravil." Accessed: Jul. 16, 2024. [Online]. Available: http://www.cbz.si/cbz/bazazdr2.nsf/Search/$searchForm?SearchView

[11] Modra jagoda d.o.o., "Mediately, hiter dostop do podatkov o zdravilih." Accessed: Feb. 15, 2024. [Online]. Available: https://mediately.co/si/

[12] European Medicines Agency, "How to prepare and review a summary of product characteristics." Accessed: Dec. 01, 2024. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/product-information-requirements/how-prepare-review-summary-product-characteristics

[13] M. Simpson, "Argument by Vaccine Package Inserts – debunking myths." Accessed: Apr. 23, 2019. [Online]. Available: https://www.skepticalraptor.com/skepticalraptorblog.php/vaccine-package-inserts-debunking-myths/

[14] U.S. Food and Drug Administration, "CFR - Code of Federal Regulations Title 21." Accessed: Dec. 01, 2024. [Online]. Available: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.56&utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=21%20CFR%20201.56&utm_content=1

[15] European Medicines Agency, "SmPC training presentation - Section 4.8: Undesirable effects," Accessed: Apr. 23, 2019. [Online]. Available: https://www.ema.europa.eu/en/documents/presentation/presentation-section-48-undesirable-effects_en.pdf

[16] European Medicines Agency, "Summary of Product Characteristics (SmPC)." Accessed: Apr. 25, 2019. [Online]. Available: https://www.ema.europa.eu/en/documents/presentation/presentation-summary-product-characteristics-what-it-what--does-it-contain_en.pdf

[17] J. Robino, "Officially — Vaccine maker admits on FDA website that DTaP vaccine causes autism." Accessed: Apr. 25, 2019. [Online]. Available: https://globalpossibilities.org/officially-vaccine-maker-admits-on-fda-website-that-dtap-vaccine-causes-autism/

[18] V. Iannelli, "Discontinued Vaccines." Accessed: Apr. 25, 2019. [Online]. Available: https://vaxopedia.org/2016/10/26/discontinued-vaccines/

[19] V. Iannelli, "Are Package Inserts Evidence That Vaccines Cause SIDS and Autism?" Accessed: Apr. 25, 2019. [Online]. Available: https://vaxopedia.org/2017/07/10/are--package-inserts-evidence-that-vaccines-cause-sids-and-autism/

[20] Lek farmacevtska družba d.d., "Lekadol 500 mg filmsko obložene tablete, Navodilo za uporabo." 2021. Accessed: Oct. 05, 2023. [Online]. Available: http://www.cbz.si/cbz/bazazdr2.nsf/o/CC18250038223E4AC12579C2003F557B/$File/a-023264.pdf

[21] Belupo d.o.o., "Ibuprofen Belupo 400 mg filmsko obložene tablete, Ibuprofen Belupo 600 mg filmsko obložene tablete, Navodilo za uporabo." Accessed: Apr. 29, 2024. [Online]. Available: http://www.cbz.si/cbz/bazazdr2.nsf/o/C22C5890BDF0E882C12579C2003F5303/$File/a-029552.pdf

[22] Bayer d.o.o., "Aspirin plus C 400 mg/240 mg šumeče tablete, Navodilo za uporabo." Accessed: Jan. 14, 2024. [Online]. Available: http://www.cbz.si/cbz/bazazdr2.nsf/o/AB7E3A58F04F0C09C12579EC001FFD93/$File/a-029184.pdf

[23] M. Černič, "Javna agencija za zdravila in medicinske pripomočke JAZMP pravi: 'Študije o varnosti in učinkovitosti cepiv so poslovna skrivnost.'" Accessed: Feb. 08, 2023. [Online]. Available: http://www.ideoloski-konstrukti.com/2019/11/05/javna-agencija-za-zdravila-in-medicinske-pripomo%C4%8Dke-jazmp-pravi-%C5%A1tudije-o--varnosti-in-u%C4%8Dinkovitosti-cepiv-so-poslovna-skrivnost/

[24] A. Waye, P. Jacobs, and A. B. Schryvers, "Vaccine development costs: a review," *Expert Rev. Vaccines*, vol. 12, no. 12, pp. 1495–1501, Dec. 2013, doi: 10.1586/14760584.2013.850035.

[25] European Federation of Pharmaceutical Industries and Associations (EFPIA), Internationl Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Japanese Pharmaceutical Manufacturers Association (JPMA), and Pharmaceutical Research and Manufacturers of America (PhRMA), "Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases."

Accessed: Jul. 16, 2018. [Online]. Available: https://www.efpia.eu/media/25015/joint-position-on-the-disclosure-of-clinical-trial-information-via-clinical-trial-registries-and-databases-november-2009.pdf

[26] National Institutes of Health, National Library of Medicine, "About ClinicalTrials.gov." Accessed: Jul. 16, 2018. [Online]. Available: https://clinicaltrials.gov/

[27] Bayer Pharmaceuticals, "Clinical trial transparency policy." Accessed: Jul. 16, 2018. [Online]. Available: https://clinicaltrials.bayer.com/transparency-policy/

[28] Sanofi, "Sanofi's Dedication to Responsible Data Sharing in Clinical Trials." Accessed: Jul. 16, 2018. [Online]. Available: https://www.sanofi.com/en/our-science/clinical-trials-and-results/our-data-sharing-commitments

[29] Pfizer, "Data Access Requests." Accessed: Jul. 16, 2018. [Online]. Available: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

[30] CEO Roundtable on Cancer, "Project Data Sphere's Data Sharing Platform." Accessed: Jul. 16, 2018. [Online]. Available: https://www.projectdatasphere.org/projectdatasphere/html/about

[31] European Medicines Agency, "Clinical data publication." Accessed: Jul. 16, 2018. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/clinical-data-publication

[32] M. López-Fauqued *et al.*, "Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials," *Vaccine*, vol. 37, no. 18, pp. 2482–2493, Apr. 2019, doi: 10.1016/j.vaccine.2019.03.043.

[33] Cochrane, "Our policies and positions." Accessed: Oct. 10, 2021. [Online]. Available: https://www.cochrane.org/about-us/our-policies-and-positions

[34] European Science Foundation, "What is cOAlition S?" Accessed: Oct. 10, 2021. [Online]. Available: https://www.coalition-s.org/about/

[35] B. Goldacre, *Bad Pharma*, 2nd ed. Fourth Estate, 2013.

[36] European Commission, "Corporate responsibility in the pharmaceutical industry," Internal Market, Industry, Entrepreneurship and SMEs - European Commission. Accessed: Feb. 05, 2019. [Online]. Available: http://ec.europa.eu/growth/sectors/healthcare/competitiveness/corporate-responsibility_en

[37] European Federation of Pharmaceutical Industries and Associations (EFPIA), "EFPIA HCP/HCO Disclosure code." 2014. Accessed: Feb. 05, 2019. [Online]. Available: https://www.efpia.eu/media/25837/efpia-disclosure-code.pdf

[38] A. Fabbri, A. la Santos, S. Mezinska, S. Mulinari, and B. Mintzes, "Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries," *Int. J. Health Policy Manag.*, vol. 7, no. 6, pp. 504–509, Jun. 2018, doi: 10.15171/ijhpm.2018.20.

[39] GlaxoSmithKline, "Disclosure of payments made to HCPs in Slovenia." Accessed: Oct. 31, 2021. [Online]. Available: https://www.gsk.com/en-gb/responsibility/operating-responsibly/engaging-with-healthcare-professionals/europe/slovenia/

[40] GlaxoSmithKline, "Poročilo za leto: 2020." Accessed: Oct. 31, 2021. [Online]. Available: http://efpiadisclosurecode.gsk.com/GSK_SI_2020_EFPIA_HCPO_Disclosure_Report.pdf

[41] GlaxoSmithKline, "Poročilo za leto: 2022," 2023. Accessed: Nov. 27, 2023. [Online]. Available: https://www.gsk.com/media/10319/gsk_si_2022_efpia_hcpo_disclosure_report.pdf

[42] Sense about Science, "BMA votes that non-publication of trials results is research misconduct," AllTrials. Accessed: Feb. 03, 2019. [Online]. Available: http://www.alltrials.net/news/bma-votes-that-non-publication-of-trials-results-is-research-misconduct/

[43] Sense about Science, "What does all trials registered and reported mean?," AllTrials. Accessed: Nov. 05, 2024. [Online]. Available: https://www.alltrials.net/find-out-more/all-trials/

[44] European Medicines Agency, "About the EU Clinical Trials Register." Accessed: Feb. 05, 2019. [Online]. Available: https://www.clinicaltrialsregister.eu/about.html

[45] B. Goldacre, "How do the world's biggest drug companies compare, in their transparency commitments?" Accessed: Aug. 08, 2018. [Online]. Available: https://www.badscience.net/2017/07/how-do-the-worlds-biggest-drug-companies-compare-in-their-transparency-commitments/

[46] B. Goldacre *et al.*, "Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource," *BMJ*, vol. 362, Sep. 2018, doi: 10.1136/bmj.k3218.

[47] University of Oxford, Bennett Institute for Applied Data Science, "EU Trials Tracker — Who's not sharing clinical trial results?" Accessed: Mar. 22, 2020. [Online]. Available: http://eu.trialstracker.net/

[48] University of Oxford, Bennett Institute for Applied Data Science, "FDAAA TrialsTracker, Who's sharing their clinical trial results?" Accessed: Mar. 22, 2020. [Online]. Available: http://fdaaa.trialstracker.net/

[49] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[50] Slovensko zdravniško društvo, Združenje za pediatrijo, "Koledar splošnih obveznih in priporočenih cepljenj." Accessed: Nov. 04, 2023. [Online]. Available: https://www.cepljenje.info/zivljenjska-obdobja/otroci/2/koledar-splosnih-obveznih-in-priporocenih-cepljenj

[51] B. Ferlič Žgajnar, "Novosti v programu cepljenja." Accessed: Nov. 17, 2024. [Online]. Available: https://www.delo.si/novice/slovenija/novosti-v-programu-cepljenja

[52] Slovensko zdravniško društvo, Združenje za pediatrijo, "Bolezni in cepiva zanje." Accessed: Jul. 02, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje

[53] Sanofi Pasteur, "Hexacima, Summary of product characteristics." Accessed: Dec. 17, 2021. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/hexacima-epar-product-information_sl.pdf

[54] Sanofi Pasteur, "Pentaxim, Povzetek glavnih značilnosti zdravila." 2020. Accessed: Dec. 17, 2021. [Online]. Available: http://www.cbz.si/cbz/bazazdr2.nsf/o/85CA50AE282B90AFC12579EC002006D2/$File/s-023987.pdf

[55] Australian Government, Department of Health, Therapeutic Goods Administration, "Australian Public Assessment Report for Diphtheria, Tetanus, Pertussis

(acellular component), Hepatitis B (rDNA), Poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)." 2015.

[56] S. Plotkin, J. Liese, S. A Mahdi, and E. Ortiz, "DTaP-IPV//PRP~T vaccine (Pentaxim): a review of 16 years' clinical experience," 2011, doi: http://dx.doi.org/10.1586/erv.11.72.

[57] Z. Li *et al.*, "Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017," *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.*, vol. 99, pp. 149–155, Oct. 2020, doi: 10.1016/j.ijid.2020.07.019.

[58] P. Barollier, "U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel®." Accessed: Dec. 17, 2021. [Online]. Available: https://www.news.sanofi.us/press-releases?item=137051

[59] J. C. Nelson *et al.*, "Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV--Hib Vaccine Safety Study," *Am. J. Epidemiol.*, vol. 177, no. 2, pp. 131–141, Jan. 2013, doi: 10.1093/aje/kws317.

[60] J. Hansen *et al.*, "Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers," *Vaccine*, vol. 34, no. 35, pp. 4172–4179, Jul. 2016, doi: 10.1016/j.vaccine.2016.06.062.

[61] Sanofi Pasteur, "Clinical study results Vaccines." Accessed: Dec. 20, 2021. [Online]. Available: https://www.sanofi.com/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pasteur

[62] P. Durando, S. N. Faust, M. Fletcher, P. Krizova, A. Torres, and T. Welte, "Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults," *Clin. Microbiol. Infect.*, vol. 19, pp. 1–9, Oct. 2013, doi: 10.1111/1469-0691.12320.

[63] World Health Organization, "Pneumococcal vaccines WHO position paper – 2012." 2012. Accessed: Feb. 06, 2019. [Online]. Available: https://www.who.int/publications/i/item/WER8714_129-144

[64] N. Lecrenier, A. Marijam, J. Olbrecht, L. Soumahoro, J. Nieto Guevara, and B. Mungall, "Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (Synflorix) in children," *Expert Rev. Vaccines*, vol. 19, no. 3, pp. 247–265, Mar. 2020, doi: 10.1080/14760584.2020.1738226.

[65] S. A. Silfverdal, V. Coremans, N. François, D. Borys, and J. Cleerbout, "Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)," *Expert Rev. Vaccines*, vol. 16, no. 2, pp. 109–121, Feb. 2017, doi: 10.1586/14760584.2016.1164044.

[66] Pfizer, "Pfizer Signs New Agreement With UNICEF To Supply A Total Of Up To 740 Million Doses Of Prevenar 13* For The World's Poorest Countries Through 2025." Accessed: Nov. 17, 2024. [Online]. Available: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_signs_new_agreement_ with_unicef_to_supply_a_total_of_up_to_740_million_doses_of_prevenar_13_for_the_world_s_poorest_countries_through_2025

[67] S. H. Yeh *et al.*, "Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers," *Pediatrics*, vol. 126, no. 3, pp. e493-505, Sep. 2010, doi: 10.1542/peds.2009-3027.

[68] S. Esposito *et al.*, "Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers," *Clin. Vaccine Immunol. CVI*, vol. 17, no. 6, pp. 1017–1026, Jun. 2010, doi: 10.1128/CVI.00062-10.

[69] European Medicines Agency, "Assessment report Prevenar 20," 2024. Accessed: Oct. 21, 2024. [Online]. Available: https://www.ema.europa.eu/en/documents/variation-report/prevenar-20-previously-apexxnar-h-c-005451-ii-0012-epar-assessment-report-variation_en.pdf

[70] Nacionalni Inštitut za javno zdravje, "Pnevmokokne okužbe in cepljenje – vprašanja in odgovori." Accessed: Jun. 06, 2024. [Online]. Available: https://nijz.si/nalezljive-bolezni/cepljenje/pnevmokokne-okuzbe-in-cepljenje-vprasanja-in-odgovori/

[71] N. P. Klein *et al.*, "A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age," *Vaccine*, vol. 39, no. 38, pp. 5428–5435, Sep. 2021, doi: 10.1016/j.vaccine.2021.07.004.

[72] M. Haranaka *et al.*, "A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan," *Vaccine*, vol. 42, no. 5, pp. 1071–1077, Feb. 2024, doi: 10.1016/j.vaccine.2024.01.004.

[73] F. Lievano *et al.*, "Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience," *Vaccine*, vol. 30, no. 48, pp. 6918–6926, Nov. 2012, doi: 10.1016/j.vaccine.2012.08.057.

[74] Merck Sharp & Dohme (MSD), "M-M-RvaxPro, Summary of product characteristics." Accessed: Apr. 04, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/m-m-rvaxpro-epar-product-information_sl.pdf

[75] Merck & Co., "M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live), Package insert." 2024. Accessed: Jul. 08, 2024. [Online]. Available: https://www.fda.gov/media/75191/download?attachment

[76] GlaxoSmithKline, "Priorix (Measles, Mumps, and Rubella Vaccine, Live), Package insert." 2022. Accessed: Jul. 08, 2024. [Online]. Available: https://www.fda.gov/media/158941/download

[77] C. Di Pietrantonj, A. Rivetti, P. Marchione, M. G. Debalini, and V. Demicheli, "Does the measles, mumps, rubella and varicella (MMRV) vaccine protect children, and does it cause harmful effects?," *Cochrane Database Syst. Rev.*, no. 11, 2021, doi: 10.1002/14651858.CD004407.pub5.

[78] World Health Organization, "Measles vaccination has saved an estimated 17.1 million lives since 2000." Accessed: Feb. 11, 2019. [Online]. Available: https://www.who.int/news-room/detail/12-11-2015-measles-vaccination-has-saved-an-estimated-17-1-million-lives-since-2000

10

Literatura

[1] A. Wakefield, *Vaxxed: From Cover-Up to Catastrophe*, (2017). Accessed: Jul. 06, 2018. [Online Video]. Available: http://www.imdb.com/title/tt5562652/

[2] U.S. Food and Drug Administration, "Development & Approval Process | Drugs." Accessed: Jun. 21, 2024. [Online]. Available: https://www.fda.gov/drugs/development-approval-process-drugs

[3] U.S. Food and Drug Administration, "Center for Biologics Evaluation and Research (CBER)." Accessed: Jun. 22, 2024. [Online]. Available: https://www.fda.gov/about-fda/fda-organization/center-biologics-evaluation-and-research-cber

[4] U.S. Food and Drug Administration, "What Are 'Biologics' Questions and Answers." Accessed: Jun. 22, 2024. [Online]. Available: https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers

[5] U.S. Food and Drug Administration, "FDA's Drug Review Process: Continued." Accessed: Jul. 13, 2018. [Online]. Available: https://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm289601.htm

[6] F. Curtin and P. Schulz, "Assessing the benefit:risk ratio of a drug - randomized and naturalistic evidence," *Dialogues Clin. Neurosci.*, vol. 13, no. 2, pp. 183–190, Jun. 2011.

[7] The College of Physicians of Philadelphia, "Vaccine Development, Testing, and Regulation." Accessed: Jul. 13, 2018. [Online]. Available: https://www.historyofvaccines.org/content/articles/vaccine-development-testing-and-regulation

[8] J. M. Robinson, *The Vaccine Book; Chapter Five: Vaccine production: Main steps and considerations*, 2nd ed. Elsevier, 2016.

[9] Syntegon, *AIM 5023V: Automated inspection machine for vials with fast delivery*, (Feb. 14, 2023). Accessed: Dec. 29, 2024. [Online Video]. Available: https://www.youtube.com/watch?v=aA9wtMu-k7I

[10] B. Trogen, D. Oshinsky, and A. Caplan, "Adverse Consequences of Rushing a SARS-CoV-2 Vaccine: Implications for Public Trust," *JAMA*, May 2020, doi: 10.1001/jama.2020.8917.

[11] P. Beckett and P. Ranjeet, "Producing Conjugate Polysaccharide (CPS) Vaccines — When to Consider Customized Ultrafiltration Membranes," in *Enabling vaccine production - solving challenges together*, Darmstadt: Merck, 2021, p. 48. Accessed: Jan. 14, 2025. [Online]. Available: https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/marketing/global/documents/366/635/BR5236EN-Vaccine-Production-eBook-mk.pdf

[12] Merck, *Vaccine bioprocessing handbook*. Darmstadt: Merck, 2021. Accessed: Jan. 14, 2025. [Online]. Available: https://www.sigmaaldrich.com/deepweb/assets/

sigmaaldrich/marketing/global/documents/165/693/vaccine-handbook-process--br5237en-mk.pdf

[13] S. Thota and A. Akbar, "Insulin," in *StatPearls*, StatPearls Publishing, 2023. Accessed: Nov. 04, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK560688/

[14] I. S. Johnson, "Human insulin from recombinant DNA technology," *Science*, vol. 219, no. 4585, pp. 632–637, Feb. 1983, doi: 10.1126/science.6337396.

[15] World Health Organization, "Potential risk of vaccines produced on yeast." Accessed: Jun. 10, 2020. [Online]. Available: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/vaccines-produced-on-yeast#cms

[16] S. Polez *et al.*, "A Simplified and Efficient Process for Insulin Production in Pichia pastoris," *PLOS ONE*, vol. 11, no. 12, p. e0167207, Dec. 2016, doi: 10.1371/journal.pone.0167207.

[17] National Institutes of Health, "M-Cresol." Accessed: Nov. 18, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/342

[18] Eli Lilly and Company, "HUMULIN R (insulin human), Package insert." Accessed: Jun. 10, 2020. [Online]. Available: https://pi.lilly.com/us/humulin-r-pi.pdf

[19] J. L. Chiang *et al.*, "Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association," *Diabetes Care*, vol. 41, no. 9, pp. 2026–2044, Sep. 2018, doi: 10.2337/dci18-0023.

[20] P. Home and B. Itzhak, "Is Insulin Therapy Safe?," *Am. J. Ther.*, vol. 27, no. 1, pp. e106–e114, 2020, doi: 10.1097/MJT.0000000000001077.

[21] L. M. Wilson and J. R. Castle, "Recent Advances in Insulin Therapy," *Diabetes Technol. Ther.*, vol. 22, no. 12, p. 929, Dec. 2020, doi: 10.1089/dia.2020.0065.

11

Literatura

[1] Informed Consent Action Network (ICAN), "Re: HHS Vaccine Safety Responsibilities and Notice Pursuant to 42 U.S.C. § 300aa-31." 2017. Accessed: Jul. 13, 2018. [Online]. Available: https://drive.google.com/file/d/1vvF0AQAm9RZMzizTtB9VDHMiL2JGgMgE/view?usp=embed_facebook

[2] U.S. Department of Health and Human Services, "HHS Response to Questions and Comments from Mr. Bigtree," 2018. Accessed: Jul. 13, 2018. [Online]. Available: https://drive.google.com/file/d/1Or65lanlqmZ94C_z8v36dGcRAONVyfls/view?usp=embed_facebook

[3] D. R. Reiss, "Anti-vaccine ICAN settles with HHS – what does this mean for vaccines?" Accessed: Feb. 23, 2019. [Online]. Available: https://www.skepticalraptor.com/skepticalraptorblog.php/anti-vaccine-ican-settles-hhs-meaning/

[4] HON. JESSEE M. FURMAN, *ICAN vs. HHS (Stipulation)*. Accessed: Feb. 23, 2019. [Online]. Available: https://www.icandecide.org/wp-content/uploads/2019/09/Stipulated-Order-copy-1.pdf

[5] J. Kucinich, "How TV's 'The Doctors' Spawned the King of the Anti-Vaxxers," *The Daily Beast*, Apr. 12, 2019. Accessed: Mar. 09, 2020. [Online]. Available: https://www.thedailybeast.com/anti-vaxxer-del-bigtree-got-his-start-on-the-tv-show-the-doctors

[6] UC Hastings Law, "Dorit Reiss, Professor of Law - UC Hastings College of the Law." Accessed: Sep. 08, 2024. [Online]. Available: https://www.uchastings.edu/people/dorit-reiss/

[7] J. C. Smith, "The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP)," *Vaccine*, vol. 28, pp. A68–A75, Apr. 2010, doi: 10.1016/j.vaccine.2010.02.037.

[8] Centers for Disease Control and Prevention, "Advisory Committee on Immunization Practices (ACIP), ACIP Work Groups." Accessed: Feb. 14, 2024. [Online]. Available: https://www.cdc.gov/acip/our-work/index.html

[9] D. R. Reiss, "February 2019 ACIP Meeting – the process for vaccine recommendations." Accessed: Mar. 09, 2019. [Online]. Available: https://www.skepticalraptor.com/skepticalraptorblog.php/february-2019-acip-meeting-the-process-for-vaccine-recommendations/

[10] M. M. McNeil *et al.*, "The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety," *Vaccine*, vol. 32, no. 42, pp. 5390–5398, Sep. 2014, doi: 10.1016/j.vaccine.2014.07.073.

[11] U.S. Department of Health and Human Services, "VAERS Data." Accessed: Dec. 03, 2019. [Online]. Available: https://vaers.hhs.gov/data.html

[12] M. Carey, "On Using VAERS," Left Brain Right Brain. Accessed: Dec. 03, 2019. [Online]. Available: https://leftbrainrightbrain.co.uk/2006/03/14/on-using-vaers/

[13] M. J. Goodman and J. Nordin, "Vaccine Adverse Event Reporting System Reporting Source: A Possible Source of Bias in Longitudinal Studies," *Pediatrics*, vol. 117, no. 2, pp. 387–390, Feb. 2006, doi: 10.1542/peds.2004-2687.

[14] T. Shimabukuro, M. Nguyen, D. Martin, and F. DeStefano, "Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)," *Vaccine*, vol. 33, no. 36, pp. 4398–4405, Aug. 2015, doi: 10.1016/j.vaccine.2015.07.035.

[15] Centers for Disease Control and Prevention, "Intussusception among recipients of rotavirus vaccine-United States, 1998-1999," *MMWR Morb. Mortal. Wkly. Rep.*, vol. 48, no. 27, pp. 577–581, Jul. 1999.

[16] J. W. Gargano, M. Wallace, S. Hadler, and et al., "Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021," *MMWR Morb. Mortal. Wkly. Rep.*, vol. 70, 2021, doi: 10.15585/mmwr.mm7027e2.

[17] S. Gavura, "Gold mine or dumpster dive? A closer look at adverse event reports," Science-Based Medicine. Accessed: Jul. 25, 2018. [Online]. Available: https://sciencebasedmedicine.org/gold-mine-or-dumpster-dive-a-closer-look-at-adverse-event-reports/

[18] Centers for Disease Control and Prevention, "Vaccine Safety Systems, About the Vaccine Safety Datalink (VSD)." Accessed: Feb. 23, 2024. [Online]. Available: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html

[19] N. P. Klein *et al.*, "Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures," *Pediatrics*, vol. 126, no. 1, pp. e1–e8, Jul. 2010, doi: 10.1542/peds.2010-0665.

[20] W. W. Thompson *et al.*, "Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years," *N. Engl. J. Med.*, vol. 357, no. 13, pp. 1281–1292, Sep. 2007, doi: 10.1056/NEJMoa071434.

[21] U.S. Food and Drug Administration, "Post-Licensure Rapid Immunization Safety Monitoring (PRISM) Public Workshop," p. 110, 2016.

[22] U.S. Food and Drug Administration, "Sentinel Initiative, Vaccines, Blood, & Biologics Studies." Accessed: Sep. 14, 2022. [Online]. Available: https://www.sentinelinitiative.org/studies/vaccines-blood-biologics#undefined

[23] U.S. Food and Drug Administration, "Sentinel Initiative final assessment report." Accessed: Sep. 14, 2022. [Online]. Available: https://www.fda.gov/media/107850/download

[24] Centers for Disease Control and Prevention, "Vaccine safety systems, About the Clinical Immunization Safety Assessment (CISA) Project." Accessed: Feb. 23, 2024. [Online]. Available: https://www.cdc.gov/vaccine-safety-systems/hcp/cisa/?CDC_AAref_Val=https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html

[25] V. Iannelli, "That Time Del Bigtree Admitted He Manipulates Folks and Their Fears of Vaccines." Accessed: May 30, 2019. [Online]. Available: https://vaxopedia.org/2019/05/24/that-time-del-bigtree-admitted-he-manipulates-folks-and-their-fears-of-vaccines/

[26] European Medicines Agency, "Pharmacovigilance: Overview." Accessed: Jun. 12, 2020. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance-overview

[27] European Medicines Agency, "Questions & answers on signal management." Accessed: Jul. 13, 2018. [Online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/09/WC500150743.pdf

[28] European Medicines Agency, "Signal management." Accessed: Jun. 12, 2024. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/signal-management

[29] European Medicines Agency, "PRAC recommendations on safety signals." Accessed: Jul. 13, 2024. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/signal-management/prac-recommendations-safety-signals

[30] European Medicines Agency, "Evropska podatkovna baza poročil o domnevnih neželenih učinkih zdravil." Accessed: Oct. 10, 2021. [Online]. Available: https://www.adrreports.eu/sl/index.html

[31] L. Wijnans *et al.*, "The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns," *Vaccine*, vol. 31, no. 8, pp. 1246–1254, Feb. 2013, doi: 10.1016/j.vaccine.2012.12.015.

[32] M. Sturkenboom *et al.*, "Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines," *Vaccine*, Oct. 2019, doi: 10.1016/j.vaccine.2019.07.081.

[33] National Centre for Immunisation, Research and Surveillance (NCIRS) Australia, "Vaccine safety." Accessed: Oct. 29, 2024. [Online]. Available: https://ncirs.org.au/health-professionals/vaccine-safety

12

Literatura

[1] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[2] Javna agencija Republike Slovenije za zdravila in medicinske pripomočke, "Poročanje o domnevnih neželenih učinkih zdravil." Accessed: Jul. 13, 2018. [Online]. Available: http://www.jazmp.si/humana-zdravila/farmakovigilanca/porocanje-o--nezelenih-ucinkih-zdravil/

[3] U.S. Department of Health and Human Services, "VAERS - Report an Adverse Event." Accessed: Jun. 04, 2024. [Online]. Available: https://vaers.hhs.gov/esub/index.jsp

[4] V. L. Hinrichsen, B. Kruskal, M. A. O'Brien, T. A. Lieu, and R. Platt, "Using Electronic Medical Records to Enhance Detection and Reporting of Vaccine Adverse Events," *J. Am. Med. Inform. Assoc. JAMIA*, vol. 14, no. 6, pp. 731–735, 2007, doi: 10.1197/jamia.M2232.

[5] D. R. Prevots, R. W. Sutter, P. M. Strebel, R. E. Weibel, and S. L. Cochi, "Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease," *Arch. Pediatr. Adolesc. Med.*, vol. 148, no. 5, pp. 479–485, May 1994, doi: 10.1001/archpedi.1994.02170050037007.

[6] M. Böttiger, V. Romanus, C. de Verdier, and G. Boman, "Osteitis and Other Complications Caused by Generalized Bcg-Itis," *Acta Paediatr.*, vol. 71, no. 3, pp. 471–478, 1982, doi: 10.1111/j.1651-2227.1982.tb09454.x.

[7] T. Shimabukuro, M. Nguyen, D. Martin, and F. DeStefano, "Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)," *Vaccine*, vol. 33, no. 36, pp. 4398–4405, Aug. 2015, doi: 10.1016/j.vaccine.2015.07.035.

[8] L. Hazell and S. A. W. Shakir, "Under-reporting of adverse drug reactions : a systematic review," *Drug Saf.*, vol. 29, no. 5, pp. 385–396, 2006, doi: 10.2165/00002018-200629050-00003.

[9] Centers for Disease Control and Prevention, "Intussusception among recipients of rotavirus vaccine-United States, 1998-1999," *MMWR Morb. Mortal. Wkly. Rep.*, vol. 48, no. 27, pp. 577–581, Jul. 1999.

[10] J. W. Gargano, M. Wallace, S. Hadler, and et al., "Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021," *MMWR Morb. Mortal. Wkly. Rep.*, vol. 70, 2021, doi: 10.15585/mmwr.mm7027e2.

[11] L. Wijnans *et al.*, "The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns," *Vaccine*, vol. 31, no. 8, pp. 1246–1254, Feb. 2013, doi: 10.1016/j.vaccine.2012.12.015.

[12] M. M. McNeil *et al.*, "The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety," *Vaccine*, vol. 32, no. 42, pp. 5390–5398, Sep. 2014, doi: 10.1016/j.vaccine.2014.07.073.

[13] European Medicines Agency, "Guideline on good pharmacovigilance practices (GVP) - Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2)," p. 144, 2017.

[14] European Medicines Agency, "The launch of the new EudraVigilance System - Questions and answers (Q&A) from stakeholders." Accessed: Jul. 13, 2018. [Online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2017/07/WC500230934.pdf

[15] Javna agencija Republike Slovenije za zdravila in medicinske pripomočke, "Kako poročati o domnevnem neželenem učinku zdravila." 2017. Accessed: Sep. 10, 2021. [Online]. Available: https://www.jazmp.si/fileadmin/datoteke/dokumenti/SFV/JAZMP_navodila/Kako_porocati_o_domnevnem_NUZ_posodobitev_julij_2017_corr.pdf

[16] Javna agencija Republike Slovenije za zdravila in medicinske pripomočke, "Zdravila, za katera se zahteva dodatno spremljanje varnosti." Accessed: Oct. 06, 2024. [Online]. Available: https://www.jazmp.si/humana-zdravila/farmakovigilanca/porocanje-o-nezelenih-ucinkih-zdravil/zdravila-za-katera-se-zahteva-dodatno-spremljanje-varnosti/

[17] Nacionalni Inštitut za javno zdravje, "Obrazci za zdravnike, ki izvajajo cepljenje." Accessed: Jul. 13, 2018. [Online]. Available: http://www.nijz.si/sl/obrazci-za-zdravnike-ki-izvajajo-cepljenje

[18] Univerzitetni klinični center Ljubljana, "Center za klinično toksikologijo in farmakologijo." Accessed: Oct. 09, 2024. [Online]. Available: https://www.kclj.si/index.php?dir=/pacienti_in_obiskovalci/klinike_in_oddelki/interna_klinika/center_za_klinicno_toksikologijo_in_farmakologijo

[19] E. Lopez-Gonzalez, M. T. Herdeiro, and A. Figueiras, "Determinants of Under-Reporting of Adverse Drug Reactions," *Drug Saf.*, vol. 32, no. 1, pp. 19–31, Jan. 2009, doi: 10.2165/00002018-200932010-00002.

[20] P. García-Abeijon, C. Costa, M. Taracido, M. T. Herdeiro, C. Torre, and A. Figueiras, "Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update," *Drug Saf.*, vol. 46, no. 7, pp. 625–636, 2023, doi: 10.1007/s40264-023-01302-7.

[21] K. Weigmann, "Consumer reporting of adverse drug reactions," *EMBO Rep.*, vol. 17, no. 7, pp. 949–952, Jul. 2016, doi: 10.15252/embr.201642616.

[22] C. Costa, P. Abeijon, D. A. Rodrigues, A. Figueiras, M. T. Herdeiro, and C. Torre, "Factors associated with underreporting of adverse drug reactions by patients: a systematic review," *Int. J. Clin. Pharm.*, vol. 45, no. 6, pp. 1349–1358, 2023, doi: 10.1007/s11096-023-01592-y.

13

Literatura

[1] SafeMinds, "IOM Fails Again to Pursue Science on Vaccine Injury." Accessed: Aug. 30, 2022. [Online]. Available: https://www.ageofautism.com/2013/01/iom-fails-again-to-pursue-science-on-vaccine-injury.html

[2] I. Ruishalme, "Myth: No Studies Compare the Health of Unvaccinated and Vaccinated People." Accessed: Jul. 06, 2018. [Online]. Available: https://thoughtscapism.com/2015/04/10/myth-no-studies-compare-the-health-of-unvaccinated-and-vaccinated-people/

[3] V. Iannelli, "Where are the Double Blind Placebo Controlled Randomized Trials about Vaccines." Accessed: Jul. 13, 2018. [Online]. Available: https://vaxopedia.org/2017/07/10/where-are-the-double-blind-placebo-controlled-randomized-trials-about-vaccines/

[4] World Medical Association, "WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects." Accessed: Jul. 06, 2018. [Online]. Available: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

[5] A. Rid *et al.*, "Placebo use in vaccine trials: Recommendations of a WHO expert panel," *Vaccine*, vol. 32, no. 37, pp. 4708–4712, Aug. 2014, doi: 10.1016/j.vaccine.2014.04.022.

[6] D. G. Evans, C. L. MIller, F. T. Perkins, T. M. Pollock, and I. Sutherland, "Vaccination Against Measles: a Clinical Trial of Live Measles Vaccine Given Alone and Live Vaccine Preceded by Killed Vaccine," *BMJ*, vol. 1, no. 5485, pp. 441–446, Feb. 1966, doi: 10.1136/bmj.1.5485.441.

[7] N. J. Ehrenkranz, A. K. Ventura, E. M. Medler, J. E. Jackson, and M. T. Kenny, "Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic," *Bull. World Health Organ.*, vol. 52, no. 1, pp. 81–85, 1975.

[8] B. Durand *et al.*, "[Antitetanus vaccination: preliminary results of a study in Africa]," *Dev. Biol. Stand.*, vol. 41, pp. 3–14, 1978.

[9] M. Blennow, M. Granström, E. Jäätmaa, and P. Olin, "Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial," *Pediatrics*, vol. 82, no. 3, pp. 293–299, Sep. 1988.

[10] R. E. Weibel *et al.*, "Live attenuated varicella virus vaccine. Efficacy trial in healthy children," *N. Engl. J. Med.*, vol. 310, no. 22, pp. 1409–1415, May 1984, doi: 10.1056/NEJM198405313102201.

[11] J. Ward, G. Brenneman, G. W. Letson, and W. L. Heyward, "Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group," *N. Engl. J. Med.*, vol. 323, no. 20, pp. 1393–1401, Nov. 1990, doi: 10.1056/NEJM199011153232006.

[12] S. Iwata *et al.*, "Efficacy and safety of pentavalent rotavirus vaccine in Japan," *Hum. Vaccines Immunother.*, vol. 9, no. 8, pp. 1626–1633, Aug. 2013, doi: 10.4161/hv.24846.

[13] R. B. Belshe *et al.*, "The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children," *N. Engl. J. Med.*, vol. 338, no. 20, pp. 1405–1412, May 1998, doi: 10.1056/NEJM199805143382002.

[14] S. Xia *et al.*, "Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial," *Front. Immunol.*, vol. 13, p. 898151, 2022, doi: 10.3389/fimmu.2022.898151.

[15] P. Karma *et al.*, "Prevention of otitis media in children by pneumococcal vaccination," *Am. J. Otolaryngol.*, vol. 6, no. 3, pp. 173–184, Jun. 1985, doi: 10.1016/s0196-0709(85)80081-8.

[16] H. S. Marshall *et al.*, "Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial," *Lancet Infect. Dis.*, vol. 17, no. 1, pp. 58–67, 2017, doi: 10.1016/S1473-3099(16)30314-0.

[17] F. Nosten *et al.*, "Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group," *Lancet Lond. Engl.*, vol. 348, no. 9029, pp. 701–707, Sep. 1996, doi: 10.1016/s0140-6736(96)04465-0.

[18] V. K. Sikand *et al.*, "Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial," *Pediatrics*, vol. 108, no. 1, pp. 123–128, Jul. 2001, doi: 10.1542/peds.108.1.123.

[19] J. S. Lambert *et al.*, "Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218)," *J. Acquir. Immune Defic. Syndr. Hum. Retrovirology Off. Publ. Int. Retrovirology Assoc.*, vol. 19, no. 5, pp. 451–461, Dec. 1998, doi: 10.1097/00042560-199812150-00003.

[20] S. Biswal *et al.*, "Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial," *Lancet Lond. Engl.*, vol. 395, no. 10234, pp. 1423–1433, May 2020, doi: 10.1016/S0140-6736(20)30414-1.

[21] D. Hallas, R. Spratling, and J. Fletcher, "Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines," *J. Pediatr. Health Care*, vol. 35, no. 4, pp. 443–448, 2021, doi: 10.1016/j.pedhc.2021.04.001.

[22] A. J. Tingle *et al.*, "Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women," *The Lancet*, vol. 349, no. 9061, pp. 1277–1281, May 1997, doi: 10.1016/S0140-6736(96)12031-6.

[23] F. E. André *et al.*, "Placebo-controlled double-blind clinical studies on the efficacy of different influenza vaccines assessed by experimental and natural infection," *Postgrad. Med. J.*, vol. 52, no. 608, pp. 352–359, Jun. 1976, doi: 10.1136/pgmj.52.608.352.

[24] M. C. Steinhoff *et al.*, "Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial," *Lancet Infect. Dis.*, vol. 17, no. 9, pp. 981–989, 2017, doi: 10.1016/S1473-3099(17)30252-9.

[25] K. P. Perrett *et al.*, "Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial," *Vaccine*, vol. 38, no. 8, pp. 2095–2104, Feb. 2020, doi: 10.1016/j.vaccine.2019.10.105.

[26] R. Konno, S. Tamura, K. Dobbelaere, and H. Yoshikawa, "Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial," *Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc.*, vol. 20, no. 5, pp. 847–855, Jul. 2010, doi: 10.1111/IGC.0b013e3181da2128.

[27] J. Desmyter *et al.*, "Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial," *Lancet Lond. Engl.*, vol. 2, no. 8363, pp. 1323–1328, Dec. 1983, doi: 10.1016/s0140-6736(83)91089-9.

[28] P. N. Peacock, "A controlled study of disturbances recorded following the use of oral poliomyelitis vaccine," *Can. Med. Assoc. J.*, vol. 89, pp. 111–115, Jul. 1963.

[29] R. A. Kuschner *et al.*, "A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits," *Vaccine*, vol. 31, no. 28, pp. 2963–2971, Jun. 2013, doi: 10.1016/j.vaccine.2013.04.035.

[30] J. M. McCarty, M. D. Lock, K. M. Hunt, J. K. Simon, and M. Gurwith, "Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45," *Vaccine*, vol. 36, no. 6, pp. 833–840, 01 2018, doi: 10.1016/j.vaccine.2017.12.062.

[31] E. M. Berkowitz *et al.*, "Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study," *J. Infect. Dis.*, vol. 211, no. 8, pp. 1279–1287, Apr. 2015, doi: 10.1093/infdis/jiu606.

[32] C. F. von Reyn *et al.*, "Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901," *PloS One*, vol. 12, no. 5, p. e0175215, 2017, doi: 10.1371/journal.pone.0175215.

[33] V. G. Fowler and R. A. Proctor, "Where does a Staphylococcus aureus vaccine stand?," *Clin. Microbiol. Infect.*, vol. 20, pp. 66–75, May 2014, doi: 10.1111/1469-0691.12570.

[34] E. C. Reisinger *et al.*, "Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial," *Lancet Lond. Engl.*, vol. 392, no. 10165, pp. 2718–2727, 22 2019, doi: 10.1016/S0140-6736(18)32488-7.

[35] G. J. Mertz *et al.*, "Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection," *J. Infect. Dis.*, vol. 161, no. 4, pp. 653–660, Apr. 1990, doi: 10.1093/infdis/161.4.653.

[36] K. Modjarrad *et al.*, "Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials," *Lancet Lond. Engl.*, vol. 391, no. 10120, pp. 563–571, 10 2018, doi: 10.1016/S0140-6736(17)33106-9.

[37] S. Abraham *et al.*, "Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial," *Lancet Infect. Dis.*, vol. 19, no. 10, pp. 1091–1100, Oct. 2019, doi: 10.1016/S1473-3099(19)30279-8.

[38] "Take Action," Vaxxed. Accessed: Jul. 06, 2018. [Online]. Available: http://vaxxedthemovie.com/take-action/

[39] M. Carey, "Generation Rescue Survey Results," Left Brain Right Brain. Accessed: Jul. 21, 2018. [Online]. Available: https://leftbrainrightbrain.co.uk/2007/06/26/generation-rescue-survey-results/

[40] A. R Mawson, B. D Ray, A. R Bhuiyan, and B. Jacob, "Pilot comparative study on the health of vaccinated and unvaccinated 6- to 12- year old U.S. children," *J. Transl. Sci.*, vol. 3, no. 3, 2017, doi: 10.15761/JTS.1000186.

[41] R. Kennedy F., "Pilot comparative study on the health of vaccinated and unvaccinated 6- to 12-year-old U.S. children," World Mercury Project. Accessed: Jul. 13, 2018. [Online]. Available: https://worldmercuryproject.org/news/unvaccinated--children-much-lower-rates-chronic-illness-jackson-state-study-finds/

[42] A. Kasprak, "'First Ever' Study Comparing Vaccinated and Unvaccinated Children Shows Harm from Vaccines?," Snopes.com. Accessed: Jul. 13, 2018. [Online]. Available: https://www.snopes.com/news/2017/05/17/vaccine-study-autism/

[43] K. Hennessy, "Why this vaxed v. unvaxed study is not valid: Update: Study retracted AGAIN." Accessed: Jul. 13, 2018. [Online]. Available: https://vaccinesworkblog.wordpress.com/2017/05/06/why-this-vaxed-v-unvaxed-study-is-not-valid/

[44] N. Miller, "Neil Miller | LinkedIn." Accessed: Nov. 18, 2024. [Online]. Available: https://www.linkedin.com/in/neil-miller-13b34968/

[45] H. Hall, "Another Anti-Vaccine Book," Science-Based Medicine. Accessed: Jun. 08, 2019. [Online]. Available: https://sciencebasedmedicine.org/another-anti-vaccine--book/

[46] D. Gorski, "Combining childhood vaccines at one visit is not safe? Wrong, wrong, wrong!" Accessed: Dec. 03, 2019. [Online]. Available: https://respectfulinsolence.com/2016/06/16/combining-childhood-vaccines-at-one-visit-is-not-safe-not-so/

[47] B. S. Hooker and N. Z. Miller, "Analysis of health outcomes in vaccinated and unvaccinated children: Developmental delays, asthma, ear infections and gastrointestinal disorders," *SAGE Open Med.*, vol. 8, p. 2050312120925344, Jan. 2020, doi: 10.1177/2050312120925344.

[48] D. Gorski, "Brian Hooker and Neil Z. Miller publish another terrible 'vaxxed/unvaxxed' study." Accessed: Jun. 08, 2020. [Online]. Available: https://respectfulinsolence.com/2020/05/29/hooker-and-miller-publish-terrible-vaxxed-unvaxxed-study/

[49] A. L. Wagner, K. Top, and N. Masters, "Significant methodological flaws in a 2020 study claiming to show unvaccinated children are healthier," Health Feedback. Accessed: Aug. 31, 2022. [Online]. Available: https://healthfeedback.org/claimreview/significant-methodological-flaws-in-a-2020-study-claiming-to-show-unvaccinated-children-are-healthier-brian-hooker-childrens-health-defense/

[50] A. Jain, J. Marshall, A. Buikema, T. Bancroft, J. P. Kelly, and C. J. Newschaffer, "Autism Occurrence by MMR Vaccine Status Among US Children With Older Siblings With and Without Autism," *JAMA*, vol. 313, no. 15, pp. 1534–1540, Apr. 2015, doi: 10.1001/jama.2015.3077.

[51] R. Schmitz, C. Poethko-Müller, S. Reiter, and M. Schlaud, "Vaccination Status and Health in Children and Adolescents," *Dtsch. Ärztebl. Int.*, vol. 108, no. 7, pp. 99–104, Feb. 2011, doi: 10.3238/arztebl.2011.0099.

[52] University of North Carolina at Chapel Hill, "Cebu Longitudinal Health and Nutrition Survey, About the CLHNS." Accessed: Apr. 09, 2024. [Online]. Available: https://cebu.cpc.unc.edu/about/

[53] D. E. Bloom, D. Canning, and E. S. Shenoy, "The effect of vaccination on children's physical and cognitive development in the Philippines," *Appl. Econ.*, vol. 44, no. 21, pp. 2777–2783, Jul. 2011, doi: 10.1080/00036846.2011.566203.

[54] D. Gorski, "Reviewing Andrew Wakefield's VAXXED: Antivaccine propaganda at its most pernicious," Science-Based Medicine. Accessed: Jul. 13, 2018. [Online]. Available: https://sciencebasedmedicine.org/andrew-wakefields-vaxxed-antivaccine-propaganda-at-its-most-pernicious/

[55] D. Gorski, "Bernard and Lisa Selz (and Albert Dwoskin): Name and shame wealthy donors funding antivaxers." Accessed: Aug. 21, 2020. [Online]. Available: https://respectfulinsolence.com/2019/06/21/selz-dwoskin-name-shame-antivaxer/

[56] E. Szeto, K. Pedersen, and A. Tomlinson, "Hidden cameras capture misinformation, fundraising tactics used by anti-vaxx movement," CBC. Accessed: Jan. 20, 2020. [Online]. Available: https://www.cbc.ca/news/health/marketplace-anti-vaccination-hidden-camera-washington-1.5429805

14

Literatura

[1] Naravna imunost, "O nas," Naravna imunost. Accessed: Nov. 22, 2024. [Online]. Available: https://www.naravnaimunost.si/o-nas/

[2] Naravna imunost, "Varnost cepiv," Naravna imunost. Accessed: Apr. 16, 2024. [Online]. Available: https://www.naravnaimunost.si/varnost-cepiv/

[3] Naravna imunost, "O cepivih," Naravna imunost. Accessed: Jul. 28, 2024. [Online]. Available: http://www.naravnaimunost.si/Cepiva/varnostCepiv.php

[4] U.S. House of Representatives, Office of the Law Revision Counsel, *Federal Food, Drug and Cosmetic Act (FD&C Act)*. 2018. Accessed: Nov. 05, 2019. [Online]. Available: https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act

[5] U.S. Food and Drug Administration, "Development & Approval Process | Drugs." Accessed: Jun. 21, 2024. [Online]. Available: https://www.fda.gov/drugs/development-approval-process-drugs

[6] K. Scott-Mumby, "About Prof. Keith Scott-Mumby." Accessed: Jan. 27, 2020. [Online]. Available: https://alternative-doctor.com/about-prof-keith-scott-mumby/

[7] K. Scott-Mumby, "21 Reasons Not To Vaccinate." Accessed: Oct. 26, 2023. [Online]. Available: https://alternative-doctor.com/reasons-not-to-vaccinate/

[8] Bayer d.o.o., "Claritine 1 mg/ml sirup, Povzetek glavnih značilnosti zdravila." 2023. Accessed: Aug. 19, 2023. [Online]. Available: http://www.cbz.si/cbz/bazazdr2.nsf/o/0FBFFB60693990E7C12579C2003F56D3/$File/s-028047.pdf

[9] E. Birchley, "Ibuprofen Allergic Reaction 'Nearly Kills' Boy," Sky News. Accessed: Dec. 14, 2024. [Online]. Available: https://news.sky.com/story/ibuprofen-allergic-reaction-nearly-kills-boy-10465464

[10] A. Kraigher, A. Ihan, and T. Avčin, *Cepljenje in cepiva - dobre prakse varnega cepljenja: univerzitetni učbenik za študente medicinske in zdravstvene fakultete*. Ljubljana: Sekcija za preventivno medicino SZD : Sekcija za klinično mikrobiologijo in bolnišnične okužbe SZD : Inštitut za varovanje zdravja RS, 2011.

[11] K. Scott-Mumby, "Here's Proof That Vaccination Works, Says CDC - Vaccine-Preventable Deaths Reach New Low in U.S." Accessed: Jan. 27, 2020. [Online]. Available: https://www.alternative-doctor.com/vaccination/CDCproof.html

[12] K. Scott-Mumby, "Vaccination Does Work. Let's Talk About Polio." Accessed: Oct. 26, 2023. [Online]. Available: https://alternative-doctor.com/vaccination-does-work-lets-talk-about-polio/

[13] K. Scott-Mumby, "Dr. Keith's Own." Accessed: Jan. 27, 2024. [Online]. Available: https://drkeithsown.myshopify.com/collections/dr-keiths-own

[14] R. S. Mendelsohn, "The medical timebomb of immunization against disease," *East West J.*, 1984, Accessed: Oct. 27, 2023. [Online]. Available: http://www.whale.to/vaccines/mendelsohn.html

[15] National Institute of Neurological Disorders and Stroke, "Febrile Seizures Fact Sheet." Accessed: Jan. 28, 2020. [Online]. Available: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Febrile-Seizures-Fact-Sheet

[16] B. Feenstra *et al.*, "Common variants associated with general and MMR vaccine–related febrile seizures," *Nat. Genet.*, vol. 46, no. 12, pp. 1274–1282, Dec. 2014, doi: 10.1038/ng.3129.

[17] E. Hall, P. Wodi A., J. Hamborsky, V. Morelli, and S. Schillie, *Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases*, 14th ed. Washington: Public Health Foundation, 2021. Accessed: Mar. 15, 2021. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html

[18] National Health Service, "Complications, Mumps." Accessed: Jul. 18, 2021. [Online]. Available: https://www.nhs.uk/conditions/mumps/complications/

[19] L. Pöyhönen, J. Bustamante, J.-L. Casanova, E. Jouanguy, and Q. Zhang, "Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity," *J. Clin. Immunol.*, vol. 39, no. 4, pp. 376–390, May 2019, doi: 10.1007/s10875-019-00642-3.

[20] S. Pearce and J. Jones, "Wyoming Vaccine Information Network, Quotations." Accessed: Jul. 18, 2018. [Online]. Available: http://www.vaclib.org/chapter/wyinfo2.htm

[21] J. Luna *et al.*, "Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women," *PloS One*, vol. 8, no. 12, p. e83431, 2013, doi: 10.1371/journal.pone.0083431.

[22] American College for Advancement in Medicine, "In Memoriam: Harold Buttrum, MD, FAAEM: 1925-2016." Accessed: Jun. 20, 2024. [Online]. Available: https://www.acam.org/news/275263/Harold-Buttrum-MD-FAAEM-1925-2016.htm

[23] H. E. Buttram and A. R. Yurko, "Vaccine Safety Tests: What Are They? Why Do We Need Them? Why Are They Not Being Done?," Vaccine Choice Canada. Accessed: Jul. 19, 2018. [Online]. Available: https://vaccinechoicecanada.com/health-risks/anaphylaxis-allergies-asthma/vaccine-safety-tests/

[24] C. Lahariya, "Vaccine epidemiology: A review," *J. Fam. Med. Prim. Care*, vol. 5, no. 1, pp. 7–15, 2016, doi: 10.4103/2249-4863.184616.

[25] A. Di Pasquale, P. Bonanni, N. Garçon, L. R. Stanberry, M. El-Hodhod, and F. Tavares Da Silva, "Vaccine safety evaluation: Practical aspects in assessing benefits and risks," *Vaccine*, vol. 34, no. 52, pp. 6672–6680, 20 2016, doi: 10.1016/j.vaccine.2016.10.039.

[26] R. Schmitz, C. Poethko-Müller, S. Reiter, and M. Schlaud, "Vaccination Status and Health in Children and Adolescents," *Dtsch. Ärztebl. Int.*, vol. 108, no. 7, pp. 99–104, Feb. 2011, doi: 10.3238/arztebl.2011.0099.

[27] A. Grignolio, *Kdo se boji cepiv?*, 1st ed. *cf, 2018.

[28] A. Gagneur, D. Pinquier, and C. Quach, "Immunization of preterm infants," *Hum. Vaccines Immunother.*, vol. 11, no. 11, pp. 2556–2563, Aug. 2015, doi: 10.1080/21645515.2015.1074358.

[29] E. Chiappini *et al.*, "Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian

Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology," *Expert Rev. Vaccines*, vol. 18, no. 5, pp. 523–545, May 2019, doi: 10.1080/14760584.2019.1604230.

[30] A. J. Prendergast, "Malnutrition and vaccination in developing countries," *Philos. Trans. R. Soc. B Biol. Sci.*, vol. 370, no. 1671, Jun. 2015, doi: 10.1098/rstb.2014.0141.

[31] L. F. Pittet and K. M. Posfay-Barbe, "Vaccination of immune compromised children—an overview for physicians," *Eur. J. Pediatr.*, vol. 180, no. 7, pp. 2035–2047, Jul. 2021, doi: 10.1007/s00431-021-03997-1.

[32] A. Gagro, "Vaccinating an immunocompromised child," *Period. Biol.*, vol. 114, no. 2, 2012, Accessed: Nov. 12, 2023. [Online]. Available: https://hrcak.srce.hr/file/138507

[33] Nacionalni Inštitut za javno zdravje, "Priporočila za cepljenje oseb z anatomsko ali funkcionalno asplenijo." Accessed: Dec. 09, 2023. [Online]. Available: https://www.nijz.si/sites/www.nijz.si/files/uploaded/2020_priporocila_za_cepljenje_po_splenektomiji.pdf

15

Literatura

[1] Naravna imunost, "Sestavine cepiv," Naravna imunost. Accessed: May 04, 2024. [Online]. Available: https://www.naravnaimunost.si/sestavine-cepiv/

[2] S. C. Corriher, "Vaccine Ingredients and Vaccine Secrets," The Health Wyze Report. Accessed: Nov. 08, 2024. [Online]. Available: https://mail.healthwyze.org/reports/60-vaccine-secrets

[3] P. Grandjean, "Paracelsus Revisited: The Dose Concept in a Complex World," *Basic Clin. Pharmacol. Toxicol.*, vol. 119, no. 2, pp. 126–132, Aug. 2016, doi: 10.1111/bcpt.12622.

[4] Mayo Clinic, "Hyponatremia, Symptoms and causes." Accessed: Nov. 27, 2023. [Online]. Available: https://www.mayoclinic.org/diseases-conditions/hyponatremia/symptoms-causes/syc-20373711

[5] S. S. Arnon *et al.*, "Botulinum toxin as a biological weapon: medical and public health management," *JAMA*, vol. 285, no. 8, pp. 1059–1070, Feb. 2001, doi: 10.1001/jama.285.8.1059.

[6] P. K. Nigam and A. Nigam, "Botulinum toxin," *Indian J. Dermatol.*, vol. 55, no. 1, pp. 8–14, 2010, doi: 10.4103/0019-5154.60343.

[7] University of Oxford, Department of Pediatrics, "Vaccine ingredients." Accessed: Jul. 19, 2018. [Online]. Available: https://vk.ovg.ox.ac.uk/vk/vaccine-ingredients

[8] The College of Physicians of Philadelphia, "Different Types of Vaccines." Accessed: Jul. 19, 2018. [Online]. Available: https://www.historyofvaccines.org/content/articles/different-types-vaccines

[9] E. Hall, P. Wodi A., J. Hamborsky, V. Morelli, and S. Schillie, *Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases*, 14th ed. Washington: Public Health Foundation, 2021. Accessed: Mar. 15, 2021. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html

[10] M. T. Yeh *et al.*, "Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence," *Cell Host Microbe*, vol. 27, no. 5, pp. 736-751.e8, May 2020, doi: 10.1016/j.chom.2020.04.003.

[11] Slovensko zdravniško društvo, Združenje za pediatrijo, "Koledar splošnih obveznih in priporočenih cepljenj." Accessed: Nov. 04, 2023. [Online]. Available: https://www.cepljenje.info/zivljenjska-obdobja/otroci/2/koledar-splosnih-obveznih-in-priporocenih-cepljenj

[12] Sanofi Pasteur, "Hexacima, Summary of product characteristics." Accessed: Dec. 17, 2021. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/hexacima-epar-product-information_sl.pdf

[13] Merck Sharp & Dohme (MSD), "M-M-RvaxPro, Summary of product characteristics." Accessed: Apr. 04, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/m-m-rvaxpro-epar-product-information_sl.pdf

[14] Merck Sharp & Dohme (MSD), "Gardasil 9, Summary of product characteristics." Accessed: Apr. 04, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/gardasil-9-epar-product-information_en.pdf

[15] Centers for Disease Control and Prevention, "Adjuvants and Vaccines." Accessed: Sep. 10, 2021. [Online]. Available: https://www.cdc.gov/vaccine-safety/about/adjuvants.html?CDC_AAref_Val=https://www.cdc.gov/vaccinesafety/concerns/adjuvants.html

[16] D. Krewski *et al.*, "Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide," *J. Toxicol. Environ. Health B Crit. Rev.*, vol. 10, no. Suppl 1, pp. 1–269, 2007, doi: 10.1080/10937400701597766.

[17] C. Hethey, N. Hartung, G. Wangorsch, K. Weisser, and W. Huisinga, "Physiology--based toxicokinetic modelling of aluminium in rat and man," *Arch. Toxicol.*, vol. 95, no. 9, pp. 2977–3000, 2021, doi: 10.1007/s00204-021-03107-y.

[18] The Children's Hospital of Philadelphia, "Aluminum in vaccines: what you should know." Accessed: Jul. 20, 2018. [Online]. Available: https://media.chop.edu/data/files/pdfs/vaccine-education-center-aluminum.pdf

[19] D. Newton and R. Talbot, "Long-term retention of injected aluminium-26," *Hum. Exp. Toxicol.*, vol. 31, no. 12, pp. 1195–1198, Dec. 2012, doi: 10.1177/0960327112441038.

[20] T. I. Lidsky, "Is the Aluminum Hypothesis Dead?," *J. Occup. Environ. Med.*, vol. 56, no. 5 Suppl, pp. S73–S79, May 2014, doi: 10.1097/JOM.0000000000000063.

[21] P. M. Rob, C. Niederstadt, and E. Reusche, "Dementia in patients undergoing long--term dialysis: aetiology, differential diagnoses, epidemiology and management," *CNS Drugs*, vol. 15, no. 9, pp. 691–699, 2001.

[22] GlaxoSmithKline, "Infanrix hexa, Summary of product characteristics." Accessed: Apr. 04, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/infanrix-hexa-epar-product-information_sl.pdf

[23] Pfizer, "Prevenar 13, Summary of product characteristics." Accessed: Apr. 04, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/prevenar-13-epar-product-information_sl.pdf

[24] T. Jefferson, M. Rudin, and C. Di Pietrantonj, "Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence," *Lancet Infect. Dis.*, vol. 4, no. 2, pp. 84–90, Feb. 2004, doi: 10.1016/S1473-3099(04)00927-2.

[25] N. J. Bishop, R. Morley, J. P. Day, and A. Lucas, "Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions," *N. Engl. J. Med.*, vol. 336, no. 22, pp. 1557–1561, May 1997, doi: 10.1056/NEJM199705293362203.

[26] Centers for Disease Control and Prevention, "Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease." Accessed: Jun. 08, 2020. [Online]. Available: https://stacks.cdc.gov/view/cdc/143156/cdc_143156_DS1.pdf

[27] M. Montana, P. Verhaeghe, C. Ducros, T. Terme, P. Vanelle, and P. Rathelot, "Safety review: squalene and thimerosal in vaccines," *Therapie*, vol. 65, no. 6, pp. 533–541, Dec. 2010, doi: 10.2515/therapie/2010069.

[28] Centers for Disease Control and Prevention, "Influenza (Flu) Vaccine Safety." Accessed: Jul. 21, 2024. [Online]. Available: https://www.cdc.gov/vaccine-safety/

vaccines/flu.html?CDC_AAref_Val=https://www.cdc.gov/vaccinesafety/concerns/history/narcolepsy-flu.html

[29] G. Vogel, "Why a pandemic flu shot caused narcolepsy," Science. Accessed: Jul. 21, 2018. [Online]. Available: http://www.sciencemag.org/news/2015/07/why-pandemic-flu-shot-caused-narcolepsy

[30] B. Pulendran, P. Arunachalam S., and D. O'Hagan T., "Emerging concepts in the science of vaccine adjuvants," *Nat. Rev. Drug Discov.*, no. 20, pp. 454–475, 2021.

[31] Johns Hopkins Bloomberg School of Public Health, Institute for Vaccine Safety, "Excipients in routinely recommended vaccines." Accessed: Jul. 19, 2018. [Online]. Available: https://www.vaccinesafety.edu/components-excipients/

[32] Johns Hopkins Bloomberg School of Public Health, Institute for Vaccine Safety, "Excipients in Vaccines Not Routinely Recommended in the US." Accessed: Nov. 08, 2024. [Online]. Available: https://www.vaccinesafety.edu/excipients-in-vaccines-not-routine/

[33] GlaxoSmithKline, "Pandemrix, Package leaflet." Accessed: Apr. 04, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/other/pandemrix-package-leaflet_en.pdf

[34] Viatris Healthcare Limited, "Influvac Tetra, Povzetek glavnih značilnosti zdravila." 2024. Accessed: Apr. 11, 2024. [Online]. Available: http://www.cbz.si/cbz/bazazdr2.nsf/o/0DA496BC45752D49C12583E100002AD4/$File/s-029126.pdf

[35] F. Roman *et al.*, "Adjuvant system AS01: from mode of action to effective vaccines," *Expert Rev. Vaccines*, vol. 23, no. 1, pp. 715–729, Dec. 2024.

[36] G. Leroux-Roels, "Old and new adjuvants for hepatitis B vaccines," *Med. Microbiol. Immunol. (Berl.)*, vol. 204, no. 1, pp. 69–78, Feb. 2015, doi: 10.1007/s00430-014-0375-9.

[37] GlaxoSmithKline, "Mosquirix, WHO Product information." 2022. Accessed: Sep. 14, 2022. [Online]. Available: https://extranet.who.int/prequal/sites/default/files/vwa_vaccine/pq_376_Mosquirix_2dose_GSK_PI.pdf

[38] GlaxoSmithKline, "Shingrix, Package insert." 2023. Accessed: Nov. 23, 2023. [Online]. Available: https://www.fda.gov/media/108597/download

[39] GlaxoSmithKline, "Arexvy, Package insert." 2024. Accessed: Nov. 15, 2024. [Online]. Available: https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert-AREXVY.pdf

[40] GlaxoSmithKline, "Arepanrix, Package leaflet." Accessed: Nov. 15, 2024. [Online]. Available: https://www.ema.europa.eu/en/documents/other/arepanrix-package-leaflet_en.pdf

[41] GlaxoSmithKline, "Fendrix, Summary of product characteristics." Accessed: Nov. 15, 2024. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/fendrix-epar-product-information_en.pdf

[42] GlaxoSmithKline, "Cervarix, Summary of product characteristics." Accessed: Nov. 15, 2024. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/cervarix-epar-product-information_en.pdf

[43] D. Bi *et al.*, "Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18

vaccine in adolescents aged 12–15 years: end-of-study results from a community--randomized study up to 6.5 years," *Hum. Vaccines Immunother.*, vol. 16, no. 6, p. 1392, Dec. 2019, doi: 10.1080/21645515.2019.1692557.

[44] Slovensko zdravniško društvo, Združenje za pediatrijo, "Bolezni in cepiva zanje." Accessed: Jul. 02, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in--cepiva-zanje

[45] European Medicines Agency, "Emea public statement on thiomersal in vaccines for human use - recent evidence supports safety of thiomersal-containing vaccines." 2004. Accessed: Nov. 15, 2023. [Online]. Available: https://www.ema.europa.eu/en/documents/scientific-guideline/emea-public-statement-thiomersal-vaccines-human-use-recent-evidence-supports-safety-thiomersal_en.pdf

[46] National Institutes of Health, "Thimerosal." Accessed: Nov. 12, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/16684434

[47] U.S. Food and Drug Administration, "Thimerosal and Vaccines." Accessed: Jul. 19, 2018. [Online]. Available: https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096228#othr

[48] American Academy of Pediatrics, "Vaccine Safety: Examine the Evidence," HealthyChildren.org. Accessed: Jul. 13, 2018. [Online]. Available: http://www.healthychildren.org/English/safety-prevention/immunizations/Pages/Vaccine-Studies-Examine-the-Evidence.aspx

[49] P. A. Offit and R. K. Jew, "Addressing Parents' Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals?," *Pediatrics*, vol. 112, no. 6, pp. 1394–1397, Dec. 2003.

[50] Vaccine Choice Canada, "Thimerosal Containing Vaccines and Neurodevelopment Outcomes." Accessed: Jul. 20, 2018. [Online]. Available: https://vaccinechoicecanada.com/vaccine-ingredients/thimerosal-containing-vaccines-and-neurodevelopment-outcomes/

[51] L. Magos, "Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical products," *J. Appl. Toxicol.*, vol. 21, no. 1, pp. 1–5, doi: 10.1002/jat.721.

[52] World Health Organization, "Weight-for-age." Accessed: Nov. 15, 2024. [Online]. Available: https://www.who.int/tools/child-growth-standards/standards/weight--for-age

[53] Medscape, "Estimated Blood Volume Calculator." Accessed: Jul. 20, 2020. [Online]. Available: https://reference.medscape.com/calculator/estimated-blood-volume

[54] J. G. Dórea, M. Farina, and J. B. T. Rocha, "Toxicity of ethylmercury (and Thimerosal): a comparison with methylmercury," *J. Appl. Toxicol. JAT*, vol. 33, no. 8, pp. 700–711, Aug. 2013, doi: 10.1002/jat.2855.

[55] M. E. Pichichero *et al.*, "Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines," *Pediatrics*, vol. 121, no. 2, pp. e208-214, Feb. 2008, doi: 10.1542/peds.2006-3363.

[56] Vaclib.org, "Vaccine excipient & media summary." Accessed: Jul. 28, 2018. [Online].

Available: http://www.vaclib.org/basic/MSDSwithVaxInsertInfo.pdf
[57] Centers for Disease Control and Prevention, "Vaccine excipient & media summary." 2021. Accessed: Aug. 21, 2022. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
[58] National Institutes of Health, "Phenol." Accessed: Nov. 10, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/996
[59] Agency for Toxic Substances and Disease Registry, "Phenol." Accessed: Nov. 09, 2023. [Online]. Available:https://wwwn.cdc.gov/TSP/PHS/PHS.aspx?phsid=146&toxid=27
[60] P. L. Gomez, J. M. Robinson, and J. A. Rogalewicz, "Vaccine manufacturing," *Vaccines*, p. 44, Nov. 2012, doi: 10.1016/B978-1-4557-0090-5.00019-7.
[61] National Institutes of Health, "2-Phenoxyethanol." Accessed: Nov. 09, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/31236
[62] National Institutes of Health, "Ethylene Glycol." Accessed: Jun. 24, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/174
[63] B. Dréno, T. Zuberbier, C. Gelmetti, G. Gontijo, and M. Marinovich, "Safety review of phenoxyethanol when used as a preservative in cosmetics," *J. Eur. Acad. Dermatol. Venereol.*, vol. 33, no. S7, pp. 15–24, 2019, doi: 10.1111/jdv.15944.
[64] Gospodarska zbornica Slovenije, Združenje kemijske industrije, Sekcija proizvajalcev kozmetike, čistil in pralnih sredstev, "Kaj se nahaja v kozmetičnih izdelkih?" Accessed: Jun. 06, 2024. [Online]. Available: https://www.gzs.si/lepota-kozmetike/vsebina/Kaj-je-v-izdelkih#F
[65] U. Musshoff, M. Madeja, N. Binding, U. Witting, and E. J. Speckmann, "Effects of 2-phenoxyethanol on N-methyl-D-aspartate (NMDA) receptor-mediated ion currents," *Arch. Toxicol.*, vol. 73, no. 1, pp. 55–59, Feb. 1999.
[66] W. E. Morton, "Occupational phenoxyethanol neurotoxicity: a report of three cases," *J. Occup. Med. Off. Publ. Ind. Med. Assoc.*, vol. 32, no. 1, pp. 42–45, Jan. 1990.
[67] National Institutes of Health, "Sorbitol." Accessed: Nov. 08, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/5780
[68] Merck, Sharpe and Dohme (MSD), "ProQuad, Summary of product characteristics." Accessed: Nov. 08, 2024. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/proquad-epar-product-information_en.pdf
[69] U.S. Food and Drug Administration, "Questions and Answers on Monosodium glutamate (MSG)," *FDA*, 2012, Accessed: Nov. 15, 2023. [Online]. Available: https://www.fda.gov/food/food-additives-petitions/questions-and-answers-monosodium-glutamate-msg
[70] K. Beyreuther *et al.*, "Consensus meeting: monosodium glutamate - an update," *Eur. J. Clin. Nutr.*, vol. 61, no. 3, pp. 304–313, Mar. 2007, doi: 10.1038/sj.ejcn.1602526.
[71] Univerza v Ljubljani, Medicinska fakulteta, "Farmakologija." Accessed: Nov. 20, 2023. [Online]. Available: https://www.mf.uni-lj.si/o-studiju/drugi-studijski-programi/ems-program-farmacija/farmakologija?q=%2Fo-studiju%2Fdrugi-studijski-programi%2Fems-program-farmacija%2Ffarmakologija
[72] National Institutes of Health, "Polysorbate 80." Accessed: Nov. 20, 2024. [Online].

Available: https://pubchem.ncbi.nlm.nih.gov/compound/Polysorbate-80

[73] European Medicines Agency, "Information for the package leaflet regarding polysorbates used as excipients in medicinal products for human use," 2018, Accessed: May 06, 2019. [Online]. Available: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-regarding-polysorbates--used-excipients-medicinal-products-human_en.pdf

[74] V. Ravichandran, M. Lee, T. G. Nguyen Cao, and M. S. Shim, "Polysorbate-Based Drug Formulations for Brain-Targeted Drug Delivery and Anticancer Therapy," *Appl. Sci.*, vol. 11, no. 19, Art. no. 19, Jan. 2021, doi: 10.3390/app11199336.

[75] M. K. Spigelman *et al.*, "Effect of intracarotid etoposide on opening the blood--brain barrier," *Cancer Drug Deliv.*, vol. 1, no. 3, pp. 207–211, 1984, doi: 10.1089/cdd.1984.1.207.

[76] J. Gadzinowski *et al.*, "Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of age," *Pediatr. Infect. Dis. J.*, vol. 34, no. 2, pp. 180–185, Feb. 2015, doi: 10.1097/INF.0000000000000511.

[77] P. J. Turner *et al.*, "Safety of live attenuated influenza vaccine in atopic children with egg allergy," *J. Allergy Clin. Immunol.*, vol. 136, no. 2, pp. 376–381, Aug. 2015, doi: 10.1016/j.jaci.2014.12.1925.

[78] L. Wang *et al.*, "Therapeutic peptides: current applications and future directions," *Signal Transduct. Target. Ther.*, vol. 7, no. 1, Art. no. 1, Feb. 2022, doi: 10.1038/s41392-022-00904-4.

[79] A. Kraigher, A. Ihan, and T. Avčin, *Cepljenje in cepiva - dobre prakse varnega cepljenja: univerzitetni učbenik za študente medicinske in zdravstvene fakultete*. Ljubljana: Sekcija za preventivno medicino SZD : Sekcija za klinično mikrobiologijo in bolnišnične okužbe SZD : Inštitut za varovanje zdravja RS, 2011.

[80] U.S. Food and Drug Administration, "Bovine Derived Materials Used in Vaccine Manufacturing Questions and Answers." Accessed: Jul. 19, 2018. [Online]. Available: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm143521.htm

[81] National Catholic Bioethics Center, "FAQ on the Use of Vaccines." Accessed: Apr. 20, 2019. [Online]. Available: https://www.ncbcenter.org/resources-and-statements--cms/faq-on-the-use-of-vaccines?rq=FAQ%20on%20the%20Use%20of%20Vaccines

[82] P. A. Offit, "Vaccine Ingredients: DNA." Accessed: Jun. 24, 2024. [Online]. Available: https://www.chop.edu/centers-programs/vaccine-education-center/vaccine--ingredients/dna

[83] H. V. Ratajczak, "Theoretical aspects of autism: causes--a review," *J. Immunotoxicol.*, vol. 8, no. 1, pp. 68–79, Mar. 2011, doi: 10.3109/1547691X.2010.545086.

[84] K. Stratton, D. A. Almario, and M. C. McCormick, "Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer," in *Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer*, National Academies Press (US), 2002. Accessed: Jun. 26, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/

books/NBK221112/

[85] J. C. Rotondo, E. Mazzoni, I. Bononi, M. Tognon, and F. Martini, "Association Between Simian Virus 40 and Human Tumors," *Front. Oncol.*, vol. 9, Jul. 2019, doi: 10.3389/fonc.2019.00670.

[86] I. Hussain *et al.*, "Human BK and JC polyomaviruses: Molecular insights and prevalence in Asia," *Virus Res.*, vol. 278, p. 197860, Mar. 2020, doi: 10.1016/j.virusres.2020.197860.

[87] J. S. Butel, A. S. Arrington, C. Wong, J. A. Lednicky, and M. J. Finegold, "Molecular Evidence of Simian Virus 40 Infections in Children," *J. Infect. Dis.*, vol. 180, no. 3, pp. 884–887, Sep. 1999, doi: 10.1086/314915.

[88] Centers for Disease Control and Prevention, "Historical Vaccine Safety Concerns." Accessed: Mar. 22, 2019. [Online]. Available: https://www.cdc.gov/vaccinesafety/concerns/concerns-history.html

[89] H. H. Han, N. Karkada, G. Jayadeva, and G. Dubin, "Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, Rotarix™: A retrospective laboratory analysis," *Hum. Vaccines Immunother.*, vol. 13, no. 1, pp. 237–244, Sep. 2016, doi: 10.1080/21645515.2016.1231262.

[90] J. Ellis, "Porcine circovirus: a historical perspective," *Vet. Pathol.*, vol. 51, no. 2, pp. 315–327, Mar. 2014, doi: 10.1177/0300985814521245.

[91] B. L. Fisher, "Vaccine Contamination: A Threat To Human Health." Accessed: Jun. 30, 2024. [Online]. Available: https://www.nvic.org/newsletter/may-2010/vaccine--contamination-a-threat-to-human-health

[92] J. Guo *et al.*, "Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances," *Viruses*, vol. 14, no. 9, p. 2005, Sep. 2022, doi: 10.3390/v14092005.

[93] Q. Yu, Y. Liu, J. Du, Y. Liu, L. Zhang, and T. Guo, "Porcine circovirus type 1 was undetected in vaccine but could be cultured in the cell substrate of Lanzhou lamb rotavirus vaccine," *J. Gen. Virol.*, vol. 99, no. 1, pp. 103–108, Jan. 2018, doi: 10.1099/jgv.0.000875.

[94] H. Ma, S. Shaheduzzaman, D. K. Willliams, Y. Gao, and A. S. Khan, "Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines," *Vaccine*, vol. 29, no. 46, pp. 8429–8437, Oct. 2011, doi: 10.1016/j.vaccine.2011.07.123.

[95] U.S. Food and Drug Administration, "Vaccines, Blood and Biologics, Approved Products, Information for Parents and Caregivers." Accessed: Jul. 19, 2018. [Online]. Available: https://wayback.archive-it.org/7993/20170723151910/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm205547.htm

[96] S. Razin and L. Hayflick, "Highlights of mycoplasma research--an historical perspective," *Biol. J. Int. Assoc. Biol. Stand.*, vol. 38, no. 2, pp. 183–190, Mar. 2010, doi: 10.1016/j.biologicals.2009.11.008.

[97] C. Morris, Y. S. Lee, and S. Yoon, "Adventitious agent detection methods in bio-pharmaceutical applications with a focus on viruses, bacteria, and mycoplasma," *Curr. Opin. Biotechnol.*, vol. 71, pp. 105–114, Oct. 2021, doi: 10.1016/j.copbio.2021.06.027.

[98] A. Lovatt, "Detection of mycoplasma in biopharmaceuticals vaccines and gene

cell therapies," *Eur. Pharm. Rev.*, 2019, Accessed: Jul. 01, 2024. [Online]. Available: https://www.europeanpharmaceuticalreview.com/pdf/110727/detection-of-mycoplasma-in-biopharmaceuticals-vaccines-and-gene-cell-therapies/

[99] S. A. W. David, D. V. Volokhov, Z. Ye, and V. Chizhikov, "Evaluation of Mycoplasma Inactivation during Production of Biologics: Egg-Based Viral Vaccines as a Model," *Appl. Environ. Microbiol.*, vol. 76, no. 9, pp. 2718–2728, May 2010, doi: 10.1128/AEM.02776-09.

[100] C. Escudero, P. Prieto-Montaño, and M. T. Audicana, "Adverse Reactions to Anti--Infective Vaccines: an Emerging Problem in the COVID-19 Era," *Curr. Treat. Options Allergy*, vol. 9, no. 3, pp. 250–272, 2022, doi: 10.1007/s40521-022-00311-8.

[101] Drugsite Limited, "Neomycin Dosage Guide with Precautions," Drugs.com. Accessed: Jul. 19, 2018. [Online]. Available: https://www.drugs.com/dosage/neomycin.html

[102] P. L. Kwittken, S. Rosen, and S. K. Sweinberg, "MMR Vaccine and Neomycin Allergy," *Am. J. Dis. Child.*, vol. 147, no. 2, pp. 128–129, 1993, doi: 10.1001/archpedi.1993.02160260018005.

[103] National Institutes of Health, "Ammonium Sulfate." Accessed: Nov. 08, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/6097028

[104] S. A. Plotkin, P. A. Offit, W. A. Orenstein, and K. M. Edwards, *Plotkin's vaccines*. Elsevier, 2018.

[105] Centers for Disease Control and Prevention, "Adenovirus Vaccine Information Statement." Accessed: Nov. 09, 2023. [Online]. Available: https://www.cdc.gov/vaccines/hcp/vis/vis-statements/adenovirus.html

[106] G. Sam, J. Stenos, S. R. Graves, and B. H. A. Rehm, "Q fever immunology: the quest for a safe and effective vaccine," *NPJ Vaccines*, vol. 8, no. 1, pp. 1–14, Sep. 2023, doi: 10.1038/s41541-023-00727-6.

[107] Nacionalni Inštitut za javno zdravje, "Vročica Q." Accessed: Jul. 01, 2024. [Online]. Available: https://nijz.si/nalezljive-bolezni/nalezljive-bolezni-od-a-do-z/vrocica-q/

[108] J. A. Kiernan, "Formaldehyde, formalin, paraformaldehyde and glutaraldehyde: What they are and what they do.," *Microsc. Today*, vol. 8, no. 1, pp. 8–13, 2000, doi: 10.1017/S1551929500057060.

[109] P. A. Offit, "Vaccine Ingredients: Formaldehyde." Accessed: Nov. 10, 2023. [Online]. Available: https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-ingredients/formaldehyde

[110] Y. Li, J. Ou, C. Huang, F. Liu, S. Ou, and J. Zheng, "Chemistry of formation and elimination of formaldehyde in foods," *Trends Food Sci. Technol.*, vol. 139, p. 104134, Sep. 2023, doi: 10.1016/j.tifs.2023.104134.

[111] National Institutes of Health, "Formaldehyde." Accessed: Nov. 15, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/712

[112] A. Songur, O. A. Ozen, and M. Sarsilmaz, "The toxic effects of formaldehyde on the nervous system," *Rev. Environ. Contam. Toxicol.*, vol. 203, pp. 105–118, 2010, doi: 10.1007/978-1-4419-1352-4_3.

[113] U.S. Food and Drug Administration, "Common Ingredients in FDA - Approved

Vaccines." Accessed: Jun. 06, 2019. [Online]. Available: http://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-us-licensed-vaccines

[114] National Institutes of Health, "Glutaraldehyde." Accessed: Jul. 19, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/3485

[115] S. M. Ravis, M. P. Shaffer, C. L. Shaffer, S. Dehkharghani, S. Dehkhaghani, and D. V. Belsito, "Glutaraldehyde-induced and formaldehyde-induced allergic contact dermatitis among dental hygienists and assistants," *J. Am. Dent. Assoc. 1939*, vol. 134, no. 8, pp. 1072–1078, Aug. 2003.

[116] P. F. Gannon, P. Bright, M. Campbell, S. P. O'Hickey, and P. S. Burge, "Occupational asthma due to glutaraldehyde and formaldehyde in endoscopy and x ray departments.," *Thorax*, vol. 50, no. 2, pp. 156–159, Feb. 1995, doi: 10.1136/thx.50.2.156.

[117] National Toxicology Program, "NTP Toxicology and Carcinogenesis Studies of Glutaraldehyde (CAS NO. 111-30-8) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)," *Natl. Toxicol. Program Tech. Rep. Ser.*, vol. 490, pp. 1–234, Sep. 1999.

[118] Centers for Disease Control and Prevention, "About Diphtheria, Tetanus, and Pertussis Vaccination." Accessed: Jul. 19, 2024. [Online]. Available: https://www.cdc.gov/vaccines/vpd/dtap-tdap-td/hcp/about-vaccine.html

[119] National Institutes of Health, "Borax." Accessed: Nov. 22, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/16211214

[120] M. Petrovič, "Boraks – čudežno naravno čistilo in belilo?," Bodi eko - prvi slovenski eko portal. Accessed: Jul. 20, 2018. [Online]. Available: https://www.bodieko.si/boraks

[121] Oregon State University, National Pesticide Information Center, "Boric Acid Technical Fact Sheet." Accessed: Apr. 06, 2020. [Online]. Available: http://npic.orst.edu/factsheets/archive/borictech.html

[122] I. Carballo-Carbajal, "Tromethamine in the Pfizer-BioNTech COVID-19 vaccine for children acts to improve the stability of the vaccine; it isn't in the vaccine as a heart medication," Science Feedback. Accessed: Nov. 08, 2024. [Online]. Available: https://science.feedback.org/review/tromethamine-in-the-pfizer-biontech-covid-19-vaccine-for-children-acts-to-improve-the-stability-of-the-vaccine-it-isnt-in-the-vaccine-as-a-heart-medication/

[123] National Institutes of Health, "Tromethamine." Accessed: Nov. 08, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/6503

[124] Hospira Inc., "Tham Solution, Tromethamine Injection, Package insert." 2005. Accessed: Nov. 08, 2024. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/013025s040lbl.pdf

[125] National Institutes of Health, "Propiolactone." Accessed: Nov. 08, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/2365

[126] National Institutes of Health, "Potassium thiocyanate." Accessed: Nov. 11, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/516872

[127] Merck Sharp & Dohme (MSD), "HBVaxPro, Summary of products characteristics."

Accessed: Nov. 22, 2023. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/hbvaxpro-epar-product-information_sl.pdf
[128] Merck & Co., "Vaqta, Package insert." Accessed: Nov. 18, 2024. [Online]. Available: https://www.fda.gov/media/74519/download
[129] Novartis, "Bexsero, Povzetek glavnih značilnosti zdravila." Accessed: Nov. 22, 2023. [Online]. Available: https://ec.europa.eu/health/documents/community-register/2013/20130114125155/anx_125155_sl.pdf
[130] Bavarian Nordic A/S, "Encepur, Povzetek glavnih značilnosti zdravila." Accessed: Nov. 22, 2023. [Online]. Available: http://www.cbz.si/zzzs/pao/bazazdr2.nsf/o/4B220A09E1979BC4C12579EC001FFBFA/$File/s-025164.pdf
[131] Nacionalni Inštitut za javno zdravje, "Pojasnilna dolžnost pred cepljenjem." Accessed: Jul. 20, 2024. [Online]. Available: http://www.nijz.si/sl/pojasnilna-dolznost--pred-cepljenjem
[132] M. Russell, V. Pool, J. M. Kelso, and V. J. Tomazic-Jezic, "Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS)," *Vaccine*, vol. 23, no. 5, pp. 664–667, Dec. 2004, doi: 10.1016/j.vaccine.2004.06.042.
[133] A. M Gatti and S. Montanari, "New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination," *Int. J. Vaccines Vaccin.*, vol. 4, no. 1, Jan. 2017, doi: 10.15406/ijvv.2017.04.00072.
[134] D. Gorski, "I love it when an antivax 'study' meant to show how 'dirty' vaccines are backfires so spectacularly." Accessed: Jan. 13, 2020. [Online]. Available: https://respectfulinsolence.com/2017/02/02/antivaccinationists-try-to-show-vaccines-are--dirty-but-really-show-that-they-are-amazingly-free-from-contamination/
[135] P. Home and B. Itzhak, "Is Insulin Therapy Safe?," *Am. J. Ther.*, vol. 27, no. 1, pp. e106–e114, 2020, doi: 10.1097/MJT.0000000000001077.
[136] S. Lv, J. Wang, and Y. Xu, "Safety of insulin analogs during pregnancy: a meta--analysis," *Arch. Gynecol. Obstet.*, vol. 292, no. 4, pp. 749–756, Oct. 2015, doi: 10.1007/s00404-015-3692-3.
[137] M. K. Smatti, F. S. Cyprian, G. K. Nasrallah, A. A. Al Thani, R. O. Almishal, and H. M. Yassine, "Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms," *Viruses*, vol. 11, no. 8, p. 762, Aug. 2019, doi: 10.3390/v11080762.

16

Literatura

[1] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[2] D. Krewski *et al.*, "Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide," *J. Toxicol. Environ. Health B Crit. Rev.*, vol. 10, no. Suppl 1, pp. 1–269, 2007, doi: 10.1080/10937400701597766.

[3] N. D. Priest, "The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update," *J. Environ. Monit. JEM*, vol. 6, no. 5, pp. 375–403, May 2004, doi: 10.1039/b314329p.

[4] C. C. Willhite *et al.*, "Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts," *Crit. Rev. Toxicol.*, vol. 44, no. Suppl 4, pp. 1–80, Oct. 2014, doi: 10.3109/10408444.2014.934439.

[5] R. Ameratunga, D. Gillis, M. Gold, A. Linneberg, and J. M. Elwood, "Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)," *J. Allergy Clin. Immunol. Pract.*, vol. 5, no. 6, pp. 1551-1555.e1, Nov. 2017, doi: 10.1016/j.jaip.2017.06.033.

[6] Centers for Disease Control and Prevention, "Adjuvants and Vaccines." Accessed: Sep. 10, 2021. [Online]. Available: https://www.cdc.gov/vaccine-safety/about/adjuvants.html?CDC_AAref_Val=https://www.cdc.gov/vaccinesafety/concerns/adjuvants.html

[7] The Children's Hospital of Philadelphia, "Vaccine Ingredients - Aluminum." Accessed: Feb. 06, 2020. [Online]. Available: https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-ingredients/aluminum

[8] Sanofi Pasteur, "Hexacima, Summary of product characteristics." Accessed: Dec. 17, 2021. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/hexacima-epar-product-information_sl.pdf

[9] Pfizer, "Prevenar 13, Summary of product characteristics." Accessed: Apr. 04, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/prevenar-13-epar-product-information_sl.pdf

[10] Merck Sharp & Dohme (MSD), "Gardasil 9, Summary of product characteristics." Accessed: Apr. 04, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/gardasil-9-epar-product-information_en.pdf

[11] Slovensko zdravniško društvo, Združenje za pediatrijo, "Koledar splošnih obveznih in priporočenih cepljenj." Accessed: Nov. 04, 2023. [Online]. Available: https://www.cepljenje.info/zivljenjska-obdobja/otroci/2/koledar-splosnih-obveznih-in-priporocenih-cepljenj

[12] P. Marrack, A. S. McKee, and M. W. Munks, "Towards an understanding of the adjuvant action of aluminium," *Nat. Rev. Immunol.*, vol. 9, no. 4, pp. 287–293, Apr. 2009, doi: 10.1038/nri2510.

[13] E. Nirenberg, "In defense of aluminum-based vaccine adjuvants: much ado about nothing." Accessed: Jun. 08, 2020. [Online]. Available: https://medium.com/@edwardnirenberg/in-defense-of-aluminum-based-vaccine-adjuvants-much-ado-about-nothing-633151d35c30

[14] P. He, Y. Zou, and Z. Hu, "Advances in aluminum hydroxide-based adjuvant research and its mechanism," *Hum. Vaccines Immunother.*, vol. 11, no. 2, pp. 477–488, Feb. 2015, doi: 10.1080/21645515.2014.1004026.

[15] H. HogenEsch, D. T. O'Hagan, and C. B. Fox, "Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want," *NPJ Vaccines*, vol. 3, no. 51, 2018, doi: 10.1038/s41541-018-0089-x.

[16] European Commission, Joint Research Centre, "Toxicokinetics." Accessed: Apr. 18, 2024. [Online]. Available: https://joint-research-centre.ec.europa.eu/eu-reference-laboratory-alternatives-animal-testing-eurl-ecvam/alternative-methods-toxicity-testing/validated-test-methods-health-effects/toxicokinetics_en

[17] European Food Safety Authority (EFSA), "Safety of aluminium from dietary intake - Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Food Contact Materials (AFC)," *EFSA J. Eur. Food Saf. Auth.*, vol. 6, no. 7, p. 754, Jul. 2008, doi: 10.2903/j.efsa.2008.754.

[18] R. J. Mitkus, D. B. King, M. A. Hess, R. A. Forshee, and M. O. Walderhaug, "Updated aluminum pharmacokinetics following infant exposures through diet and vaccination," *Vaccine*, vol. 29, no. 51, pp. 9538–9543, Nov. 2011, doi: 10.1016/j.vaccine.2011.09.124.

[19] A. Al-Ahmad, "Debunking the aluminum fact sheet of PIC." Accessed: Apr. 18, 2024. [Online]. Available: https://scientistabe.wordpress.com/

[20] R. E. Flarend *et al.*, "In vivo absorption of aluminium-containing vaccine adjuvants using 26Al," *Vaccine*, vol. 15, no. 12, pp. 1314–1318, Aug. 1997, doi: 10.1016/S0264-410X(97)00041-8.

[21] L. Tomljenovic and C. A. Shaw, "Aluminum vaccine adjuvants: are they safe?," *Curr. Med. Chem.*, vol. 18, no. 17, pp. 2630–2637, 2011, doi: 10.2174/092986711795933740.

[22] World Health Organization, "Aluminium adjuvants," *Wkly. Epidemiol. Rec.*, vol. 87, no. 30, pp. 277–288, 2012.

[23] C. Hethey, N. Hartung, G. Wangorsch, K. Weisser, and W. Huisinga, "Physiology-based toxicokinetic modelling of aluminium in rat and man," *Arch. Toxicol.*, vol. 95, no. 9, pp. 2977–3000, 2021, doi: 10.1007/s00204-021-03107-y.

[24] D. Newton and R. Talbot, "Long-term retention of injected aluminium-26," *Hum. Exp. Toxicol.*, vol. 31, no. 12, pp. 1195–1198, Dec. 2012, doi: 10.1177/0960327112441038.

[25] Z. Khan *et al.*, "Slow CCL2-dependent translocation of biopersistent particles from muscle to brain," *BMC Med.*, vol. 11, p. 99, Apr. 2013, doi: 10.1186/1741-7015-11-99.

[26] K. Klotz, W. Weistenhöfer, F. Neff, A. Hartwig, C. van Thriel, and H. Drexler, "The Health Effects of Aluminum Exposure," *Dtsch. Arzteblatt Int.*, vol. 114, no. 39, pp. 653–659, Sep. 2017, doi: 10.3238/arztebl.2017.0653.

[27] Y. Chen, X. Tian, and X. Wang, "Advances in dialysis encephalopathy research: a

review," *Neurol. Sci.*, vol. 39, no. 7, pp. 1151–1159, Jul. 2018, doi: 10.1007/s10072-018-3426-y.

[28] M. R. Rahimzadeh, M. R. Rahimzadeh, S. Kazemi, R. J. Amiri, M. Pirzadeh, and A. A. Moghadamnia, "Aluminum Poisoning with Emphasis on Its Mechanism and Treatment of Intoxication," *Emerg. Med. Int.*, vol. 2022, p. 1480553, Jan. 2022, doi: 10.1155/2022/1480553.

[29] P. Löffler, "Review: Vaccine Myth-Buster – Cleaning Up With Prejudices and Dangerous Misinformation," *Front. Immunol.*, vol. 12, p. 663280, Jun. 2021, doi: 10.3389/fimmu.2021.663280.

[30] N. J. Bishop, R. Morley, J. P. Day, and A. Lucas, "Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions," *N. Engl. J. Med.*, vol. 336, no. 22, pp. 1557–1561, May 1997, doi: 10.1056/NEJM199705293362203.

[31] M. S. Fewtrell, C. J. Edmonds, E. Isaacs, N. J. Bishop, and A. Lucas, "Aluminium exposure from parenteral nutrition in preterm infants and later health outcomes during childhood and adolescence," *Proc. Nutr. Soc.*, vol. 70, no. 3, pp. 299–304, Aug. 2011, doi: 10.1017/S0029665111000498.

[32] T. Jefferson, M. Rudin, and C. Di Pietrantonj, "Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence," *Lancet Infect. Dis.*, vol. 4, no. 2, pp. 84–90, Feb. 2004, doi: 10.1016/S1473-3099(04)00927-2.

[33] Centers for Disease Control and Prevention, "Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease." Accessed: Jun. 08, 2020. [Online]. Available: https://stacks.cdc.gov/view/cdc/143156/cdc_143156_DS1.pdf

[34] N. Janus, L.-V. Vacher, S. Karie, E. Ledneva, and G. Deray, "Vaccination and chronic kidney disease," *Nephrol. Dial. Transplant.*, vol. 23, no. 3, pp. 800–807, Mar. 2008, doi: 10.1093/ndt/gfm851.

[35] R. Sam *et al.*, "Vaccination for Patients Receiving Dialysis," *Kidney Med.*, vol. 6, no. 3, p. 100775, Mar. 2024, doi: 10.1016/j.xkme.2023.100775.

[36] R. D. Terry and C. Peña, "Experimental Production of Neurofibrillary Degeneration: 2. Electron Microscopy, Phosphatase Histochemistry and Electron Prose Analysis*†," *J. Neuropathol. Exp. Neurol.*, vol. 24, no. 2, pp. 200–210, Apr. 1965, doi: 10.1097/00005072-196504000-00003.

[37] D. R. Crapper, S. S. Krishnan, and A. J. Dalton, "Brain Aluminum Distribution in Alzheimer's Disease and Experimental Neurofibrillary Degeneration," *Science*, vol. 180, no. 4085, pp. 511–513, May 1973, doi: 10.1126/science.180.4085.511.

[38] I. Grundke-Iqbal, G. P. Wang, K. Iqbal, Y. C. Tung, and H. M. Wisniewski, "Alzheimer paired helical filaments: identification of polypeptides with monoclonal antibodies," *Acta Neuropathol. (Berl.)*, vol. 68, no. 4, pp. 279–283, 1985, doi: 10.1007/BF00690830.

[39] A. H. Chafi, J.-J. Hauw, G. Rancurel, J.-P. Berry, and C. Galle, "Absence of aluminium in Alzheimer's disease brain tissue: Electron microprobe and ion microprobe studie," *Neurosci. Lett.*, vol. 123, no. 1, pp. 61–64, Feb. 1991, doi: 10.1016/0304-3940(91)90158-P.

[40] M. A. Lovell, W. D. Ehmann, and W. R. Markesberry, "Laser microprobe analysis of brain aluminum in Alzheimer's disease," *Ann. Neurol.*, vol. 33, no. 1, pp. 36–42, 1993, doi: 10.1002/ana.410330107.

[41] S. A. Virk and G. D. Eslick, "Aluminum Levels in Brain, Serum, and Cerebrospinal Fluid are Higher in Alzheimer's Disease Cases than in Controls: A Series of Meta--Analyses," *J. Alzheimers Dis. JAD*, vol. 47, no. 3, pp. 629–638, 2015, doi: 10.3233/JAD-150193.

[42] S. A. Virk and G. D. Eslick, "Occupational Exposure to Aluminum and Alzheimer Disease: A Meta-Analysis," *J. Occup. Environ. Med.*, vol. 57, no. 8, pp. 893–896, Aug. 2015, doi: 10.1097/JOM.0000000000000487.

[43] E. Reusche, V. Koch, B. Lindner, A. P. Harrison, and H. J. Friedrich, "Alzheimer morphology is not increased in dialysis-associated encephalopathy and long-term hemodialysis," *Acta Neuropathol. (Berl.)*, vol. 101, no. 3, pp. 211–216, Mar. 2001, doi: 10.1007/s004010000253.

[44] N. Van Dyke *et al.*, "Association between aluminum in drinking water and incident Alzheimer's disease in the Canadian Study of Health and Aging cohort," *NeuroToxicology*, vol. 83, pp. 157–165, Mar. 2021, doi: 10.1016/j.neuro.2020.04.002.

[45] E. Bergfors, B. Trollfors, and A. Inerot, "Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer," *Vaccine*, vol. 22, no. 1, pp. 64–69, Dec. 2003, doi: 10.1016/S0264-410X(03)00531-0.

[46] E. Bergfors, B. Trollfors, A. Inerot, and A. Gente Lidholm, "Contact allergy to aluminium induced by commonly used pediatric vaccines," *Clin. Transl. Med.*, vol. 6, Jan. 2017, doi: 10.1186/s40169-016-0129-y.

[47] K. K. Dewan, B. Linz, S. E. DeRocco, and E. T. Harvill, "Acellular Pertussis Vaccine Components: Today and Tomorrow," *Vaccines*, vol. 8, no. 2, Art. no. 2, Jun. 2020, doi: 10.3390/vaccines8020217.

[48] R. K. Gherardi *et al.*, "Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM)," *Lancet Lond. Engl.*, vol. 352, no. 9125, pp. 347–352, Aug. 1998, doi: 10.1016/s0140-6736(98)02326-5.

[49] R. K. Gherardi and F.-J. Authier, "Macrophagic myofasciitis: characterization and pathophysiology," *Lupus*, vol. 21, no. 2, pp. 184–189, Feb. 2012, doi: 10.1177/0961203311429557.

[50] G. Crépeaux *et al.*, "Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity," *Toxicology*, vol. 375, pp. 48–57, Jan. 2017, doi: 10.1016/j.tox.2016.11.018.

[51] J. Boulier, "Gherardi: a media story (2 or 3 embarrassing truths about his research)," Rougeole Epidémiologie. Accessed: Apr. 03, 2019. [Online]. Available: http://rougeole-epidemiologie.overblog.com/2017/10/gherardi-a-media-story-2-or-3-embarrassing-truths-about-his-research.html

[52] A. Batista-Duharte, E. B. Lindblad, and E. Oviedo-Orta, "Progress in understanding

adjuvant immunotoxicity mechanisms," *Toxicol. Lett.*, vol. 203, no. 2, pp. 97–105, Jun. 2011, doi: 10.1016/j.toxlet.2011.03.001.

[53] World Health Organization, "Statements by WHO Global Advisory Committee on Vaccine Safety on the safety of human papillomavirus (HPV) vaccines 2013–2016." 2016. Accessed: Apr. 17, 2019. [Online]. Available: https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Oct2016/3_session_report_from_advisory_committees/Oct2016_session3_GACVS.pdf

[54] D. Hawkes, J. Benhamu, T. Sidwell, R. Miles, and R. A. Dunlop, "Revisiting adverse reactions to vaccines: A critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA)," *J. Autoimmun.*, vol. 59, pp. 77–84, May 2015, doi: 10.1016/j.jaut.2015.02.005.

[55] L. Prestor and M. Bratkovič, Eds., *Zdravstvena nega pacienta z astmo in alergijo; zbornik predavanj z recenzijo*. Maribor: Zbornica zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, Sekcija medicinskih sester in zdravstvenih tehnikov v pulmologiji, 2012. Accessed: May 04, 2019. [Online]. Available: https://www.zbornica-zveza.si/wp-content/uploads/2019/12/Zdravstvena-nega-pacienta-z-astmo-in-alergijo-2012.pdf

[56] A. Linneberg, R. K. Jacobsen, L. Jespersen, and S. Z. Abildstrøm, "Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality," *J. Allergy Clin. Immunol.*, vol. 129, no. 2, pp. 413–419, Feb. 2012, doi: 10.1016/j.jaci.2011.09.007.

17

Literatura

[1] T. Deisher, "Sound Choice Institute - About us," Sound Choice. Accessed: Mar. 09, 2024. [Online]. Available: https://soundchoice.org/about/

[2] T. Deisher and K. Koyama, "Spontaneous Integration of Human DNA Fragments into Host Genome." Accessed: Mar. 09, 2024. [Online]. Available: https://soundchoice.org/wp-content/uploads/2021/01/DNA_Contaminants_in_Vaccines_Can_Integrate_Into_Childrens_Genes.pdf

[3] T. Deisher, "Our research," Sound Choice. Accessed: Jul. 13, 2024. [Online]. Available: https://soundchoice.org/our-research/

[4] F. Horaud, "Viral vaccines and residual cellular DNA," *Biol. J. Int. Assoc. Biol. Stand.*, vol. 23, no. 3, pp. 225–228, Sep. 1995, doi: 10.1006/biol.1995.0037.

[5] The College of Physicians of Philadelphia, "Human Cell Strains in Vaccine Development." Accessed: Apr. 17, 2019. [Online]. Available: https://www.historyofvaccines.org/index.php/content/articles/human-cell-strains-vaccine-development

[6] C. A. Moser and P. A. Offit, "News & Views: Getting Familiar with COVID-19 Adenovirus-replication-deficient Vaccines." Accessed: Sep. 22, 2022. [Online]. Available: https://www.chop.edu/news/news-views-getting-familiar-covid-19-adenovirus-replication-deficient-vaccines

[7] R. K. Zimmerman, "Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines," *Vaccine*, vol. 39, no. 31, pp. 4242–4244, Jul. 2021, doi: 10.1016/j.vaccine.2021.06.027.

[8] T. Deisher, V. D. Ngoc, O. Angelica, K. Kumiko, and B. Sarah, "Impact of environmental factors on the prevalence of autistic disorder after 1979," *J. Public Health Epidemiol.*, vol. 6, no. 9, pp. 271–286, Sep. 2014, doi: 10.5897/JPHE2014.0649.

[9] D. S. Pisetsky, "Antibody Responses to DNA in Normal Immunity and Aberrant Immunity," *Clin. Diagn. Lab. Immunol.*, vol. 5, no. 1, pp. 1–6, 1998.

[10] World Health Organization, "Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks." Accessed: Apr. 16, 2019. [Online]. Available: https://cdn.who.int/media/docs/default-source/biologicals/documents/trs_978_annex_3.pdf?sfvrsn=fe61af77_3&download=true

[11] Milipore Sigma, "Efficient DNA Clearance: Better, Faster Virus Production." Accessed: Jun. 09, 2020. [Online]. Available: https://cellculturedish.com/efficient-dna--clearance-enables-better-faster-virus-production/

[12] M. Dupuis *et al.*, "Distribution of DNA Vaccines Determines Their Immunogenicity After Intramuscular Injection in Mice," *J. Immunol.*, vol. 165, no. 5, pp. 2850–2858, Sep. 2000, doi: 10.4049/jimmunol.165.5.2850.

[13] S. Khier and L. Lohan, "Kinetics of circulating cell-free DNA for biomedical

applications: critical appraisal of the literature," *Future Sci. OA*, vol. 4, no. 4, Feb. 2018, doi: 10.4155/fsoa-2017-0140.

[14] Y. M. D. Lo, J. Zhang, T. N. Leung, T. K. Lau, A. M. Z. Chang, and N. M. Hjelm, "Rapid Clearance of Fetal DNA from Maternal Plasma," *Am. J. Hum. Genet.*, vol. 64, no. 1, pp. 218–224, Jan. 1999, doi: 10.1086/302205.

[15] K. Fesenmeier, "Delivering Genes Across the Blood-Brain Barrier." Accessed: Apr. 15, 2019. [Online]. Available: https://www.caltech.edu/about/news/delivering-genes-across-blood-brain-barrier-49679

[16] U.S. Food and Drug Administration, "What is Gene Therapy?" Accessed: Nov. 19, 2024. [Online]. Available: https://www.fda.gov/vaccines-blood-biologics/cellular--gene-therapy-products/what-gene-therapy

[17] K. B. Kaufmann, H. Büning, A. Galy, A. Schambach, and M. Grez, "Gene therapy on the move," *EMBO Mol. Med.*, vol. 5, no. 11, p. 1642, Sep. 2013, doi: 10.1002/emmm.201202287.

[18] N. Shimizu, F. Kamezaki, and S. Shigematsu, "Tracking of microinjected DNA in live cells reveals the intracellular behavior and elimination of extrachromosomal genetic material," *Nucleic Acids Res.*, vol. 33, no. 19, pp. 6296–6307, 2005, doi: 10.1093/nar/gki946.

[19] T. Deisher, "Open Letter to Legislators Regarding Fetal Cell DNA in Vaccines," 2019. Accessed: Sep. 28, 2022. [Online]. Available: https://soundchoice.org/open--letter-to-legislators-regarding-fetal-cell-dna-in-vaccines/

[20] A. Rouers, M. Vacca, and T. Celhar, "Article claiming vaccines cause autoimmunity and autism due to fetal DNA contaminants found unsupported and implausible," Health Feedback. Accessed: Mar. 30, 2020. [Online]. Available: https://healthfeedback.org/evaluation/article-claiming-vaccines-cause-autoimmunity-and-autism-due-to--fetal-dna-contaminants-found-unsupported-and-implausible-theresa-deisher/

[21] D. Gorski, "'Aborted fetal tissue' and vaccines: Combining pseudoscience and religion to demonize vaccines," Science-Based Medicine. Accessed: Jul. 13, 2018. [Online]. Available: https://sciencebasedmedicine.org/aborted-fetal-tissue-and-vaccines-combining-pseudoscience-and-religion-to-demonize-vaccines-2/

[22] D. R. Reiss, "NVICP Mini-Omnibus Autism decision – vaccines still do not cause autism." Accessed: Jul. 13, 2018. [Online]. Available: https://www.skepticalraptor.com/skepticalraptorblog.php/nvicp-mini-omnibus-autism-decision-vaccines/

[23] D. Gorski, "Vaccines and infant mortality rates." Accessed: Dec. 07, 2018. [Online]. Available: https://respectfulinsolence.com/2011/05/16/vaccines-and-infant-mortality-rates/

[24] M. Chu-Carroll, "Iterative Hockey Stick Analysis? Gimme a break!," Good Math/Bad Math. Accessed: Apr. 20, 2019. [Online]. Available: http://www.goodmath.org/blog/2010/04/29/iterative-hockey-stick-analysis-gimme-a-break/

[25] F. Man, "Vaccines and autism: A thorough review of the evidence (2019 update)." Accessed: Sep. 05, 2021. [Online]. Available: https://thelogicofscience.com/2019/03/12/vaccines-and-autism-a-thorough-review-of-the-evidence-2019-update/#jump

[26] B. Taylor *et al.*, "Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association," *Lancet Lond. Engl.*, vol. 353, no. 9169, pp. 2026–2029, Jun. 1999, doi: 10.1016/s0140-6736(99)01239-8.

[27] E. Fombonne, R. Zakarian, A. Bennett, L. Meng, and D. McLean-Heywood, "Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations," *Pediatrics*, vol. 118, no. 1, pp. e139–e150, Jul. 2006, doi: 10.1542/peds.2005-2993.

[28] L. C, "Problems with Deisher's study— Part I: The numbers." Accessed: Jul. 13, 2018. [Online]. Available: https://rationalcatholicblog.wordpress.com/2014/09/12/the-problems-with-deishers-study-part-i-the-numbers/

[29] N. B. Chief Special Master Dorsey, *J.M. and V.M., in their Own Right and as Best Friends of their Son, V.J.M., v. Secretary of Health and Human Services*. 2018. Accessed: Jul. 13, 2018. [Online]. Available: https://www.skepticalraptor.com/blog/wp-content/uploads/2018/03/JM-Mini-OMnibus-NVICP.pdf

[30] P. E. Campbell-Smith, "Ruling concerning petitioners' motion to supplement the record on motions to compel, and petitioners' motion to compel access to the Vaccine Safety Datalink, petitioners' motion for authority to issue subpoena, petitioners' motion for pre-payment of expert expenses, and petitioners' motion to compel production of FDA documents." 2013. Accessed: Sep. 22, 2022. [Online]. Available: https://www.uscfc.uscourts.gov/sites/default/files/opinions/CAMPBELL-SMITH.MOSTOVOY061213.pdf

[31] Siol.net and A. P. K., "Argument: Kako je priznani kardiolog ostal brez raziskovalnega programa." Accessed: Apr. 20, 2019. [Online]. Available: https://siol.net/novice/slovenija/argument-kako-je-priznani-kardiolog-ostal-brez-raziskovalnega-programa-foto-video-487525

[32] Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije (ARIS), "Javni razpis za (so)financiranje raziskovalnih projektov za leto 2019." Accessed: Apr. 20, 2019. [Online]. Available: https://www.arrs.si/sl/progproj/rproj/razpisi/18/razp-proj-18.asp

[33] G. Guglielmi, "Italian scientists protest funding for vaccine-safety investigation," *Nature*, vol. 564, no. 7736, pp. 310–311, Dec. 2018, doi: 10.1038/d41586-018-07464-0.

[34] M. Simpson, "Vaccine pseudoscience from Corvelva anti-vaccine 'researchers.'" Accessed: Jan. 13, 2020. [Online]. Available: https://www.skepticalraptor.com/skepticalraptorblog.php/vaccine-pseudoscience-corvelva-anti-vaccine-researchers/

[35] Corvelva, "Vaccinegate: MRC-5 contained in Priorix Tetra - Complete genome sequencing," Associazione Corvelva. Accessed: Jan. 13, 2020. [Online]. Available: https://www.corvelva.it/speciale-corvelva/vaccinegate-en/vaccinegate-mrc-5-contained-in-priorix-tetra-complete-genome-sequencing.html

[36] D. Gorski, "Corvelva and 'Vaccinegate': Italian antivaxers produce a dubious 'scientific report' on fetal DNA in vaccines." Accessed: Jan. 13, 2020. [Online]. Available: https://respectfulinsolence.com/2019/10/09/corvelva/

[37] T. Celhar and A. Rouers, "Mike Adams falsely claims cancer genes and 'entire genetic code' are found in vaccines, based on unverified report," Health Feedback. Accessed: Nov. 13, 2022. [Online]. Available: https://healthfeedback.org/claimreview/mike-adams-falsely-claims-cancer-genes-and-entire-genetic-code-are-found-in-vaccines-based-on-unverified-report/

[38] M. Simpson, "Corvelva promotes fake HPV vaccine 'research' – anti-vaxxers dance in the streets." Accessed: Jan. 13, 2020. [Online]. Available: https://www.skepticalraptor.com/skepticalraptorblog.php/corvelva-promotes-fake-hpv-vaccine-research/

[39] D. E. Wierenga, J. Cogan, and J. C. Petricciani, "Administration of Tumor Cell Chromatin to Immunosuppressed and Non-immunosuppressed Non-human Primates," *Biologicals*, vol. 23, no. 3, pp. 221–224, Sep. 1995, doi: 10.1006/biol.1995.0036.

[40] G. Edgren *et al.*, "Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study," *The Lancet*, vol. 369, no. 9574, pp. 1724–1730, May 2007, doi: 10.1016/S0140-6736(07)60779-X.

[41] Planet lepote, "Cepiva vsebujejo DNK človeškega zarodka, ki povzroča avtoimunske bolezni in raka že pri otrocih," Planet Lepote. Accessed: Dec. 08, 2019. [Online]. Available: https://m.planet-lepote.com/cepiva-vsebujejo-dnk-cloveskega-zarodka-ki-povzroca-avtoimunske-bolezni-in-raka-ze-pri-otrocih/

[42] National Catholic Bioethics Center, "FAQ on the Use of Vaccines." Accessed: Apr. 20, 2019. [Online]. Available: https://www.ncbcenter.org/resources-and-statements-cms/faq-on-the-use-of-vaccines?rq=FAQ%20on%20the%20Use%20of%20Vaccines

18

Literatura

[1] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[2] J. Lazarou, B. H. Pomeranz, and P. N. Corey, "Incidence of Adverse Drug Reactions in Hospitalized PatientsA Meta-analysis of Prospective Studies," *JAMA*, vol. 279, no. 15, pp. 1200–1205, Apr. 1998, doi: 10.1001/jama.279.15.1200.

[3] P. L. Moro, J. Arana, M. Cano, P. Lewis, and T. Shimabukuro, "Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997–2013," *Clin. Infect. Dis.*, vol. 61, no. 6, pp. 980–987, Sep. 2015, doi: 10.1093/cid/civ423.

[4] P. A. Offit, "Vaccine Safety: Are Vaccines Safe?" Accessed: Nov. 19, 2024. [Online]. Available: https://www.chop.edu/vaccine-education-center/vaccine-safety/other--vaccine-safety-concerns/are-vaccines-safe

[5] Centers for Disease Control and Prevention, "JYNNEOS Vaccine Effectiveness." Accessed: Nov. 19, 2024. [Online]. Available: https://www.cdc.gov/mpox/data-research/vaccines/index.html

[6] E. Hall, P. Wodi A., J. Hamborsky, V. Morelli, and S. Schillie, *Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases*, 14th ed. Washington: Public Health Foundation, 2021. Accessed: Mar. 15, 2021. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html

[7] Centers for Disease Control and Prevention, "Symptoms of Whooping Cough." Accessed: Sep. 23, 2021. [Online]. Available: https://www.cdc.gov/pertussis/signs--symptoms/?CDC_AAref_Val=https://www.cdc.gov/pertussis/about/complications.html

[8] Slovensko zdravniško društvo, Združenje za pediatrijo, "Bolezni in cepiva zanje." Accessed: Jul. 02, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in--cepiva-zanje

[9] National Institute for Health and Care Excellence, "Measles: What are the complications?" Accessed: Dec. 10, 2023. [Online]. Available: https://cks.nice.org.uk/topics/measles/background-information/complications/

[10] Centers for Disease Control and Prevention, "Measles Symptoms and Complications." Accessed: Sep. 24, 2024. [Online]. Available: https://www.cdc.gov/measles/signs-symptoms/?CDC_AAref_Val=https://www.cdc.gov/measles/symptoms/complications.html

[11] R. Schoenbohm, "How measles can change a life," VaccinesToday. Accessed: Dec. 23, 2024. [Online]. Available: https://www.vaccinestoday.eu/stories/how-measles--can-change-a-life/

[12] B. Feenstra *et al.*, "Common variants associated with general and MMR vaccine–related febrile seizures," *Nat. Genet.*, vol. 46, no. 12, pp. 1274–1282, Dec. 2014, doi: 10.1038/ng.3129.

[13] L. Pöyhönen, J. Bustamante, J.-L. Casanova, E. Jouanguy, and Q. Zhang, "Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity," *J. Clin. Immunol.*, vol. 39, no. 4, pp. 376–390, May 2019, doi: 10.1007/s10875-019-00642-3.
[14] National Health Service, "Complications, Mumps." Accessed: Jul. 18, 2021. [Online]. Available: https://www.nhs.uk/conditions/mumps/complications/
[15] National Institute for Health and Care Excellence, "Rubella: When should I suspect rubella?" Accessed: Dec. 10, 2023. [Online]. Available: https://cks.nice.org.uk/topics/rubella/diagnosis/clinical-features/
[16] European Centre for Disease Prevention and Control, "Factsheet about congenital rubella syndrome (CRS)." Accessed: Dec. 10, 2023. [Online]. Available: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts
[17] M. J. Alter, "Epidemiology of hepatitis B in Europe and worldwide," *J. Hepatol.*, vol. 39, pp. 64–69, Jan. 2003, doi: 10.1016/S0168-8278(03)00141-7.
[18] S. A. Plotkin, P. A. Offit, W. A. Orenstein, and K. M. Edwards, *Plotkin's vaccines*. Elsevier, 2018.
[19] S. Blume and I. Geesink, "A Brief History of Polio Vaccines," *Science*, vol. 288, no. 5471, pp. 1593–1594, Jun. 2000, doi: 10.1126/science.288.5471.1593.
[20] A. Sabin, "Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. - PubMed - NCBI," *J. Infect. Dis.*, vol. 151, no. 3, pp. 420–436, 1985, doi: 10.1093/infdis/151.3.420.
[21] M. E. Birmingham *et al.*, "National Immunization Days: State of the Art," *J. Infect. Dis.*, vol. 175, no. 1, pp. 183–188, 1997, doi: 0.1093/infdis/175.Supplement_1.S183.
[22] N. C. Grassly, "The final stages of the global eradication of poliomyelitis," *Philos. Trans. R. Soc. B Biol. Sci.*, vol. 368, no. 1623, Aug. 2013, doi: 10.1098/rstb.2012.0140.
[23] C. Lahariya, "A brief history of vaccines & vaccination in India," *Indian J. Med. Res.*, vol. 139, no. 4, pp. 491–511, Apr. 2014.
[24] T. J. John and V. M. Vashishtha, "Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status," *Indian J. Med. Res.*, vol. 137, no. 5, p. 881, May 2013.
[25] World Health Organization, "Poliomyelitis." Accessed: Jul. 25, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/poliomyelitis
[26] Worldometers, "India Population (2019)." Accessed: Mar. 19, 2019. [Online]. Available: http://www.worldometers.info/world-population/india-population/
[27] Ministry of Home Affairs, Office of the Registrar General & Census Commissioner, "Census 2011, Provisional population totals," 2011, Accessed: Nov. 15, 2024. [Online]. Available: https://censusindia.gov.in/census.website/
[28] Statistični urad Republike Slovenije, "Osnovni podatki o rojenih, Slovenija, letno." 2024. Accessed: Nov. 12, 2024. [Online]. Available: https://pxweb.stat.si/SiStatData/pxweb/sl/Data/-/05J1002S.px
[29] World Health Organization, Global Polio Eradication Initiative, "India celebrates six years polio free." Accessed: Aug. 24, 2021. [Online]. Available: https://polioeradication.org/news-post/india-celebrates-six-years-polio-free/

[30] World Health Organization, Global Polio Eradication Initiative, "Stopping Vaccine-Derived Poliovirus Outbreaks." Accessed: Mar. 19, 2019. [Online]. Available: http://polioeradication.org/news-post/stopping-vaccine-derived-poliovirus-outbreaks/

[31] World Health Organization, "Polio vaccines: WHO position paper – March 2016," *Wkly. Epidemiol. Rec.*, vol. 91, no. 12, pp. 145–168, 2016.

[32] Queensland Government, Queensland Health, "Acute Flaccid Paralysis." Accessed: Mar. 20, 2019. [Online]. Available: https://www.health.qld.gov.au/cdcg/index/afp

[33] World Health Organization, Global Polio Eradication Initiative, "OPV Cessation." Accessed: Mar. 21, 2019. [Online]. Available: http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/opv-cessation/

[34] L. Roberts, "Polio eradication program faces hard choices as endgame strategy falters," Science. Accessed: Mar. 15, 2020. [Online]. Available: https://www.sciencemag.org/news/2019/12/polio-eradication-program-faces-hard-choices-endgame-strategy-fails

[35] K. Stratton, D. A. Almario, and M. C. McCormick, "Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer," in *Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer*, National Academies Press (US), 2002. Accessed: Jun. 26, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK221112/

[36] J. C. Rotondo, E. Mazzoni, I. Bononi, M. Tognon, and F. Martini, "Association Between Simian Virus 40 and Human Tumors," *Front. Oncol.*, vol. 9, Jul. 2019, doi: 10.3389/fonc.2019.00670.

[37] J. S. Butel, A. S. Arrington, C. Wong, J. A. Lednicky, and M. J. Finegold, "Molecular Evidence of Simian Virus 40 Infections in Children," *J. Infect. Dis.*, vol. 180, no. 3, pp. 884–887, Sep. 1999, doi: 10.1086/314915.

[38] C. Carroll-Pankhurst, E. A. Engels, H. D. Strickler, J. J. Goedert, J. Wagner, and E. A. Mortimer, "Thirty-five year mortality following receipt of SV40- contaminated polio vaccine during the neonatal period," *Br. J. Cancer*, vol. 85, no. 9, pp. 1295–1297, Nov. 2001, doi: 10.1054/bjoc.2001.2065.

[39] G. O. Thu *et al.*, "Is there an association between SV40 contaminated polio vaccine and lymphoproliferative disorders? An age-period-cohort analysis on Norwegian data from 1953 to 1997," *Int. J. Cancer*, vol. 118, no. 8, pp. 2035–2039, Apr. 2006, doi: 10.1002/ijc.21603.

[40] Centers for Disease Control and Prevention, "Historical Vaccine Safety Concerns." Accessed: Mar. 22, 2019. [Online]. Available: https://www.cdc.gov/vaccinesafety/concerns/concerns-history.html

[41] K. Lacapria, "Did the CDC 'Admit' 98 Million Americans Were Given a 'Cancer Virus' via the Polio Shot?," 2015, Accessed: Mar. 22, 2019. [Online]. Available: https://www.snopes.com/fact-check/cdc-admits-98-million-got-cancer-polio-vaccine/

[42] W. Huynh, D. J. Cordato, E. Kehdi, L. T. Masters, and C. Dedousis, "Post-vaccination encephalomyelitis: literature review and illustrative case," *J. Clin. Neurosci. Off. J.*

Neurosurg. Soc. Australas., vol. 15, no. 12, pp. 1315–1322, Dec. 2008, doi: 10.1016/j.jocn.2008.05.002.

[43] National Institute of Neurological Disorders and Stroke, "Transverse Myelitis." Accessed: Mar. 31, 2024. [Online]. Available: https://www.ninds.nih.gov/health-information/disorders/transverse-myelitis

[44] R. Baxter *et al.*, "Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis," *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.*, vol. 63, no. 11, pp. 1456–1462, Dec. 2016, doi: 10.1093/cid/ciw607.

[45] J. B. Classen and D. C. Classen, "Clustering of cases of insulin dependent diabetes (IDDM) occurring three years after hemophilus influenza B (HiB) immunization support causal relationship between immunization and IDDM," *Autoimmunity*, vol. 35, no. 4, pp. 247–253, Jul. 2002, doi: 10.1080/08916930290028175.

[46] J. B. Classen, "Clustering of Cases of IDDM 2 to 4 Years after Hepatitis B Immunization is Consistent with Clustering after Infections and Progression to IDDM in Autoantibody Positive Individuals [Abstract]," *Open Pediatr. Med. J.*, vol. 2, no. 1, Feb. 2008, doi: 10.2174/1874309900802010001.

[47] National Centre for Immunisation, Research and Surveillance (NCIRS) Australia, "Diabetes and vaccines fact sheet." Accessed: Mar. 23, 2019. [Online]. Available: http://www.ncirs.org.au/sites/default/files/2018-12/diabetes-and-vaccines-fact-sheet.pdf

[48] E. Morgan, S. R. Halliday, G. R. Campbell, C. R. Cardwell, and C. C. Patterson, "Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies," *Diabetologia*, vol. 59, no. 2, pp. 237–243, Feb. 2016, doi: 10.1007/s00125-015-3800-8.

[49] C. D. Pietrantonj, A. Rivetti, P. Marchione, M. G. Debalini, and V. Demicheli, "Vaccines for measles, mumps, rubella, and varicella in children," *Cochrane Database Syst. Rev.*, no. 4, 2020, doi: 10.1002/14651858.CD004407.pub4.

[50] N. P. Klein *et al.*, "Long term risk of developing type 1 diabetes after HPV vaccination in males and females," *Vaccine*, vol. 37, no. 14, pp. 1938–1944, Mar. 2019, doi: 10.1016/j.vaccine.2019.02.051.

[51] C. Idlebrook, "Diabetes, Vaccines, and the Patent Troll," Insulin Nation. Accessed: Mar. 23, 2019. [Online]. Available: https://insulinnation.com/living/diabetes-vaccines-and-the-patent-troll/

[52] E. Check Hayden, "'Patent trolls' target biotechnology firms," *Nature*, vol. 477, no. 7366, pp. 521–521, Sep. 2011, doi: 10.1038/477521a.

19

Literatura

[1] Naravna imunost, "Študije o cepivih," Naravna imunost. Accessed: Jul. 16, 2018. [Online]. Available: https://www.naravnaimunost.si/studije/

[2] J. Pogačnik, "MZ in NIJZ naj investirata v nakup strokovne literature o cepljenju," Peticija.online. Accessed: Dec. 09, 2019. [Online]. Available: https://www.peticija.online/mz_in_nijz_naj_investirata_v_nakup_strokovne_literature_o_cepljenju

[3] C. M. Benjamin, G. C. Chew, and A. J. Silman, "Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine.," *BMJ*, vol. 304, no. 6834, pp. 1075–1078, 1992, doi: 10.1136/bmj.304.6834.1075.

[4] E. Hall, P. Wodi A., J. Hamborsky, V. Morelli, and S. Schillie, *Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases*, 14th ed. Washington: Public Health Foundation, 2021. Accessed: Mar. 15, 2021. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html

[5] M. W. Heijstek *et al.*, "Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial," *JAMA*, vol. 309, no. 23, pp. 2449–2456, Jun. 2013, doi: 10.1001/jama.2013.6768.

[6] M. W. Heijstek *et al.*, "Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis," *Ann. Rheum. Dis.*, vol. 66, no. 10, pp. 1384–1387, Oct. 2007, doi: 10.1136/ard.2006.063586.

[7] C. A. Panozzo, F. Pourmalek, Y. Brauchli Pernus, G. S. Pileggi, A. Woerner, and J. Bonhoeffer, "Arthritis and arthralgia as an adverse event following immunization: A systematic literature review," *Vaccine*, vol. 37, no. 2, pp. 372–383, Jan. 2019, doi: 10.1016/j.vaccine.2018.06.067.

[8] T. M. McKeever, S. A. Lewis, C. Smith, and R. Hubbard, "Vaccination and Allergic Disease: A Birth Cohort Study," *Am. J. Public Health*, vol. 94, no. 6, pp. 985–989, 2004, doi: 10.2105/ajph.94.6.985.

[9] H. Vogt, L. Bråbäck, A.-M. Kling, M. Grünewald, and L. Nilsson, "Pertussis Immunization in Infancy and Adolescent Asthma Medication," *Pediatrics*, vol. 134, no. 4, pp. 721–728, Oct. 2014, doi: 10.1542/peds.2014-0723.

[10] F. DeStefano, D. Pfeifer, and H. Nohynek, "Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data," *Bull. World Health Organ.*, vol. 86, no. 5, pp. 373–380, May 2008, doi: 10.2471/BLT.07.048025.

[11] A. Meyer, P. Rotman-Pikielny, A. Natour, and Y. Levy, "Antiphospholipid syndrome following a diphtheria-tetanus vaccination: coincidence vs. causality," *Isr. Med. Assoc. J. IMAJ*, vol. 12, no. 10, pp. 638–639, Oct. 2010.

[12] D. L. Miller, R. Alderslade, and E. M. Ross, "Whooping cough and whooping cough vaccine: the risks and benefits debate," *Epidemiol. Rev.*, vol. 4, pp. 1–24, 1982, doi: 10.1093/oxfordjournals.epirev.a036242.

[13] P. Offit, *Deadly choices: how the anti-vaccine movement threatens us all*. Basic books, 2011.

[14] P. Ray *et al.*, "Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study," *Pediatr. Infect. Dis. J.*, vol. 25, no. 9, pp. 768–773, Sep. 2006, doi: 10.1097/01.inf.0000234067.84848.e1.

[15] K. R. Wentz and E. K. Marcuse, "Diphtheria-tetanus-pertussis vaccine and serious neurologic illness: an updated review of the epidemiologic evidence," *Pediatrics*, vol. 87, no. 3, pp. 287–297, Mar. 1991.

[16] J. D. Cherry, "Historical review of pertussis and the classical vaccine," *J. Infect. Dis.*, vol. 174 Suppl 3, pp. S259-263, Nov. 1996, doi: 10.1093/infdis/174.supplement_3.s259.

[17] J. H. Menkes and M. Kinsbourne, "Workshop on neurologic complications of pertussis and pertussis vaccination," *Neuropediatrics*, vol. 21, no. 4, pp. 171–176, Nov. 1990, doi: 10.1055/s-2008-1071488.

[18] C. Black, J. A. Kaye, and H. Jick, "MMR vaccine and idiopathic thrombocytopaenic purpura," *Br. J. Clin. Pharmacol.*, vol. 55, no. 1, pp. 107–111, Jan. 2003, doi: 10.1046/j.1365-2125.2003.01790.x.

[19] T. Heller, "Vaccination against mumps, measles, and rubella: is there a case for deepening the debate?," *BMJ*, vol. 323, no. 7317, pp. 838–840, Oct. 2001.

[20] S. Blitshteyn, "Postural tachycardia syndrome after vaccination with Gardasil," *Eur. J. Neurol.*, vol. 17, no. 7, p. e52, Jul. 2010, doi: 10.1111/j.1468-1331.2010.03021.x.

[21] S. Vernino *et al.*, "Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1," *Auton. Neurosci. Basic Clin.*, vol. 235, p. 102828, Jun. 2021, doi: 10.1016/j.autneu.2021.102828.

[22] European Medicines Agency, "HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS." Accessed: Jul. 23, 2018. [Online]. Available: https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_en.pdf

[23] A. Barboi *et al.*, "Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society," *Auton. Neurosci.*, vol. 223, p. 102550, Jan. 2020, doi: 10.1016/j.autneu.2019.05.002.

[24] N. P. Klein *et al.*, "Safety of quadrivalent human papillomavirus vaccine administered routinely to females," *Arch. Pediatr. Adolesc. Med.*, vol. 166, no. 12, pp. 1140–1148, Dec. 2012, doi: 10.1001/archpediatrics.2012.1451.

[25] L. Arnheim-Dahlström, B. Pasternak, H. Svanström, P. Sparén, and A. Hviid, "Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study," *BMJ*, vol. 347, p. f5906, Oct. 2013, doi: 10.1136/bmj.f5906.

[26] P. Haber *et al.*, "An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?," *Pediatrics*, vol. 113, no. 4, pp. e353-359, Apr. 2004, doi: 10.1542/peds.113.4.e353.

[27] L. Samad *et al.*, "Intussusception incidence among infants in the UK and Republic of Ireland: A pre-rotavirus vaccine prospective surveillance study," *Vaccine*, vol. 31, no. 38, pp. 4098–4102, Aug. 2013, doi: 10.1016/j.vaccine.2013.06.084.

[28] H.-K. Cho *et al.*, "Incidence of intussusception before and after the introduction of rotavirus vaccine in Korea," *PLoS ONE*, vol. 15, no. 8, p. e0238185, Aug. 2020, doi: 10.1371/journal.pone.0238185.

[29] S. Foster, "Rotavirus Vaccine and Intussusception," *J. Pediatr. Pharmacol. Ther. JPPT*, vol. 12, no. 1, p. 4, Mar. 2007, doi: 10.5863/1551-6776-12.1.4.

[30] Centers for Disease Control and Prevention, "Rotavirus Vaccine (RotaShield®) and Intussusception." Accessed: Nov. 19, 2024. [Online]. Available: https://archive.cdc.gov/www_cdc_gov/vaccines/vpd-vac/rotavirus/vac-rotashield-historical.htm

[31] J. Koch, T. Harder, R. von Kries, and O. Wichmann, "Risk of Intussusception After Rotavirus Vaccination," *Dtsch. Ärztebl. Int.*, vol. 114, no. 15, pp. 255–262, Apr. 2017, doi: 10.3238/arztebl.2017.0255.

[32] S. Vora *et al.*, "Severe Eczema Vaccinatum in a Household Contact of a Smallpox Vaccinee," *Clin. Infect. Dis.*, vol. 46, no. 10, pp. 1555–1561, May 2008, doi: 10.1086/587668.

[33] A. R. Kemper, M. M. Davis, and G. L. Freed, "Expected adverse events in a mass smallpox vaccination campaign," *Eff. Clin. Pract. ECP*, vol. 5, no. 2, pp. 84–90, Apr. 2002.

[34] A. Miravalle and K. L. Roos, "Encephalitis complicating smallpox vaccination," *Arch. Neurol.*, vol. 60, no. 7, pp. 925–928, Jul. 2003, doi: 10.1001/archneur.60.7.925.

[35] T. J. Aragón, S. Ulrich, S. Fernyak, and G. W. Rutherford, "Risks of serious complications and death from smallpox vaccination: A systematic review of the United States experience, 1963–1968," *BMC Public Health*, vol. 3, no. 1, Dec. 2003, doi: 10.1186/1471-2458-3-26.

[36] D. C. Cassimatis, J. E. Atwood, R. M. Engler, P. E. Linz, J. D. Grabenstein, and M. N. Vernalis, "Smallpox vaccination and myopericarditis: a clinical review," *J. Am. Coll. Cardiol.*, vol. 43, no. 9, pp. 1503–1510, 2004.

[37] E. A. Belongia and A. L. Naleway, "Smallpox Vaccine: The Good, the Bad, and the Ugly," *Clin. Med. Res.*, vol. 1, no. 2, pp. 87–92, Apr. 2003, doi: 10.3121/cmr.1.2.87.

[38] Centers for Disease Control and Prevention, "Child and Adolescent Immunization Schedule by Age (Addendum updated June 27, 2024)." Accessed: Jul. 22, 2024. [Online]. Available: https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html

[39] Slovensko zdravniško društvo, Združenje za pediatrijo, "Koledar splošnih obveznih in priporočenih cepljenj." Accessed: Nov. 04, 2023. [Online]. Available: https://www.cepljenje.info/zivljenjska-obdobja/otroci/2/koledar-splosnih-obveznih-in-priporocenih-cepljenj

[40] P. B. Croft, "Para-infectious and post-vaccinal encephalomyelitis," *Postgrad. Med. J.*, vol. 45, no. 524, pp. 392–400, 1969, doi: 10.1136/pgmj.45.524.392.

[41] Sanofi Pasteur, "Rabies Vaccine Imovax Rabies." 2019. [Online]. Available: https://www.fda.gov/media/75709/download?attachment

[42] Sanofi Pasteur, "Verorab Rabies vaccine, Product information." 2015. [Online]. Available: https://nijz.si/wp-content/uploads/2022/12/24.08.2018_4057_001.pdf
[43] R. Li *et al.*, "A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China," *Vaccine*, vol. 31, no. 50, pp. 5940–5947, Dec. 2013, doi: 10.1016/j.vaccine.2013.10.043.
[44] Institute of Medicine, Board on Health Promotion and Disease Prevention, "Scientific background on smallpox and smallpox vaccination," in *Scientific and Policy Considerations in Developing Smallpox Vaccination Options: A Workshop Report*, National Academies Press (US), 2002. Accessed: Nov. 19, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK221063/
[45] World Health Organization, "Rabies." Accessed: Feb. 02, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/rabies
[46] W. E. Barlow *et al.*, "The Risk of Seizures after Receipt of Whole-Cell Pertussis or Measles, Mumps, and Rubella Vaccine," *N. Engl. J. Med.*, vol. 345, no. 9, pp. 656–661, Aug. 2001, doi: 10.1056/NEJMoa003077.
[47] J. Nabe-Nielsen and B. Walter, "Unilateral deafness as a complication of the mumps, measles, and rubella vaccination.," *BMJ*, vol. 297, no. 6646, p. 489, Aug. 1988, doi: 10.1136/bmj.297.6646.489.
[48] National Health Service, "Complications, Mumps." Accessed: Jul. 18, 2021. [Online]. Available: https://www.nhs.uk/conditions/mumps/complications/
[49] B. J. Stewart and P. U. Prabhu, "Reports of sensorineural deafness after measles, mumps, and rubella immunisation.," *Arch. Dis. Child.*, vol. 69, no. 1, pp. 153–154, Jul. 1993, doi: 10.1136/adc.69.1.153.
[50] Institute of Medicine, *Adverse Effects of Vaccines: Evidence and Causality*. Washington, D.C.: The National Academies Press, 2012. doi: 10.17226/13164.
[51] R. Baxter, N. Lewis, P. Bohrer, T. Harrington, L. Aukes, and N. P. Klein, "Sudden--Onset Sensorineural Hearing Loss after Immunization: A Case-Centered Analysis," *Otolaryngol.--Head Neck Surg. Off. J. Am. Acad. Otolaryngol.-Head Neck Surg.*, vol. 155, no. 1, p. 81, Mar. 2016, doi: 10.1177/0194599816639043.
[52] Johns Hopkins Bloomberg School of Public Health, Institute for Vaccine Safety, "Do Vaccines Cause Hearing Loss?" Accessed: Oct. 27, 2024. [Online]. Available: https://www.vaccinesafety.edu/do-vaccines-cause-hearing-loss/
[53] T. Jefferson, A. Rivetti, C. Di Pietrantonj, and V. Demicheli, "Vaccines for preventing influenza in healthy children," *Cochrane Database Syst. Rev.*, vol. 2, no. 2, 2018, doi: 10.1002/14651858.CD004879.pub5.
[54] Nacionalni Inštitut za javno zdravje, "Cepljenje proti gripi v sezoni 2023/24." Accessed: Feb. 07, 2024. [Online]. Available: https://nijz.si/wp-content/uploads/2023/09/Priporocila_navodila-za-cepljenje-proti-gripi-sezoni-2023_2024.pdf
[55] M. G. Thompson *et al.*, "Influenza vaccine effectiveness in preventing influenza--associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015," *Vaccine*, vol. 36, no. 39, pp. 5916–5925, Sep. 2018, doi: 10.1016/j.vaccine.2018.07.028.

[56] M. Rondy, N. El Omeiri, M. G. Thompson, A. Levêque, A. Moren, and S. G. Sullivan, "Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies," *J. Infect.*, vol. 75, no. 5, pp. 381–394, 2017, doi: 10.1016/j.jinf.2017.09.010.

[57] M. G. Thompson *et al.*, "Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016," *Clin. Infect. Dis.*, vol. 68, no. 9, pp. 1444–1453, 2019, doi: 10.1093/cid/ciy737.

[58] S. M. Olson *et al.*, "Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children," *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.*, vol. 75, no. 2, pp. 230–238, Aug. 2022, doi: 10.1093/cid/ciab931.

[59] A. P. Campbell *et al.*, "Vaccine Effectiveness Against Pediatric Influenza Hospitalizations and Emergency Visits," *Pediatrics*, vol. 146, no. 5, p. e20201368, Nov. 2020, doi: 10.1542/peds.2020-1368.

[60] A. C. Tricco *et al.*, "Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis," *BMC Med.*, vol. 11, p. 153, Jun. 2013, doi: 10.1186/1741-7015-11-153.

[61] J. Cohen, "Why flu vaccines so often fail." Accessed: Oct. 10, 2019. [Online]. Available: https://www.science.org/content/article/why-flu-vaccines-so-often-fail

[62] M. Eisenstein, "Towards a universal flu vaccine," *Nature*, vol. 573, no. 7774, pp. S50–S52, Sep. 2019, doi: 10.1038/d41586-019-02751-w.

[63] B. J. Cowling *et al.*, "Increased Risk of Noninfluenza Respiratory Virus Infections Associated With Receipt of Inactivated Influenza Vaccine," *Clin. Infect. Dis.*, vol. 54, no. 12, pp. 1778–1783, Jun. 2012, doi: 10.1093/cid/cis307.

[64] S. Rikin *et al.*, "Assessment of temporally-related acute respiratory illness following influenza vaccination," *Vaccine*, vol. 36, no. 15, pp. 1958–1964, Apr. 2018, doi: 10.1016/j.vaccine.2018.02.105.

[65] Public Health Ontario, "Sentinel Practitioner Surveillance Network (SPSN) — Influenza Vaccine Effectiveness Program." Accessed: Jan. 28, 2025. [Online]. Available: https://www.publichealthontario.ca/en/Health-Topics/Immunization/SPSN

[66] D. M. Skowronski *et al.*, "Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010–2011 to 2016–2017," *Clin. Infect. Dis.*, vol. 71, no. 16, pp. 2285–2288, Nov. 2020, doi: 10.1093/cid/ciaa626.

[67] J. R. Hamilton, D. Sachs, J. K. Lim, R. A. Langlois, P. Palese, and N. S. Heaton, "Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 113, no. 14, pp. 3861–3866, Apr. 2016, doi: 10.1073/pnas.1522376113.

[68] Z. Mosenifar, "Viral pneumonia," 2024, Accessed: Dec. 12, 2019. [Online]. Available: https://emedicine.medscape.com/article/300455-overview#a5

[69] CDC, "New Grim Milestone for Flu Pediatric Deaths Set." Accessed: Jan. 28, 2025. [Online]. Available: https://www.cdc.gov/flu/whats-new/2023-2024-pediatric-deaths-200.html

[70] M. Shang, L. Blanton, L. Brammer, S. J. Olsen, and A. M. Fry, "Influenza-Associated Pediatric Deaths in the United States, 2010-2016," *Pediatrics*, vol. 141, no. 4, 2018, doi: 10.1542/peds.2017-2918.

[71] G. Chowell *et al.*, "Severe Respiratory Disease Concurrent with the Circulation of H1N1 Influenza," *N. Engl. J. Med.*, vol. 361, no. 7, pp. 674–679, Aug. 2009, doi: 10.1056/NEJMoa0904023.

[72] World Health Organization, "Influenza: A(H5N1)." Accessed: Nov. 13, 2024. [Online]. Available: https://www.who.int/news-room/questions-and-answers/item/influenza-h5n1

[73] K. J. Henrickson, "Parainfluenza Viruses," *Clin. Microbiol. Rev.*, vol. 16, no. 2, pp. 242–264, Apr. 2003, doi: 10.1128/CMR.16.2.242-264.2003.

[74] P. F. Lewis *et al.*, "A community-based outbreak of severe respiratory illness caused by human adenovirus serotype 14," *J. Infect. Dis.*, vol. 199, no. 10, pp. 1427–1434, May 2009, doi: 10.1086/598521.

[75] G. Matias, R. Taylor, F. Haguinet, C. Schuck-Paim, R. Lustig, and V. Shinde, "Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status," *Influenza Other Respir. Viruses*, vol. 8, no. 5, pp. 507–515, Sep. 2014, doi: 10.1111/irv.12258.

[76] C. L. Byington, J. Wilkes, K. Korgenski, and X. Sheng, "Respiratory Syncytial Virus--Associated Mortality in Hospitalized Infants and Young Children," *Pediatrics*, vol. 135, no. 1, pp. e24–e31, Jan. 2015, doi: 10.1542/peds.2014-2151.

[77] Nacionalni Inštitut za javno zdravje, "Respiratorni sincicijski virus (RSV)." Accessed: Dec. 13, 2019. [Online]. Available: https://www.nijz.si/sl/respiratorni-sincicijski-virus-rsv

[78] Centers for Disease Control and Prevention, "Respiratory syncytical virus infection (RSV), Vaccines for older adults." Accessed: Feb. 07, 2024. [Online]. Available: https://www.cdc.gov/rsv/about/prevention.html

[79] European Medicines Agency, "First RSV vaccine to protect infants up to 6 months of age and older adults." Accessed: Feb. 07, 2024. [Online]. Available: https://www.ema.europa.eu/en/news/first-rsv-vaccine-protect-infants-6-months-age-and-older-adults

[80] G. C., "Zaradi gripe je v Sloveniji umrlo 160 bolnikov," RTVSLO. Accessed: Dec. 13, 2019. [Online]. Available: https://www.rtvslo.si/zdravje/novice/zaradi-gripe-je-v-sloveniji-umrlo-160-bolnikov/484309

[81] M. Sočan, K. Prosenc Trilar, N. Berginc, and S. Steiner Rihtar, "Integrirano mrežno spremljanje gripe, covid-19 in ostalih akutnih okužb dihal v Sloveniji v sezoni 2021/2022," Ljubljana, 2023. Accessed: Feb. 07, 2024. [Online]. Available: https://nijz.si/wp-content/uploads/2023/10/Integrirano-mrezno-spremljanje-gripe-covid-19-in-ostalih-akutnih-okuzb-dihal-v-Sloveniji-v-sezoni-2021-2022.pdf

[82] M. Sočan, K. Prosenc Trilar, and S. Steiner Rihtar, "Spremljanje respiratornega sincicijskega virusa v Sloveniji v sezoni 2021/2022," Ljubljana, 2023. Accessed: Feb. 07, 2024. [Online]. Available: https://nijz.si/wp-content/uploads/2023/10/Spremljanje-respiratornega-sincicijskega-virusa-v-Sloveniji-v-sezoni-2021-2022.pdf

[83] M. Koutsakos, A. K. Wheatley, K. Laurie, S. J. Kent, and S. Rockman, "Influenza lineage extinction during the COVID-19 pandemic?," *Nat. Rev. Microbiol.*, vol. 19, no. 12, Art. no. 12, Dec. 2021, doi: 10.1038/s41579-021-00642-4.

[84] Y. Xiaolong, L. Ke, L. Zhiqun, L. Jiayao, W. Qi, and W. Sheng, "Prevalence and associated outcomes of coinfection between SARS-CoV-2 and influenza: a systematic review and meta-analysis," *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.*, vol. 136, Nov. 2023, doi: 10.1016/j.ijid.2023.08.021.

[85] J. Sarangi, K. Cartwright, J. Stuart, S. Brookes, R. Morris, and M. Slack, "Invasive Haemophilus influenzae disease in adults.," *Epidemiol. Infect.*, vol. 124, no. 3, pp. 441–447, Jun. 2000, doi: 10.1017/s0950268899003611.

[86] CDC, "About Haemophilus influenzae Disease," CDC. Accessed: Jan. 30, 2025. [Online]. Available: https://www.cdc.gov/hi-disease/about/index.html

[87] European Center for Disease Prevention and Control, "Invasive Haemophilus influenzae disease." Accessed: Jan. 30, 2025. [Online]. Available: https://www.ecdc.europa.eu/en/invasive-haemophilus-influenzae-disease

[88] Slovensko zdravniško društvo, Združenje za pediatrijo, "Hemofilus influence B (HIB)." Accessed: Feb. 12, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje/hemofilus-influence-b-hib

[89] M. G. Bruce *et al.*, "Haemophilus influenzae Serotype a Invasive Disease, Alaska, USA, 1983–2011," *Emerg. Infect. Dis.*, vol. 19, no. 6, pp. 932–937, Jun. 2013, doi: 10.3201/eid1906.121805.

[90] C. Gallagher and M. Goodman, "Hepatitis B triple series vaccine and developmental disability in US children aged 1–9 years," *Toxicol. Environ. Chem.*, vol. 90, no. 5, pp. 997–1008, Sep. 2008, doi: 10.1080/02772240701806501.

[91] N. Andrews, E. Miller, A. Grant, J. Stowe, V. Osborne, and B. Taylor, "Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association," *Pediatrics*, vol. 114, no. 3, pp. 584–591, Sep. 2004, doi: 10.1542/peds.2003-1177-L.

[92] J. Heron, J. Golding, and ALSPAC Study Team, "Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association," *Pediatrics*, vol. 114, no. 3, pp. 577–583, Sep. 2004, doi: 10.1542/peds.2003-1176-L.

[93] E. Fombonne, R. Zakarian, A. Bennett, L. Meng, and D. McLean-Heywood, "Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations," *Pediatrics*, vol. 118, no. 1, pp. e139–e150, Jul. 2006, doi: 10.1542/peds.2005-2993.

[94] C. M. da Silveira, C. I. Kmetzsch, R. Mohrdieck, A. F. Sperb, and D. R. Prevots, "The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997," *Int. J. Epidemiol.*, vol. 31, no. 5, pp. 978–982, Oct. 2002, doi: 10.1093/ije/31.5.978.

[95] R. M. Cantu and J. M. Das, "Viral Meningitis," in *StatPearls*, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Oct. 28, 2024. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK545217/

[96] I. Almansour, "Mumps Vaccines: Current Challenges and Future Prospects," *Front. Microbiol.*, vol. 11, Aug. 2020, doi: 10.3389/fmicb.2020.01999.

[97] J. Ivancic *et al.*, "Genetic characterization of L-Zagreb mumps vaccine strain," *Virus Res.*, vol. 109, no. 1, pp. 95–105, Apr. 2005, doi: 10.1016/j.virusres.2004.11.013.

[98] World Health Organization, "Safety of mumps vaccine strains." Accessed: Oct. 28, 2024. [Online]. Available: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/mumps-vaccines

[99] Merck Sharp & Dohme (MSD), "M-M-RvaxPro, Summary of product characteristics." Accessed: Apr. 04, 2022. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/m-m-rvaxpro-epar-product-information_sl.pdf

[100] S. Black *et al.*, "Risk of hospitalization because of aseptic meningitis after measles--mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project," *Pediatr. Infect. Dis. J.*, vol. 16, no. 5, pp. 500–503, May 1997, doi: 10.1097/00006454-199705000-00009.

[101] M. A. Hernán, S. S. Jick, M. J. Olek, and H. Jick, "Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study," *Neurology*, vol. 63, no. 5, pp. 838–842, Sep. 2004, doi: 10.1212/01.wnl.0000138433.61870.82.

[102] Centers for Disease Control and Prevention, "Hepatitis B Vaccine Safety." Accessed: Dec. 30, 2024. [Online]. Available: https://www.cdc.gov/vaccine-safety/vaccines/hepatitis-b.html?CDC_AAref_Val=

[103] P.-Y. Wu, H.-D. I. Wu, T.-C. Chou, and F.-C. Sung, "Varicella Vaccination Alters the Chronological Trends of Herpes Zoster and Varicella," *PLoS ONE*, vol. 8, no. 10, Oct. 2013, doi: 10.1371/journal.pone.0077709.

[104] Nacionalni Inštitut za javno zdravje, "Pasovec ali herpes zoster." Accessed: Feb. 14, 2024. [Online]. Available: https://nijz.si/nalezljive-bolezni/nalezljive-bolezni-od--a-do-z/pasavec-ali-herpes-zoster/

[105] E. Gowin, J. Wysocki, and M. Michalak, "Don't forget how severe varicella can be--complications of varicella in children in a defined Polish population," *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.*, vol. 17, no. 7, pp. e485-489, Jul. 2013, doi: 10.1016/j.ijid.2012.11.024.

[106] J. C. Cameron, G. Allan, F. Johnston, A. Finn, P. T. Heath, and R. Booy, "Severe complications of chickenpox in hospitalised children in the UK and Ireland," *Arch. Dis. Child.*, vol. 92, no. 12, pp. 1062–1066, Dec. 2007, doi: 10.1136/adc.2007.123232.

[107] A. A. Gershon, M. D. Gershon, and E. D. Shapiro, "Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster," *J. Infect. Dis.*, vol. 224, no. Suppl 4, pp. S387–S397, Sep. 2021, doi: 10.1093/infdis/jiaa573.

[108] R. Civen *et al.*, "The Incidence and Clinical Characteristics of Herpes Zoster Among Children and Adolescents After Implementation of Varicella

Vaccination," *Pediatr. Infect. Dis. J.*, vol. 28, no. 11, p. 954, Nov. 2009, doi: 10.1097/INF.0b013e3181a90b16.

[109] Centers for Disease Control and Prevention, "Varicella vaccine recommendations." Accessed: Jul. 24, 2024. [Online]. Available: https://www.cdc.gov/vaccines/vpd/varicella/hcp/recommendations.html

[110] J. M. Kramer *et al.*, "Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child," *Pediatrics*, vol. 108, no. 2, p. E39, Aug. 2001, doi: 10.1542/peds.108.2.e39.

[111] Centers for Disease Control and Prevention, "Chickenpox Vaccination." Accessed: Jan. 05, 2024. [Online]. Available: https://www.cdc.gov/vaccines/vpd/varicella/public/index.html

[112] D. Montefiore, M. F. Jamieson, P. Collard, and H. Jolly, "Trial of Type 1 Oral Poliomyelitis Vaccine (Sabin) in Nigerian Children," *Br. Med. J.*, vol. 1, no. 5345, pp. 1569–1572, Jun. 1963.

[113] World Health Organization, "Poliomyelitis." Accessed: Jul. 25, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/poliomyelitis

[114] A. B. Brueggemann, R. Pai, D. W. Crook, and B. Beall, "Vaccine Escape Recombinants Emerge after Pneumococcal Vaccination in the United States," *PLoS Pathog.*, vol. 3, no. 11, p. E168, 2007, doi: 10.1371/journal.ppat.0030168.

[115] B. Henriques-Normark and E. I. Tuomanen, "The Pneumococcus: Epidemiology, Microbiology, and Pathogenesis," *Cold Spring Harb. Perspect. Med.*, vol. 3, no. 7, p. a010215, Jul. 2013, doi: 10.1101/cshperspect.a010215.

[116] European Center for Disease Prevention and Control, "Invasive pneumococcal disease." Accessed: Jan. 30, 2025. [Online]. Available: https://www.ecdc.europa.eu/en/invasive-pneumococcal-disease

[117] M. Likar, *Cepiva danes in jutri*. Arkadija, 2004.

[118] K. A. Geno *et al.*, "Pneumococcal Capsules and Their Types: Past, Present, and Future," *Clin. Microbiol. Rev.*, vol. 28, no. 3, pp. 871–899, Jul. 2015, doi: 10.1128/CMR.00024-15.

[119] R. K. Holmes and M. G. Jobling, "Medical microbiology: Genetics," in *Medical Microbiology*, 4th ed., S. Baron, Ed., Galveston (TX): University of Texas Medical Branch at Galveston, 1996. Accessed: Jan. 09, 2024. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK7908/

[120] T. A. Brown, "Mutation, Repair and Recombination," in *Genomes*, 2nd ed., Oxford: Wiley-Liss, 2002. Accessed: Jul. 25, 2018. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK21114/

[121] S. A. Plotkin, P. A. Offit, W. A. Orenstein, and K. M. Edwards, *Plotkin's vaccines*. Elsevier, 2018.

[122] Slovensko zdravniško društvo, Združenje za pediatrijo, "Pnevmokokne okužbe." Accessed: Nov. 14, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje/pnevmokokne-okuzbe

[123] S. Tomczyk *et al.*, "Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine," *Clin. Infect.*

Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 62, no. 9, pp. 1119–1125, May 2016, doi: 10.1093/cid/ciw067.

[124] E. Janssens, J. Flamaing, C. Vandermeulen, W. E. Peetermans, S. Desmet, and P. De Munter, "The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value," *Acta Clin. Belg.*, vol. 78, no. 1, pp. 78–86, Feb. 2023, doi: 10.1080/17843286.2022.2039865.

[125] M. Gratten, G. Nimmo, J. Carlisle, and J. Schooneveldt, "Emergence of further serotypes of multiple drug-resistant Streptococcus pneumoniae in Queensland," *Commun. Dis. Intell.*, vol. 21, no. 10, pp. 133–136, 1997.

[126] V. A. Soldatenkova and F. E. Yazbak, "An investigation of infant deaths following initial hepatitis B vaccination based on the Vaccine Adverse Event Reporting System (VAERS) , 1992-2002," *Med. Veritas*, vol. 4, pp. 1414–1421, 2007, doi: 10.1588/medver.2007.04.00154.

[127] A. Vincent *et al.*, "Sudden Infant Death Syndrome: Risk Factors and Newer Risk Reduction Strategies," *Cureus*, vol. 15, no. 6, p. e40572, doi: 10.7759/cureus.40572.

[128] S. Perrone *et al.*, "Sudden Infant Death Syndrome: Beyond Risk Factors," *Life*, vol. 11, no. 3, p. 184, Feb. 2021, doi: 10.3390/life11030184.

[129] Centers for Disease Control and Prevention, "Sudden Infant Death Syndrome (SIDS) and Vaccines." Accessed: Nov. 14, 2024. [Online]. Available: https://www.cdc.gov/vaccine-safety/about/sids.html

[130] Centers for Disease Control and Prevention, "Trends in SUID Rates by Cause of Death, 1990—2022," Sudden Unexpected Infant Death and Sudden Infant Death Syndrome. Accessed: Nov. 14, 2024. [Online]. Available: https://www.cdc.gov/sudden-infant-death/data-research/data/sids-deaths-by-cause.html

[131] Centers for Disease Control and Prevention, "A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States - Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents." Accessed: Jul. 26, 2018. [Online]. Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1.htm

[132] Centers for Disease Control and Prevention, "Vaccines when your child is sick." Accessed: Jul. 19, 2024. [Online]. Available: https://www.cdc.gov/vaccines-children/before-during-after-shots/when-your-child-is-sick.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/parents/visit/sick-child.html

[133] Nacionalni Inštitut za javno zdravje, "Program cepljenja in zaščite z zdravili za leto 2019." 2019. [Online]. Available: https://www.nijz.si/sites/www.nijz.si/files/uploaded/rs_-2019-026-01204-obp001-0000.pdf

[134] M. T. Niu, M. E. Salive, and S. S. Ellenberg, "Neonatal Deaths After Hepatitis B Vaccine: The Vaccine Adverse Event Reporting System, 1991-1998," *Arch. Pediatr. Adolesc. Med.*, vol. 153, no. 12, pp. 1279–1282, Dec. 1999, doi: 10.1001/archpedi.153.12.1279.

[135] R. Y. Moon, R. A. Darnall, L. Feldman-Winter, M. H. Goodstein, and F. R. Hauck, "SIDS and Other Sleep-Related Infant Deaths: Updated 2016 Recommendations

for a Safe Infant Sleeping Environment," *Pediatrics*, vol. 138, no. 5, p. e20162938, Nov. 2016, doi: 10.1542/peds.2016-2938.

[136] M. Al-Bayati, "Analysis of causes that led to baby Jackie Ray's developmental delay and intracranial bleeding," *Med. Veritas*, vol. 5, pp. 1836–1844, Jan. 2008.

[137] I. Blumenthal, "Shaken baby syndrome," *Postgrad. Med. J.*, vol. 78, no. 926, pp. 732–735, Dec. 2002, doi: 10.1136/pmj.78.926.732.

[138] K.-L. Hung, "Pediatric abusive head trauma," *Biomed. J.*, vol. 43, no. 3, pp. 240–250, Jun. 2020, doi: 10.1016/j.bj.2020.03.008.

[139] A. Maiese *et al.*, "Pediatric Abusive Head Trauma: A Systematic Review," *Diagnostics*, vol. 11, no. 4, p. 734, Apr. 2021, doi: 10.3390/diagnostics11040734.

[140] A. K. Choudhary *et al.*, "Consensus statement on abusive head trauma in infants and young children," *Pediatr. Radiol.*, vol. 48, no. 8, 2018, doi: 10.1007/s00247-018-4149-1.

[141] L. Hayes, "Beware of 'Standard of Care,'" Age of autism. Accessed: Feb. 22, 2020. [Online]. Available: https://www.ageofautism.com/2016/04/beware-of-standard-of-care.html

[142] N. K. Choudhary, J. Mallik, and K. Diwakar, "Acute-on-Chronic Subdural Hemorrhage Due to Late Vitamin K Deficiency," *Cureus*, vol. 15, no. 1, p. e34297, doi: 10.7759/cureus.34297.

[143] N. Z. Miller and G. S. Goldman, "Infant mortality rates regressed against number of vaccine doses routinely given: is there a biochemical or synergistic toxicity?," *Hum. Exp. Toxicol.*, vol. 30, no. 9, pp. 1420–1428, Sep. 2011, doi: 10.1177/0960327111407644.

[144] N. Green, "Correlation is not causation," *The Guardian*, Jan. 06, 2012. Accessed: Jul. 26, 2018. [Online]. Available: http://www.theguardian.com/science/blog/2012/jan/06/correlation-causation

[145] A. Suresh, "Autism increase mystery solved? No, it's not vaccines, GMOs, glyphosate—or organic foods." Accessed: Jul. 26, 2018. [Online]. Available: https://geneticliteracyproject.org/2023/11/13/autism-increase-mystery-solved-no-its-not-vaccines-gmos-glyphosate-or-organic-foods/

[146] N. Agmon-Levin, S. Kivity, M. Szyper-Kravitz, and Y. Shoenfeld, "Transverse myelitis and vaccines: a multi-analysis," *Lupus*, vol. 18, no. 13, pp. 1198–1204, Nov. 2009, doi: 10.1177/0961203309345730.

[147] C. G. Simone and P. D. Emmady, "Transverse Myelitis," in *StatPearls*, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Jan. 31, 2024. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK559302/

[148] European Medicines Agency, "Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 13 January 2022," 2022. Accessed: Apr. 17, 2023. [Online]. Available: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-january-2022

[149] R. Baxter *et al.*, "Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis," *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.*, vol. 63, no. 11, pp. 1456–1462, Dec. 2016, doi: 10.1093/cid/ciw607.

[150] V. Učakar, M. Grgič Vitek, and K. Krnc, "Neželeni učinki pridruženi cepljenju v Sloveniji v letu 2020," NIJZ, 2021. Accessed: Feb. 01, 2024. [Online]. Available: https://nijz.si/wp-content/uploads/2022/07/porocilo_nu_2020.pdf

[151] V. Učakar, T. Bertole, K. Krnc, M. Mrzel, and M. Grgič Vitek, "Neželeni učinki pridruženi cepljenju v Sloveniji v letu 2021," NIJZ, 2022. Accessed: Feb. 01, 2024. [Online]. Available: https://nijz.si/wp-content/uploads/2023/10/Nezeleni-ucinki--pridruzeni-cepljenju-v-Sloveniji-v-letu-2021.pdf

[152] V. Učakar, T. Bertole, K. Krnc, M. Mrzel, and M. Grgič Vitek, "Neželeni učinki pridruženi cepljenju v Sloveniji v letu 2022," NIJZ, 2023. Accessed: Feb. 01, 2024. [Online]. Available: https://nijz.si/wp-content/uploads/2023/12/Nezeleni-ucinki--pridruzeni-cepljenju-v-Sloveniji-v-letu-2022.pdf

[153] C. T. Hsing, "Local complications of BCG vaccination in pre-school children and newborn babies," *Bull. World Health Organ.*, vol. 11, no. 6, pp. 1023–1029, 1954.

[154] J. Tomažič and F. Strle, *Infekcijske bolezni*, Druga izdaja. Ljubljana: Združenje za infektologijo, Slovensko zdravniško društvo, 2017.

[155] W. M. Chan, "Management of Bacillus Calmette-Guérin Lymphadenitis," *Hong Kong J. Paediatr.*, vol. 16, pp. 85–94, 2011.

[156] S. O. Baek, H. S. Ko, and H. H. Han, "BCG vaccination-induced suppurative lymphadenitis: four signs to pay attention to," *Int. Wound J.*, vol. 14, no. 6, pp. 1385–1387, Apr. 2017, doi: 10.1111/iwj.12755.

[157] World Health Organization, "BCG vaccines: WHO position paper - February 2018," *Wkly. Epidemiol. Rec.*, vol. 93, no. 8, pp. 73–96, 2018.

[158] S. Rangesh, P. C. Vaidya, N. Mehra, S. Gupta, and B. Bharti, "Incidence of lymphadenitis following Bacillus Calmette-Guérin (BCG) vaccination in north Indian children," *Indian J. Tuberc.*, vol. 69, no. 4, pp. 596–601, Oct. 2022, doi: 10.1016/j.ijtb.2021.09.008.

[159] K. Rižner, "Cepiva spodjedajo naše zdravje," Center za bioresonanco. Accessed: Aug. 21, 2020. [Online]. Available: https://czb8.wordpress.com/pomembne-informacije/cepiva-spodjedajo-nase-zdravje/

20

Literatura

[1] Institute of Medicine, *Adverse Effects of Vaccines: Evidence and Causality*. Washington, D.C.: The National Academies Press, 2012. doi: 10.17226/13164.

[2] Naravna imunost, "Varnost cepiv," Naravna imunost. Accessed: Apr. 16, 2024. [Online]. Available: https://www.naravnaimunost.si/varnost-cepiv/

[3] C. Frompovich, "Vaccine recalls," VacTruth.com. Accessed: Nov. 01, 2023. [Online]. Available: https://vactruth.com/2012/04/09/vaccine-recalls/

[4] N. Bombourg, "Regulatory Intelligence on Biologics Recalls - Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes." Accessed: Nov. 01, 2023. [Online]. Available: https://www.prnewswire.com/news-releases/regulatory-intelligence-on-biologics-recalls---immunoglobulins-and-vaccines-are--involved-in-more-recalls-than-other-drug-classes-148489415.html

[5] U.S. Food and Drug Administration, "Recalls (Biologics)." Accessed: Jul. 18, 2023. [Online]. Available: https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/default.htm

[6] Centers for Disease Control and Prevention, "Vaccine Recalls: Frequently Asked Questions." Accessed: Jul. 18, 2024. [Online]. Available: https://www.cdc.gov/vaccine-safety/recalls/?CDC_AAref_Val=https://www.cdc.gov/vaccinesafety/concerns/recalls.html

[7] P. Offit, *Deadly choices: how the anti-vaccine movement threatens us all*. Basic books, 2011.

[8] J. Hamblin, "Why the Government Pays Billions to People Who Claim Injury by Vaccines," The Atlantic. Accessed: Apr. 16, 2020. [Online]. Available: https://www.theatlantic.com/health/archive/2019/05/vaccine-safety-program/589354/

[9] J. Keelan and K. Wilson, "Balancing Vaccine Science and National Policy Objectives: Lessons From the National Vaccine Injury Compensation Program Omnibus Autism Proceedings," *Am. J. Public Health*, vol. 101, no. 11, pp. 2016–2021, Nov. 2011, doi: 10.2105/AJPH.2011.300198.

[10] U.S. Health Resources & Services Administration, "National Vaccine Injury Compensation Program." Accessed: Jul. 28, 2020. [Online]. Available: https://www.hrsa.gov/vaccine-compensation

[11] U.S. Health Resources & Services Administration, "Data & Statistics," 2023. Accessed: Jan. 03, 2024. [Online]. Available: https://www.hrsa.gov/sites/default/files/hrsa/vicp/vicp-stats-12-01-23.pdf

[12] Institute of Medicine (US) Committee on the Children's Vaccine Initiative, *National Vaccine Injury Compensation Program*. National Academies Press (US), 1993. Accessed: Apr. 16, 2020. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK236419/

[13] U.S. Health Resources & Services Administration, "National Vaccine Injury Compensation Program." Accessed: Jul. 18, 2018. [Online]. Available: https://www.hrsa.gov/vaccine-compensation/index.html
[14] Nacionalni Inštitut za javno zdravje, "Borelioza (Lymska bolezen)." Accessed: Aug. 08, 2022. [Online]. Available: https://www.nijz.si/sl/borelioza-lymska-bolezen
[15] Centers for Disease Control and Prevention, "Chronic Symptoms and Lyme Disease." Accessed: Aug. 09, 2024. [Online]. Available: https://www.cdc.gov/lyme/signs-symptoms/chronic-symptoms-and-lyme-disease.html?CDC_AAref_Val=https://www.cdc.gov/lyme/postlds/index.html
[16] Centers for Disease Control and Prevention, "Signs and Symptoms of Untreated Lyme Disease." Accessed: Aug. 08, 2024. [Online]. Available: https://www.cdc.gov/lyme/signs-symptoms/?CDC_AAref_Val=https://www.cdc.gov/lyme/signs_symptoms/index.html
[17] Nacionalni Inštitut za javno zdravje, "Lymska borelioza." Accessed: Aug. 09, 2024. [Online]. Available: https://www.nijz.si/sl/lymska-borelioza-razsirjenost-in-zascita
[18] L. E. Nigrovic and K. M. Thompson, "The Lyme vaccine: a cautionary tale," *Epidemiol. Infect.*, vol. 135, no. 1, pp. 1–8, 2007, doi: 10.1017/S0950268806007096.
[19] Valneva, "Lyme Disease - VLA15," Valneva. Accessed: Nov. 01, 2023. [Online]. Available: https://valneva.com/research-development/lyme-disease/

21

Literatura

[1] M. Černič, Ideološki konstrukti o cepljenju, 1st ed. Vega, 2014.

[2] World Health Organization, "Vaccines and immunization: Myths and misconceptions." Accessed: Jun. 07, 2021. [Online]. Available: https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-myths-and-misconceptions

[3] Centers for Disease Control and Prevention, "Achievements in Public Health, 1900-1999: Control of Infectious Diseases." Accessed: Mar. 10, 2019. [Online]. Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4829a1.htm

[4] Centers for Disease Control and Prevention, "History of drinking water treatment: a century of U.S. water chlorination and treatment: one of the ten greatest public health achievements of the 20th century." Accessed: Mar. 10, 2019. [Online]. Available: https://stacks.cdc.gov/view/cdc/92155

[5] World Health Organization, The World Health Report 2007: A Safer Future: Global Public Health Security in the 21st Century. Geneva: World Health Organization, 2007. Accessed: Mar. 10, 2019. [Online]. Available: https://iris.who.int/bitstream/handle/10665/43713/9789241563444_eng.pdf?sequence=1

[6] Institute of Medicine (US) Committee for the Study of the Future of Public Health, A History of the Public Health System. National Academies Press (US), 1988. Accessed: Mar. 10, 2019. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK218224/

[7] B. H. Sheingold and J. A. Hahn, "The history of healthcare quality: The first 100 years 1860–1960," Int. J. Afr. Nurs. Sci., vol. 1, pp. 18–22, Jan. 2014, doi: 10.1016/j.ijans.2014.05.002.

[8] J. Trdič, M. Gabrijelčič Blenkuš, T. Kofol Bric, P. Truden-Dobrin, and T. Albreht, Eds., Zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja Republike Slovenije, 2010. Accessed: Mar. 02, 2020. [Online]. Available: http://www.nijz.si/sites/www.nijz.si/files/publikacije-datoteke/zdravje_v_slovenji.pdf

[9] Nacionalni Inštitut za javno zdravje, "5. maj – mednarodni dan higiene rok – »Ohranimo življenja: očistimo roke«." Accessed: Nov. 20, 2024. [Online]. Available: http://www.nijz.si/sl/resujte-zivljenja-skrbite-za-higieno-rok-5maj-2017-mednarodni-dan-higiene-rok

[10] Naravna imunost, "Zgodovina nalezljivih bolezni," Naravna imunost. Accessed: Mar. 03, 2023. [Online]. Available: https://www.naravnaimunost.si/zgodovina-nalezljivih-bolezni/

[11] F. Man, "Yes, vaccines did save us from disease: a graphic analysis," The Logic of Science. Accessed: Jul. 17, 2018. [Online]. Available: https://thelogicofscience.com/2015/07/05/yes-vaccines-did-save-us-from-disease-a-graphic-analysis/

[12] Centers for Disease Control and Prevention, "History of measles." Accessed: Nov. 20, 2024. [Online]. Available: https://www.cdc.gov/measles/about/history.html
[13] Centers for Disease Control and Prevention, "Measles cases and outbreaks." Accessed: Nov. 20, 2024. [Online]. Available: https://www.cdc.gov/measles/data-research/?CDC_AAref_Val=https://www.cdc.gov/measles/cases-outbreaks.html
[14] R. M. Barkin, "Measles mortality: a retrospective look at the vaccine era," Am. J. Epidemiol., vol. 102, no. 4, pp. 341–349, Oct. 1975, doi: 10.1093/oxfordjournals.aje.a112170.
[15] UK Health Security Agency, "Measles notifications and deaths in England and Wales: 1940 to 2023." Accessed: Feb. 01, 2024. [Online]. Available: https://www.gov.uk/government/publications/measles-deaths-by-age-group-from-1980-to-2013-ons-data/measles-notifications-and-deaths-in-england-and-wales-1940-to-2013
[16] M. Ramsay, "Measles in England 2012 and 2013," Public Health England. Accessed: Mar. 02, 2020. [Online]. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/192611/Presentation_by_Mary_Ramsay_-_Measles_in_England_2012___2013.pdf
[17] E. Hall, P. Wodi A., J. Hamborsky, V. Morelli, and S. Schillie, Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases, 14th ed. Washington: Public Health Foundation, 2021. Accessed: Mar. 15, 2021. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html
[18] M. Marin, J. Leung, T. C. Anderson, and A. S. Lopez, "Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995-2019," J. Infect. Dis., vol. 226, no. Suppl 4, pp. S392–S399, Oct. 2022, doi: 10.1093/infdis/jiac221.
[19] J. F. Seward, M. Marin, and M. Vázquez, "Varicella Vaccine Effectiveness in the US Vaccination Program: A Review," J. Infect. Dis., vol. 197, no. Supplement_2, pp. S82–S89, Mar. 2008, doi: 10.1086/522145.
[20] W. G. van Panhuis, A. Cross, and D. S. Burke, "Project Tycho 2.0: a repository to improve the integration and reuse of data for global population health," J. Am. Med. Inform. Assoc. JAMIA, vol. 25, no. 12, pp. 1608–1617, Oct. 2018, doi: 10.1093/jamia/ocy123.
[21] van Panhuis Willem G. et al., "Contagious Diseases in the United States from 1888 to the Present," N. Engl. J. Med., vol. 369, no. 22, pp. 2152–2158, 2013, doi: 10.1056/NEJMms1215400.
[22] J. E. Libbey and R. S. Fujinami, "Morbillivirus: A highly adaptable viral genus," Heliyon, vol. 9, no. 7, p. e18095, Jul. 2023, doi: 10.1016/j.heliyon.2023.e18095.
[23] European Centre for Disease Prevention and Control, "Factsheet about measles." Accessed: Jul. 19, 2024. [Online]. Available: https://www.ecdc.europa.eu/en/measles/facts
[24] National Institute for Health and Care Excellence, "Measles: What are the complications?" Accessed: Dec. 10, 2023. [Online]. Available: https://cks.nice.org.uk/topics/measles/background-information/complications/

[25] Centers for Disease Control and Prevention, "Measles Symptoms and Complications." Accessed: Sep. 24, 2024. [Online]. Available: https://www.cdc.gov/measles/signs-symptoms/?CDC_AAref_Val=https://www.cdc.gov/measles/symptoms/complications.html

[26] Z. Rocke and M. Belyayeva, "Subacute Sclerosing Panencephalitis," in StatPearls, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Jul. 08, 2024. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK560673/

[27] W. J. Bellini et al., "Subacute Sclerosing Panencephalitis: More Cases of This Fatal Disease Are Prevented by Measles Immunization than Was Previously Recognized," J. Infect. Dis., vol. 192, no. 10, pp. 1686–1693, Nov. 2005, doi: 10.1086/497169.

[28] M. Mekki, B. Eley, D. Hardie, and J. M. Wilmshurst, "Subacute sclerosing panencephalitis: clinical phenotype, epidemiology, and preventive interventions," Dev. Med. Child Neurol., vol. 61, no. 10, pp. 1139–1144, 2019, doi: https://doi.org/10.1111/dmcn.14166.

[29] M. K. Liszewski and J. P. Atkinson, "Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections," Curr. Opin. Immunol., vol. 72, pp. 126–134, Oct. 2021, doi: 10.1016/j.coi.2021.04.005.

[30] J. Nathan, D. Khedekar Kale, V. D. Naik, F. Thakker, and S. Bailur, "Substantial Remission in Subacute Sclerosing Panencephalitis by Following the Ketogenic Diet: A Case Report," Cureus, vol. 11, no. 8, p. e5485, 2019, doi: 10.7759/cureus.5485.

[31] World Health Organization, "Measles." Accessed: Mar. 05, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/measles

[32] M. J. Mina et al., "Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens," Science, vol. 366, no. 6465, pp. 599–606, Nov. 2019, doi: 10.1126/science.aay6485.

[33] V. N. Petrova et al., "Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles," Sci. Immunol., vol. 4, no. 41, p. eaay6125, Nov. 2019, doi: 10.1126/sciimmunol.aay6125.

[34] T. Obukhanych, "Should you be afraid that measles can give you immune amnesia?" Accessed: Jan. 15, 2020. [Online]. Available: http://www.tetyanaobukhanych.com/2/post/2019/11/should-you-be-afraid-that-measles-gives-you-immune-amnesia.html

[35] D. Gorski, "Tetyana Obukhanych swings at the measles immune amnesia studies—and whiffs!" Accessed: Jan. 15, 2020. [Online]. Available: https://respectfulinsolence.com/2019/11/07/obukhanych-swings-measles/

[36] H. Primic, "Virus ošpic ozdravil raka!," Ringaraja.net. Accessed: Jan. 20, 2020. [Online]. Available: http://www.ringaraja.net/clanek/virus-ospic-ozdravil-raka_9191.html

[37] E. Kelly and S. J. Russell, "History of Oncolytic Viruses: Genesis to Genetic Engineering," Mol. Ther., vol. 15, no. 4, pp. 651–659, Apr. 2007, doi: 10.1038/sj.mt.6300108.

[38] C. E. Engeland and G. Ungerechts, "Measles Virus as an Oncolytic Immunotherapy," Cancers, vol. 13, no. 3, p. 544, Feb. 2021, doi: 10.3390/cancers13030544.

[39] S. J. Russell et al., "Remission of Disseminated Cancer After Systemic Oncolytic

Virotherapy," Mayo Clin. Proc., vol. 89, no. 7, pp. 926–933, Jul. 2014, doi: 10.1016/j.mayocp.2014.04.003.

[40] S. J. Russell et al., "Oncolytic Measles Virotherapy and Opposition to Measles Vaccination," Mayo Clin. Proc., vol. 94, no. 9, pp. 1834–1839, Sep. 2019, doi: 10.1016/j.mayocp.2019.05.006.

[41] J. Feagaimaali'i, "Negligent vaccine nurses jailed for five years," Samoa Observer. Accessed: Jan. 10, 2020. [Online]. Available: https://www.samoaobserver.ws/category/samoa/46741

[42] Radio New Zealand, "Samoa MMR vaccinations to resume on April 15." Accessed: Jan. 10, 2020. [Online]. Available: https://www.rnz.co.nz/international/pacific-news/386249/samoa-mmr-vaccinations-to-resume-on-april-15

[43] BBC, "How a wrong injection helped cause Samoa's measles epidemic," 2019, Accessed: Jan. 10, 2020. [Online]. Available: https://www.bbc.co.uk/news/world-asia-50625680

[44] J. Thornton, "In the aftermath: the legacy of measles in Samoa," Lancet Lond. Engl., vol. 395, no. 10236, pp. 1535–1536, 2020, doi: 10.1016/S0140-6736(20)31137-5.

[45] V. Iannelli, "The Timeline of the Measles Epidemic in Samoa." Accessed: Jan. 10, 2020. [Online]. Available: https://vaxopedia.org/2019/12/08/the-timeline-of-the-measles-epidemic-in-samoa/

[46] J. Fennell, E. H, and ley, "Samoa measles vaccinations compared to 'Nazi Germany' by social media influencer," ABC News. Accessed: Jan. 10, 2020. [Online]. Available: https://www.abc.net.au/news/2019-11-28/australian-samoan-influencer-measles-crisis-nazi-germany/11737938

[47] V. Iannelli, "Jim Meehan Supporting a Farmer Helps Explain the Deaths in Samoa." Accessed: Jan. 10, 2020. [Online]. Available: https://vaxopedia.org/2019/12/01/jim-meehan-supporting-a-farmer-helps-explain-the-deaths-in-samoa/

[48] 1 News, TVNZ, "Anti-vax groups swamp Samoan government's online pages during massive vaccination campaign." Accessed: Jan. 10, 2020. [Online]. Available: https://www.1news.co.nz/2019/12/05/anti-vax-groups-swamp-samoan-governments-online-pages-during-massive-vaccination-campaign/

[49] D. Gorski, "Antivaxxer Robert F. Kennedy, Jr. writes to Samoan Prime Minister Tuilaepa Aiono Sailele Malielegaoi about measles in the middle of an outbreak." Accessed: Jan. 10, 2020. [Online]. Available: https://respectfulinsolence.com/2019/12/05/samoa-measles-outbreak-malielegaoi/

[50] D. Gorski, "Sherri Tenpenny and James Grundig: Desperately denying that measles kills." Accessed: Jan. 10, 2020. [Online]. Available: https://respectfulinsolence.com/2019/12/10/sherri-tenpenny-and-james-grundig-desperately-denying-that-measles-kills/

22

Literatura

[1] A. N. Desai and M. S. Majumder, "What Is Herd Immunity?," *JAMA*, vol. 324, no. 20, p. 2113, Nov. 2020, doi: 10.1001/jama.2020.20895.

[2] A. J. Pollard and E. M. Bijker, "A guide to vaccinology: from basic principles to new developments," *Nat. Rev. Immunol.*, vol. 21, no. 2, pp. 83–100, Feb. 2021, doi: 10.1038/s41577-020-00479-7.

[3] Naravna imunost, "Čredna (kolektivna) imunost," Naravna imunost. Accessed: Mar. 03, 2023. [Online]. Available: https://www.naravnaimunost.si/credna-kolektivna-imunost/

[4] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[5] I. Barberis, N. L. Bragazzi, L. Galluzzo, and M. Martini, "The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus," *J. Prev. Med. Hyg.*, vol. 58, no. 1, pp. E9–E12, Mar. 2017.

[6] E. Vynnycky and P. E. Fine, "Interpreting the decline in tuberculosis: the role of secular trends in effective contact," *Int. J. Epidemiol.*, vol. 28, no. 2, pp. 327–334, Apr. 1999, doi: 10.1093/ije/28.2.327.

[7] M. W. Borgdorff and D. van Soolingen, "The re-emergence of tuberculosis: what have we learnt from molecular epidemiology?," *Clin. Microbiol. Infect.*, vol. 19, no. 10, pp. 889–901, Oct. 2013, doi: 10.1111/1469-0691.12253.

[8] World Health Organization, "Global tuberculosis report 2022," Geneva, 2022. Accessed: Jul. 13, 2024. [Online]. Available: https://iris.who.int/bitstream/handle/10665/363752/9789240061729-eng.pdf?sequence=1

[9] S. H. E. Kaufmann, J. Weiner, and C. F. von Reyn, "Novel approaches to tuberculosis vaccine development," *Int. J. Infect. Dis.*, vol. 56, pp. 263–267, Mar. 2017, doi: 10.1016/j.ijid.2016.10.018.

[10] T. A. Thomas, "Tuberculosis in children," *Pediatr. Clin. North Am.*, vol. 64, no. 4, pp. 893–909, Aug. 2017, doi: 10.1016/j.pcl.2017.03.010.

[11] I. Suárez, S. M. Fünger, S. Kröger, J. Rademacher, G. Fätkenheuer, and J. Rybniker, "The Diagnosis and Treatment of Tuberculosis," *Dtsch. Ärztebl.*, vol. 116, no. 43, pp. 729–735, 2019, doi: 10.3238/arztebl.2019.0729.

[12] World Health Organization, "BCG vaccines: WHO position paper - February 2018," *Wkly. Epidemiol. Rec.*, vol. 93, no. 8, pp. 73–96, 2018.

[13] Centers for Disease Control and Prevention, "Clinical Testing Guidance for Tuberculosis: Tuberculin Skin Test," Tuberculosis (TB). Accessed: Jul. 12, 2024. [Online]. Available: https://www.cdc.gov/tb/hcp/testing-diagnosis/tuberculin-skin-test.html

[14] Centers for Disease Control and Prevention, "Clinical Overview of Tuberculosis," Tuberculosis (TB). Accessed: Jul. 14, 2024. [Online]. Available: https://www.cdc.gov/tb/hcp/clinical-overview/index.html

[15] Centers for Disease Control and Prevention, "The Role of BCG Vaccine in the Prevention and Control of Tuberculosis in the United States." Accessed: Mar. 05, 2020. [Online]. Available: https://www.cdc.gov/mmwr/PDF/rr/rr4504.pdf

[16] C.-Y. Chiang and L. W. Riley, "Exogenous reinfection in tuberculosis," *Lancet Infect. Dis.*, vol. 5, no. 10, pp. 629–636, Oct. 2005, doi: 10.1016/S1473-3099(05)70240-1.

[17] J. Li, J. Lu, G. Wang, A. Zhao, and M. Xu, "Past, Present and Future of Bacillus Calmette-Guérin Vaccine Use in China," *Vaccines*, vol. 10, no. 7, p. 1157, Jul. 2022, doi: 10.3390/vaccines10071157.

[18] McGill University and University of Ottawa, "The BCG World Atlas, A database of global BCG vaccination policies and practices." Accessed: Jul. 17, 2018. [Online]. Available: http://www.bcgatlas.org/

[19] University of Oxford, Department of Pediatrics, "BCG Vaccine (TB vaccine)." Accessed: Jan. 29, 2023. [Online]. Available: https://vk.ovg.ox.ac.uk/bcg-vaccine

[20] L. G. Stensballe *et al.*, "BCG vaccination at birth and early childhood hospitalisation: a randomised clinical multicentre trial," *Arch. Dis. Child.*, vol. 102, no. 3, pp. 224–231, Mar. 2017, doi: 10.1136/archdischild-2016-310760.

[21] P. Offit, "A Look at Each Vaccine: Tuberculosis Vaccine." Accessed: Jan. 29, 2023. [Online]. Available: https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-details/tuberculosis-vaccine

[22] Y. Ma, C. R. Horsburgh, L. F. White, and H. E. Jenkins, "Quantifying TB transmission: a systematic review of reproduction number and serial interval estimates for tuberculosis," *Epidemiol. Infect.*, vol. 146, no. 12, pp. 1478–1494, Sep. 2018, doi: 10.1017/S0950268818001760.

[23] Centers for Disease Control and Prevention, "Bacille Calmette-Guérin (BCG) Vaccine for Tuberculosis." Accessed: Aug. 13, 2024. [Online]. Available: https://www.cdc.gov/tb/hcp/vaccines/?CDC_AAref_Val=https://www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm

[24] A. Fromsa *et al.*, "BCG vaccination reduces bovine tuberculosis transmission, improving prospects for elimination," *Science*, vol. 383, no. 6690, p. eadl3962, Mar. 2024, doi: 10.1126/science.adl3962.

[25] P. Mangtani *et al.*, "Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials," *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.*, vol. 58, no. 4, pp. 470–480, Feb. 2014, doi: 10.1093/cid/cit790.

[26] A. Roy *et al.*, "Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis," *BMJ*, vol. 349, Aug. 2014, doi: 10.1136/bmj.g4643.

[27] I. Abubakar *et al.*, "Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis," *Health Technol. Assess. Winch. Engl.*, vol. 17, no. 37, pp. 1–372, v–vi, Sep. 2013, doi: 10.3310/hta17370.

[28] S. Chawla *et al.*, "Tuberculosis vaccine," *Hum. Vaccines Immunother.*, vol. 10, no. 2, pp. 420–422, Feb. 2014, doi: 10.4161/hv.27108.

[29] M. Likar, *Cepiva danes in jutri*. Arkadija, 2004.
[30] J. Tomažič and F. Strle, *Infekcijske bolezni*, Druga izdaja. Ljubljana: Združenje za infektologijo, Slovensko zdravniško društvo, 2017.
[31] Slovensko zdravniško društvo, Združenje za pediatrijo, "Tuberkuloza." Accessed: Jul. 16, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje/tuberkuloza
[32] M. Shelley, J. B. Court, H. Kynaston, T. J. Wilt, R. Fish, and M. Mason, "Local treatment with Bacillus Calmette-Guérin following surgery for superficial bladder cancer reduces the risk of the cancer returning.," *Cochrane Database Syst. Rev.*, 2000, doi: 10.1002/14651858.CD001986.
[33] L. Zhuang, Z. Ye, L. Li, L. Yang, and W. Gong, "Next-Generation TB Vaccines: Progress, Challenges, and Prospects," *Vaccines*, vol. 11, no. 8, p. 1304, Jul. 2023, doi: 10.3390/vaccines11081304.
[34] L. Grobler, S. Nangpal, T. D. Sudarsanam, and D. Sinclair, "Nutritional supplements for people being treated for active tuberculosis," *Cochrane Database Syst. Rev.*, no. 6, 2016, doi: 10.1002/14651858.CD006086.pub4.
[35] P. Adepoju, "New TB vaccine on trial," *Nature Africa*, Mar. 24, 2024. Accessed: Jul. 13, 2024. [Online]. Available: https://www.nature.com/articles/d44148-024-00101-1
[36] E. Hall, P. Wodi A., J. Hamborsky, V. Morelli, and S. Schillie, *Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases*, 14th ed. Washington: Public Health Foundation, 2021. Accessed: Mar. 15, 2021. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html
[37] R. Rappuoli and E. Malito, "History of Diphtheria Vaccine Development," in *Corynebacterium diphtheriae and Related Toxigenic Species: Genomics, Pathogenicity and Applications*, A. Burkovski, Ed., Dordrecht: Springer Netherlands, 2014, pp. 225–238. doi: 10.1007/978-94-007-7624-1_11.
[38] University of Oxford, Department of Pediatrics, "Diphtheria." Accessed: Jul. 17, 2024. [Online]. Available: https://vaccineknowledge.ox.ac.uk/diphtheria
[39] Slovensko zdravniško društvo, Združenje za pediatrijo, "Davica." Accessed: Jul. 15, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje/davica
[40] C. R. V. and M. Wharton, "Diphtheria in the Former Soviet Union: Reemergence of a Pandemic Disease," *Emerg. Infect. Dis.*, vol. 4, no. 4, 1998, doi: 10.3201/eid0404.980404.
[41] A. Golaz *et al.*, "Epidemic Diphtheria in the Newly Independent States of the Former Soviet Union: Implications for Diphtheria Control in the United States," *J. Infect. Dis.*, vol. 181, no. Supplement_1, pp. S237–S243, Feb. 2000, doi: 10.1086/315569.
[42] K. M. Bisgard *et al.*, "Diphtheria Toxoid Vaccine Effectiveness: A Case-Control Study in Russia," *J. Infect. Dis.*, vol. 181, no. Supplement_1, pp. S184–S187, Feb. 2000, doi: 10.1086/315562.
[43] W. J. Edmunds *et al.*, "The sero-epidemiology of diphtheria in Western Europe," *Epidemiol. Infect.*, vol. 125, pp. 113–125, 2000, doi: 10.1017/S0950268899004161.
[44] H. F. Gidding, J. L. Backhouse, G. L. Gilbert, and M. A. Burgess, "Immunity to

diphtheria and tetanus in Australia: a national serosurvey," *Med. J. Aust.*, vol. 183, no. 6, pp. 301–304, 2005, doi: 10.5694/j.1326-5377.2005.tb07059.x.

[45] M. D. Decker and K. M. Edwards, "Pertussis (Whooping Cough)," *J. Infect. Dis.*, vol. 224, no. Supplement_4, pp. S310–S320, Oct. 2021, doi: 10.1093/infdis/jiaa469.

[46] J. D. Cherry, "The History of Pertussis (Whooping Cough); 1906–2015: Facts, Myths, and Misconceptions," *Curr. Epidemiol. Rep.*, vol. 2, no. 2, pp. 120–130, Jun. 2015, doi: 10.1007/s40471-015-0041-9.

[47] S. A. Plotkin, P. A. Offit, W. A. Orenstein, and K. M. Edwards, *Plotkin's vaccines*. Elsevier, 2018.

[48] J. P. Baker, "The pertussis vaccine controversy in Great Britain, 1974–1986," *Vaccine*, vol. 21, no. 25–26, pp. 4003–4010, Sep. 2003, doi: 10.1016/S0264-410X(03)00302-5.

[49] K. K. Dewan, B. Linz, S. E. DeRocco, and E. T. Harvill, "Acellular Pertussis Vaccine Components: Today and Tomorrow," *Vaccines*, vol. 8, no. 2, Art. no. 2, Jun. 2020, doi: 10.3390/vaccines8020217.

[50] E. Szwejser-Zawislak, M. M. Wilk, P. Piszczek, J. Krawczyk, D. Wilczyńska, and D. Hozbor, "Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity," *Vaccines*, vol. 11, no. 1, p. 1, 2023, doi: 10.3390/vaccines11010001.

[51] V. Romanus, R. Jonsell, and S. O. Bergquist, "Pertussis in Sweden after the cessation of general immunization in 1979," *Pediatr. Infect. Dis. J.*, vol. 6, no. 4, pp. 364–371, Apr. 1987, doi: 10.1097/00006454-198704000-00005.

[52] D. L. Miller, R. Alderslade, and E. M. Ross, "Whooping cough and whooping cough vaccine: the risks and benefits debate," *Epidemiol. Rev.*, vol. 4, pp. 1–24, 1982, doi: 10.1093/oxfordjournals.epirev.a036242.

[53] M. Ramsay, Ed., "Pertussis," in *Immunisation against infectious disease*, London: UK Health Security Agency, 2024. Accessed: May 25, 2024. [Online]. Available: https://assets.publishing.service.gov.uk/media/667dee0bc7f64e2342090116/Green_Book_Chapter_24_260624.pdf

[54] P. Offit, *Deadly choices: how the anti-vaccine movement threatens us all*. Basic books, 2011.

[55] British Medical Journal, "The law tries to decide whether whooping cough vaccine causes brain damage: Professor Gordon Stewart gives evidence.," *Br. Med. J. Clin. Res. Ed*, vol. 292, no. 6530, pp. 1264–1266, May 1986, doi: 10.1136/bmj.292.6530.1264.

[56] G. Dick, "Reactions to routine immunization in childhood.," *Proc. R. Soc. Med.*, vol. 67, no. 5, pp. 371–372, May 1974.

[57] Naravna imunost, "Študije o cepivih," Naravna imunost. Accessed: Jul. 16, 2018. [Online]. Available: https://www.naravnaimunost.si/studije/

[58] G. T. Stewart, "Re: 'Whooping cough and whooping cough vaccine: the risks and benefits debate,'" *Am. J. Epidemiol.*, vol. 119, no. 1, pp. 135–139, Jan. 1984, doi: 10.1093/oxfordjournals.aje.a113714.

[59] P. Ray *et al.*, "Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study," *Pediatr. Infect.*

Dis. J., vol. 25, no. 9, pp. 768–773, Sep. 2006, doi: 10.1097/01.inf.0000234067.84848.e1.

[60] K. R. Wentz and E. K. Marcuse, "Diphtheria-tetanus-pertussis vaccine and serious neurologic illness: an updated review of the epidemiologic evidence," *Pediatrics*, vol. 87, no. 3, pp. 287–297, Mar. 1991.

[61] J. D. Cherry, "Historical review of pertussis and the classical vaccine," *J. Infect. Dis.*, vol. 174 Suppl 3, pp. S259-263, Nov. 1996, doi: 10.1093/infdis/174.supplement_3.s259.

[62] H. Campbell *et al.*, "Accelerating Control of Pertussis in England and Wales - Volume 18, Number 1—January 2012 - Emerging Infectious Diseases journal - CDC," *Emerg. Infect. Dis.*, vol. 18, no. 1, 2012, doi: 10.3201/eid1801.110784.

[63] S. F. Berkovic *et al.*, "De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study," *Lancet Neurol.*, vol. 5, no. 6, pp. 488–492, Jun. 2006, doi: 10.1016/S1474-4422(06)70446-X.

[64] T. Kovitwanichkanont, "Public health measures for pertussis prevention and control," *Aust. N. Z. J. Public Health*, vol. 41, no. 6, pp. 557–560, 2017, doi: 10.1111/1753-6405.12732.

[65] Public Health Agency of Sweden, "Pertussis surveillance in Sweden, 23rd annual report," 2022. Accessed: Jul. 18, 2024. [Online]. Available: https://www.folkhalsomyndigheten.se/contentassets/975cc036216b48a39b7bf34319d4ecee/pertussis-surveillance-sweden-23rd-annual-report.pdf

[66] Slovensko zdravniško društvo, Združenje za pediatrijo, "Koledar splošnih obveznih in priporočenih cepljenj." Accessed: Nov. 04, 2023. [Online]. Available: https://www.cepljenje.info/zivljenjska-obdobja/otroci/2/koledar-splosnih-obveznih-in--priporocenih-cepljenj

[67] M. A. Witt, P. H. Katz, and D. J. Witt, "Unexpectedly Limited Durability of Immunity Following Acellular Pertussis Vaccination in Preadolescents in a North American Outbreak," *Clin. Infect. Dis.*, vol. 54, no. 12, pp. 1730–1735, Jun. 2012, doi: 10.1093/cid/cis287.

[68] K. Winter *et al.*, "California Pertussis Epidemic, 2010," *J. Pediatr.*, vol. 161, no. 6, pp. 1091–1096, Dec. 2012, doi: 10.1016/j.jpeds.2012.05.041.

[69] N. Klein P., J. Bartlett, A. Rowhani-Rahbar, B. Fireman, and R. Baxter, "Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children," *N. Engl. J. Med.*, vol. 376, no. 11, pp. 1012–1019, 2012, doi: 10.1056/NEJMoa120085.

[70] K. L. Schwartz *et al.*, "Effectiveness of pertussis vaccination and duration of immunity," *CMAJ Can. Med. Assoc. J.*, vol. 188, no. 16, pp. E399–E406, Nov. 2016, doi: 10.1503/cmaj.160193.

[71] World Health Organization, "Whole Cell Pertussis Vaccines: Summary of evidence relevant to schedules." Accessed: Jul. 18, 2018. [Online]. Available: https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Apr2015/10_session_pertussis/Apr2015_session10_evidence_pertussis.pdf

[72] K. H. T. Yeung, P. Duclos, E. A. S. Nelson, and R. C. W. Hutubessy, "An update of the global burden of pertussis in children younger than 5 years: a modelling

study," *Lancet Infect. Dis.*, vol. 17, no. 9, pp. 974–980, Sep. 2017, doi: 10.1016/S1473-3099(17)30390-0.

[73] P. Pitisuttithum, C. Sirivichayakul, J. Dhitavat, A. Pitisuthitham, S. Mansouri, and H. T. Pham, "Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines," *JAMA Netw. Open*, vol. 7, no. 12, p. e2449182, Dec. 2024, doi: 10.1001/jamanetworkopen.2024.49182.

[74] M. M. Agócs, L. E. Markowitz, I. Straub, and I. Dömök, "The 1988-1989 measles epidemic in Hungary: assessment of vaccine failure," *Int. J. Epidemiol.*, vol. 21, no. 5, pp. 1007–1013, Oct. 1992, doi: 10.1093/ije/21.5.1007.

[75] Centers for Disease Control and Prevention, "International Notes Measles - Hungary." Accessed: Jul. 18, 2018. [Online]. Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/00001472.htm

[76] G. Lengyel *et al.*, "Screening of more than 2000 Hungarian healthcare workers' anti-measles antibody level: results and possible population-level consequences," *Epidemiol. Infect.*, vol. 147, p. e7, Sep. 2018, doi: 10.1017/S0950268818002571.

[77] European Centre for Disease Prevention and Control, "Surveillance Atlas of Infectious Diseases." Accessed: Jul. 21, 2024. [Online]. Available: https://atlas.ecdc.europa.eu/public/index.aspx

[78] European Centre for Disease Prevention and Control, "Factsheet about measles." Accessed: Jul. 19, 2024. [Online]. Available: https://www.ecdc.europa.eu/en/measles/facts

[79] European Centre for Disease Prevention and Control, "Disease factsheet about tetanus." Accessed: Jul. 24, 2024. [Online]. Available: https://www.ecdc.europa.eu/en/tetanus/facts

[80] J. Guzman-Cottrill A., C. Lancioni, K. Eriksson, Y. Jae Cho, and L. Juventila, "Notes from the Field: Tetanus in an Unvaccinated Child — Oregon, 2017," *MMWR Morb. Mortal. Wkly. Rep.*, vol. 68, 2019, doi: 10.15585/mmwr.mm6809a3.

[81] Slovensko zdravniško društvo, Združenje za pediatrijo, "Tetanus." Accessed: Jul. 24, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje/tetanus

[82] Statistični urad Republike Slovenije, "Rojeni, 2023: Število rojstev upadlo na najnižjo raven doslej." Accessed: Apr. 08, 2019. [Online]. Available: https://www.stat.si/StatWeb/News/Index/12936

[83] S. G. Tangye *et al.*, "Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee," *J. Clin. Immunol.*, vol. 40, no. 1, pp. 24–64, 2020, doi: 10.1007/s10875-019-00737-x.

[84] Centers for Disease Control and Prevention, "About Primary Immunodeficiency (PI)," Primary Immunodeficiency (PI). Accessed: Jul. 25, 2024. [Online]. Available: https://www.cdc.gov/primary-immunodeficiency/about/index.html

[85] P. Kirkpatrick and S. Riminton, "Primary immunodeficiency diseases in Australia and New Zealand," *J. Clin. Immunol.*, vol. 27, no. 5, pp. 517–524, Sep. 2007, doi: 10.1007/s10875-007-9105-z.

[86] L. Kobrynski, R. W. Powell, and S. Bowen, "Prevalence and Morbidity of Primary Immunodeficiency Diseases, United States 2001–2007," *J. Clin. Immunol.*, vol. 34, no. 8, pp. 954–961, Nov. 2014, doi: 10.1007/s10875-014-0102-8.

[87] V. Modell, M. Knaus, F. Modell, C. Roifman, J. Orange, and L. D. Notarangelo, "Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery," *Immunol. Res.*, vol. 60, no. 1, pp. 132–144, Oct. 2014, doi: 10.1007/s12026-014-8498-z.

[88] K. V. I. Rolston, "Infections in Cancer Patients with Solid Tumors: A Review," *Infect. Dis. Ther.*, vol. 6, no. 1, pp. 69–83, Mar. 2017, doi: 10.1007/s40121-017-0146-1.

[89] Onkološki inštitut Ljubljana, "Rak v Sloveniji 2020," Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, Ljubljana, 2023. Accessed: Jul. 26, 2024. [Online]. Available: https://www.onko-i.si/fileadmin/onko/datoteke/rrs/lp/letno_porocilo_2020.pdf

[90] Zavod Republike Slovenije za presaditve organov in tkiv Slovenija transplant, "Statistika: Življenje niso samo številke." Accessed: Apr. 09, 2019. [Online]. Available: https://www.slovenija-transplant.si/statistika/

[91] H. E. Hsu *et al.*, "Effect of pneumococcal conjugate vaccine on pneumococcal meningitis," *N. Engl. J. Med.*, vol. 360, no. 3, pp. 244–256, Jan. 2009, doi: 10.1056/NEJMoa0800836.

[92] T. R. H. Read, J. S. Hocking, M. Y. Chen, B. Donovan, C. S. Bradshaw, and C. K. Fairley, "The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme," *Sex. Transm. Infect.*, vol. 87, no. 7, pp. 544–547, Dec. 2011, doi: 10.1136/sextrans-2011-050234.

23

Literatura

[1] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[2] Z. Al Nabhani and G. Eberl, "Imprinting of the immune system by the microbiota early in life," *Mucosal Immunol.*, vol. 13, no. 2, pp. 183–189, Mar. 2020, doi: 10.1038/s41385-020-0257-y.

[3] A. Georgountzou and N. G. Papadopoulos, "Postnatal Innate Immune Development: From Birth to Adulthood," *Front. Immunol.*, vol. 8, Aug. 2017, doi: 10.3389/fimmu.2017.00957.

[4] S. Basha, N. Surendran, and M. Pichichero, "Immune Responses in Neonates," *Expert Rev. Clin. Immunol.*, vol. 10, no. 9, pp. 1171–1184, Sep. 2014, doi: 10.1586/1744666X.2014.942288.

[5] E. C. Semmes, J.-L. Chen, R. Goswami, T. D. Burt, S. R. Permar, and G. G. Fouda, "Understanding Early-Life Adaptive Immunity to Guide Interventions for Pediatric Health," *Front. Immunol.*, vol. 11, Jan. 2021, doi: 10.3389/fimmu.2020.595297.

[6] J. Omersel *et al.*, *Imunski sistem - Ključni obrambni sistem človeškega organizma*. Ljubljana: Univerza v Ljubljani, Fakulteta za farmacijo, 2017.

[7] P. Thapa *et al.*, "Infant T cells are developmentally adapted for robust lung immune responses through enhanced T cell receptor signaling," *Sci. Immunol.*, vol. 6, no. 66, p. eabj0789, Dec. 2021, doi: 10.1126/sciimmunol.abj0789.

[8] L. Peeples, "Understanding Kids and COVID," *Proc. Natl. Acad. Sci.*, vol. 119, no. 13, p. e2203753119, Mar. 2022, doi: 10.1073/pnas.2203753119.

[9] M. Duchamp *et al.*, "B-cell subpopulations in children: National reference values," *Immun. Inflamm. Dis.*, vol. 2, no. 3, pp. 131–140, Nov. 2014, doi: 10.1002/iid3.26.

[10] E. A. Clemens and M. A. Alexander-Miller, "Understanding Antibody Responses in Early Life: Baby Steps towards Developing an Effective Influenza Vaccine," *Viruses*, vol. 13, no. 7, p. 1392, Jul. 2021, doi: 10.3390/v13071392.

[11] The Children's Hospital of Philadelphia, "Development of the Immune System." Accessed: Jul. 31, 2024. [Online]. Available: https://www.chop.edu/centers-programs/vaccine-education-center/human-immune-system/development-immune-system

[12] N. Dauby, T. Goetghebuer, T. R. Kollmann, J. Levy, and A. Marchant, "Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections," *Lancet Infect. Dis.*, vol. 12, no. 4, pp. 330–340, Apr. 2012, doi: 10.1016/S1473-3099(11)70341-3.

[13] A. Olin *et al.*, "Stereotypic Immune System Development in Newborn Children," *Cell*, vol. 174, no. 5, pp. 1277-1292.e14, Aug. 2018, doi: 10.1016/j.cell.2018.06.045.

[14] G. Chirico, "Immune development in late preterm neonates," *Ital. J. Pediatr.*, vol. 40, no. Suppl 2, p. A40, Oct. 2014, doi: 10.1186/1824-7288-40-S2-A40.

[15] S. Niewiesk, "Maternal Antibodies: Clinical Significance, Mechanism of Interference with Immune Responses, and Possible Vaccination Strategies," *Front. Immunol.*, vol. 5, p. 446, Sep. 2014, doi: 10.3389/fimmu.2014.00446.

[16] J. E. Atwell, C. S. Lutz, E. G. Sparrow, and D. R. Feikin, "Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries," *Vaccine*, vol. 40, no. 32, pp. 4361–4370, Jul. 2022, doi: 10.1016/j.vaccine.2022.06.034.

[17] S. Dolatshahi *et al.*, "Selective transfer of maternal antibodies in preterm and full-term children," *Sci. Rep.*, vol. 12, no. 1, p. 14937, Sep. 2022, doi: 10.1038/s41598-022-18973-4.

[18] K. M. Edwards, "Maternal antibodies and infant immune responses to vaccines," *Vaccine*, vol. 33, no. 47, pp. 6469–6472, Nov. 2015, doi: 10.1016/j.vaccine.2015.07.085.

[19] A. Kraigher, A. Ihan, and T. Avčin, *Cepljenje in cepiva - dobre prakse varnega cepljenja: univerzitetni učbenik za študente medicinske in zdravstvene fakultete*. Ljubljana: Sekcija za preventivno medicino SZD : Sekcija za klinično mikrobiologijo in bolnišnične okužbe SZD : Inštitut za varovanje zdravja RS, 2011.

[20] S. Waaijenborg *et al.*, "Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage," *J. Infect. Dis.*, vol. 208, no. 1, pp. 10–16, Jul. 2013, doi: 10.1093/infdis/jit143.

[21] E. Leuridan, N. Hens, V. Hutse, M. Ieven, M. Aerts, and P. V. Damme, "Early waning of maternal measles antibodies in era of measles elimination: longitudinal study," *BMJ*, vol. 340, p. c1626, May 2010, doi: 10.1136/bmj.c1626.

[22] C. A. Siegrist, "Neonatal and early life vaccinology," *Vaccine*, vol. 19, no. 25–26, pp. 3331–3346, May 2001.

[23] C. A. Siegrist, "Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants," *Vaccine*, vol. 21, no. 24, pp. 3406–3412, Jul. 2003.

[24] M. Polewicz *et al.*, "Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies," *Vaccine*, vol. 31, no. 31, pp. 3148–3155, Jun. 2013, doi: 10.1016/j.vaccine.2013.05.008.

24

Literatura

[1] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[2] L. Tomljenovic and C. A. Shaw, "Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds?," *Ann. Med.*, vol. 45, no. 2, pp. 182–193, Mar. 2013, doi: 10.3109/07853890.2011.645353.

[3] A. A. A. Oyouni, "Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines," *J. Infect. Public Health*, vol. 16, no. 4, pp. 626–631, Apr. 2023, doi: 10.1016/j.jiph.2023.02.014.

[4] L. Bruni *et al.*, "Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis," *Lancet Glob. Health*, vol. 11, no. 9, pp. e1345–e1362, Aug. 2023, doi: 10.1016/S2214-109X(23)00305-4.

[5] N. Scott-Wittenborn and C. Fakhry, "Epidemiology of HPV Related Malignancies," *Semin. Radiat. Oncol.*, vol. 31, no. 4, pp. 286–296, Oct. 2021, doi: 10.1016/j.semradonc.2021.04.001.

[6] E. M. Burd and C. L. Dean, "Human Papillomavirus," *Microbiol. Spectr.*, vol. 4, no. 4, Jul. 2016, doi: 10.1128/microbiolspec.dmih2-0001-2015.

[7] B. Yin *et al.*, "Association between human papillomavirus and prostate cancer: A meta-analysis," *Oncol. Lett.*, vol. 14, no. 2, pp. 1855–1865, Aug. 2017, doi: 10.3892/ol.2017.6367.

[8] Onkološki inštitut Ljubljana, "Program Zora, Rak materničnega vratu." Accessed: Apr. 11, 2022. [Online]. Available: https://zora.onko-i.si/za-zenske/rak-maternicnega-vratu

[9] National Institutes of Health; National Library of Medicine; Medline Plus, "Pap Smear." Accessed: Apr. 11, 2022. [Online]. Available: https://medlineplus.gov/lab-tests/pap-smear/

[10] World Health Organization, "Cervical cancer." Accessed: Apr. 11, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

[11] J. D. Wright, "Cervical intraepithelial neoplasia: Management," 2024, Accessed: Mar. 23, 2024. [Online]. Available: https://www.uptodate.com/contents/cervical-intraepithelial-neoplasia-management#H1065225504

[12] Onkološki inštitut Ljubljana, "Program Zora, Zgodovinski mejniki." Accessed: Feb. 28, 2019. [Online]. Available: https://zora.onko-i.si/program-zora/zgodovinski-mejniki/

[13] Onkološki inštitut Ljubljana, "Rak v Sloveniji 2018." Onkološki inštitut Ljubljana, 2021. Accessed: Mar. 14, 2022. [Online]. Available: https://www.onko-i.si/fileadmin/onko/datoteke/rrs/lp/Letno_porocilo_2018.pdf

[14] Onkološki inštitut Ljubljana, "Rak v Sloveniji 2009." Onkološki inštitut Ljubljana, 2013. Accessed: Mar. 14, 2022. [Online]. Available: https://www.onko-i.si/fileadmin/onko/datoteke/rrs/lp/Letno_porocilo_2009.pdf

[15] Onkološki inštitut Ljubljana, "Rak v Sloveniji 2015." Onkološki inštitut Ljubljana, 2018. Accessed: Mar. 14, 2022. [Online]. Available: https://www.onko-i.si/fileadmin/onko/datoteke/rrs/lp/Letno_porocilo_2015.pdf

[16] Nacionalni Inštitut za javno zdravje, "Okužba s HPV, rak materničnega vratu in cepljenje proti HPV." Accessed: Aug. 23, 2024. [Online]. Available: http://www.nijz.si/sl/najpogostejsa-vprasanja-in-odgovori-o-okuzbi-s-hpv-raku-maternicnega-vratu-in-cepljenju-proti-hpv-1

[17] K. Tainio, K. A. O. Tikkinine, M. Kyrgiou, and I. Kalliala, "Treatment or surveillance for CIN2: when less is more," The BMJ. Accessed: Feb. 28, 2019. [Online]. Available: https://blogs.bmj.com/bmj/2018/02/28/treatment-or-surveillance-for--cin2-when-less-is-more/

[18] J. Gargano, E. Meites, M. Watson, E. Unger, and L. Markowitz, "Human Papillomavirus," in *Manual for the surveillance of vaccine-preventable diseases*, Centers for Disease Control and Prevention, 2022. Accessed: Apr. 14, 2022. [Online]. Available: https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-5-human-papillomavirus.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html

[19] J. Melnikow, C. McGahan, G. F. Sawaya, T. Ehlen, and A. Coldman, "Cervical Intraepithelial Neoplasia Outcomes After Treatment: Long-term Follow-up From the British Columbia Cohort Study," *JNCI J. Natl. Cancer Inst.*, vol. 101, no. 10, pp. 721–728, May 2009, doi: 10.1093/jnci/djp089.

[20] B. Strander, A. Andersson-Ellström, I. Milsom, and P. Sparén, "Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study," *BMJ*, vol. 335, no. 7629, p. 1077, Nov. 2007, doi: 10.1136/bmj.39363.471806.BE.

[21] K. D. Lycke *et al.*, "Preterm Birth Following Active Surveillance vs Loop Excision for Cervical Intraepithelial Neoplasia Grade 2," *JAMA Netw. Open*, vol. 7, no. 3, p. e242309, Mar. 2024, doi: 10.1001/jamanetworkopen.2024.2309.

[22] R. Liu, C. Liu, and X. Ding, "Association between loop electrosurgical excision procedure and adverse pregnancy outcomes: a meta-analysis," *J. Matern. Fetal Neonatal Med.*, vol. 36, no. 1, p. 2183769, Dec. 2023, doi: 10.1080/14767058.2023.2183769.

[23] M. Kyrgiou *et al.*, "Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease," *Cochrane Database Syst. Rev.*, vol. 2017, no. 11, Nov. 2017, doi: 10.1002/14651858.CD012847.

[24] G. Koliopoulos *et al.*, "Human papillomavirus (HPV) test compared to the Papanicolaou (Pap) test to screen for cervical cancer," 2017, doi: 10.1002/14651858.CD008587.pub2.

[25] Centers for Disease Control and Prevention, "FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)," *Morb. Mortal. Wkly. Rep. MMWR*, 2010, Accessed: Apr. 11, 2022. [Online]. Available: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm

[26] National Health Service, "HPV vaccine." Accessed: Apr. 11, 2023. [Online]. Available: https://www.nhs.uk/conditions/vaccinations/hpv-human-papillomavirus-vaccine/

[27] Slovensko zdravniško društvo, Združenje za pediatrijo, "Humani papilomavirusi (HPV)." Accessed: Apr. 11, 2022. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje/humani-papilomavirusi-hpv

[28] Centers for Disease Control and Prevention, "HPV Vaccination Recommendations." Accessed: Nov. 20, 2024. [Online]. Available: https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html

[29] B. Baldur-Felskov, C. Dehlendorff, C. Munk, and S. K. Kjaer, "Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women," *J. Natl. Cancer Inst.*, vol. 106, no. 3, p. djt460, Mar. 2014, doi: 10.1093/jnci/djt460.

[30] L. E. Markowitz *et al.*, "Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010," *J. Infect. Dis.*, vol. 208, no. 3, pp. 385–393, Aug. 2013, doi: 10.1093/infdis/jit192.

[31] T. R. H. Read, J. S. Hocking, M. Y. Chen, B. Donovan, C. S. Bradshaw, and C. K. Fairley, "The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme," *Sex. Transm. Infect.*, vol. 87, no. 7, pp. 544–547, Dec. 2011, doi: 10.1136/sextrans-2011-050234.

[32] Centers for Disease Control and Prevention, "Sexually transmitted infections treatment guidelines, Anogenital warts." Accessed: Nov. 20, 2024. [Online]. Available: https://www.cdc.gov/std/treatment-guidelines/anogenital-warts.htm

[33] S. Nygård, M. Nygård, M. Orumaa, and B. T. Hansen, "Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals," *Vaccine*, vol. 41, no. 37, pp. 5469–5476, Aug. 2023, doi: 10.1016/j.vaccine.2023.07.031.

[34] L. Mariani, P. Vici, B. Suligoi, G. Checcucci-Lisi, and R. Drury, "Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review," *Adv. Ther.*, vol. 32, no. 1, pp. 10–30, Jan. 2015, doi: 10.1007/s12325-015-0178-4.

[35] D. Normile, "Journal retracts paper claiming neurological damage from HPV vaccine," Science. Accessed: Jan. 22, 2020. [Online]. Available: https://www.sciencemag.org/news/2018/05/journal-retracts-paper-claiming-neurological-damage-hpv-vaccine

[36] L. Tomljenovic, "Death after Quadrivalent Human Papillomavirus (HPV) Vaccination:Causal or Coincidental?," *Pharm. Regul. Aff. Open Access*, vol. 05, no. 01, 2012, doi: 10.4172/2167-7689.S12-001.

[37] Centers for Disease Control and Prevention, "CISA Technical Reports: Review of a published report of cerebral vasculitis after vaccination with the Human

Papillomavirus (HPV) Vaccine." Accessed: Aug. 10, 2024. [Online]. Available: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/technicalreports.html

[38] Centers for Disease Control and Prevention, "Vaccine safety systems, About the Clinical Immunization Safety Assessment (CISA) Project." Accessed: Feb. 23, 2024. [Online]. Available: https://www.cdc.gov/vaccine-safety-systems/hcp/cisa/?CDC_AAref_Val=https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html

[39] C. M. Rice and N. J. Scolding, "The diagnosis of primary central nervous system vasculitis," *BMJ Pract. Neurol.*, vol. 20, no. 2, pp. 109–114, 2020, doi: 10.1136/practneurol-2018-002002.

[40] A. W. Amara, K. Bashir, C. A. Palmer, and H. C. Walker, "Challenges in diagnosis of isolated central nervous system vasculitis," *Brain Behav.*, vol. 1, no. 1, pp. 57–61, Sep. 2011, doi: 10.1002/brb3.12.

[41] D. Gorski, "And now death by Gardasil? Again, not so fast..." Accessed: Mar. 05, 2019. [Online]. Available: https://respectfulinsolence.com/2012/10/31/and-now-death-by-gardasil-again-not-so-fast/

[42] D. M. Harper and M. Jimbo, "Elimination of cervical cancer depends on HPV vaccination and primary HPV screening," *Lancet Infect. Dis.*, vol. 21, no. 10, pp. 1342–1344, Oct. 2021, doi: 10.1016/S1473-3099(20)30992-0.

[43] B. Goldacre, "Jabs 'as bad as the cancer.'" Accessed: Dec. 02, 2024. [Online]. Available: https://www.badscience.net/2009/10/jabs-as-bad-as-the-cancer/

[44] N. P. Klein *et al.*, "Safety of quadrivalent human papillomavirus vaccine administered routinely to females," *Arch. Pediatr. Adolesc. Med.*, vol. 166, no. 12, pp. 1140–1148, Dec. 2012, doi: 10.1001/archpediatrics.2012.1451.

[45] L. Arnheim-Dahlström, B. Pasternak, H. Svanström, P. Sparén, and A. Hviid, "Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study," *BMJ*, vol. 347, p. f5906, Oct. 2013, doi: 10.1136/bmj.f5906.

[46] D. Ferris *et al.*, "Long-term Study of a Quadrivalent Human Papillomavirus Vaccine," *Pediatrics*, vol. 134, no. 3, pp. e657–e665, Sep. 2014, doi: 10.1542/peds.2013-4144.

[47] T. Shimabukuro, J. R. Su, P. L. Marquez, A. Mba-Jonas, J. E. Arana, and M. V. Cano, "Safety of the 9-Valent Human Papillomavirus Vaccine," *Pediatrics*, p. e20191791, Nov. 2019, doi: 10.1542/peds.2019-1791.

[48] J. G. Donahue *et al.*, "Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine," *Pediatrics*, Nov. 2019, doi: 10.1542/peds.2019-1808.

[49] Centers for Disease Control and Prevention, "Vaccine Safety Systems, About the Vaccine Safety Datalink (VSD)." Accessed: Feb. 23, 2024. [Online]. Available: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html

[50] A. Meggiolaro, G. Migliara, and G. La Torre, "Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review," *Hum. Vaccines Immunother.*, vol. 14, no. 5, pp. 1266–1274, May 2018, doi: 10.1080/21645515.2017.1423155.

[51] M. Arbyn, L. Xu, C. Simoens, and P. P. Martin-Hirsch, "Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors," *Cochrane Database Syst. Rev.*, no. 5, 2018, doi: 10.1002/14651858.CD009069.pub3.

[52] L. Jørgensen, P. C. Gøtzsche, and T. Jefferson, "The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias," *BMJ Evid.-Based Med.*, vol. 23, no. 5, pp. 165–168, Oct. 2018, doi: 10.1136/bmjebm-2018-111012.

[53] D. Tovey and K. Soares-Weiser, "Cochrane's Editor in Chief responds to a BMJ Evidence-Based Medicine article criticizing the Cochrane Review of HPV vaccines." Cochrane, Sep. 2018. Accessed: May 13, 2020. [Online]. Available: https://www.cochrane.org/sites/default/files/public/uploads/cochrane_hpv_response_3sep18.pdf

[54] H. Bastian, "Boilover: The Cochrane HPV Vaccine Fire Isn't Really About the Evidence – but it's Critical to Science," Absolutely Maybe. Accessed: Mar. 07, 2019. [Online]. Available: https://blogs.plos.org/absolutely-maybe/2018/09/18/boilover--the-cochrane-hpv-vaccine-fire-isnt-really-about-the-evidence-but-its-critical-to--science/

[55] Društvo za biološko-dinamično gospodarjenje AJDA Sostro, "Odlomek predavanja Antona Komata 'Strokovno manipuliranje resnice.'" Accessed: Feb. 02, 2020. [Online]. Available: https://www.youtube.com/watch?v=0w9-ypYQ-C4

25

Literatura

[1] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[2] E. Hall, P. Wodi A., J. Hamborsky, V. Morelli, and S. Schillie, *Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases*, 14th ed. Washington: Public Health Foundation, 2021. Accessed: Mar. 15, 2021. [Online]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html

[3] J. Daley, "16th-Century Child Mummy Had Oldest Known Case of Hepatitis B," Smithsonian Magazine. Accessed: Apr. 13, 2020. [Online]. Available: https://www.smithsonianmag.com/smart-news/childs-mummy-rewrites-history-hepatitis-b-180967776/

[4] R. Zampino *et al.*, "Hepatitis B virus burden in developing countries," *World J. Gastroenterol.*, vol. 21, no. 42, pp. 11941–11953, Nov. 2015, doi: 10.3748/wjg.v21.i42.11941.

[5] S. Bivegete *et al.*, "Estimates of hepatitis B virus prevalence among general population and key risk groups in EU/EEA/UK countries: a systematic review," *Eurosurveillance*, vol. 28, no. 30, p. 2200738, Jul. 2023, doi: 10.2807/1560-7917.ES.2023.28.30.2200738.

[6] N. G. Kmet, M. Poljak, B. Zakotnik, and M. Matičič, "Hepatitis B Elimination in Children of Slovenian Origin Born in Slovenia After the Introduction of Preventive Strategies: the Results of a National Study," *Slov. J. Public Health*, vol. 61, no. 2, pp. 109–114, Mar. 2022, doi: 10.2478/sjph-2022-0015.

[7] W. Bond, M. Favero, N. Petersen, C. Gravelle, J. Ebert, and J. Maynard, "Survival of hepatitis B virus after drying and storage for one week," *The Lancet*, vol. 317, no. 8219, pp. 550–551, Mar. 1981, doi: 10.1016/S0140-6736(81)92877-4.

[8] T. T. Than *et al.*, "High Environmental Stability of Hepatitis B Virus and Inactivation Requirements for Chemical Biocides," *J. Infect. Dis.*, vol. 219, no. 7, pp. 1044–1048, Apr. 2019, doi: 10.1093/infdis/jiy620.

[9] J. Pattyn, G. Hendrickx, A. Vorsters, and P. Van Damme, "Hepatitis B Vaccines," *J. Infect. Dis.*, vol. 224, no. Suppl 4, pp. S343–S351, Sep. 2021, doi: 10.1093/infdis/jiaa668.

[10] H. Komatsu, A. Inui, T. Murano, T. Tsunoda, T. Sogo, and T. Fujisawa, "Lack of infectivity of HBV in feces from patients with chronic hepatitis B virus infection, and infection using chimeric mice," *BMC Res. Notes*, vol. 8, p. 366, Aug. 2015, doi: 10.1186/s13104-015-1337-z.

[11] J. N. Bennett, "Pediatric Hepatitis B: Etiology," Nov. 2019, Accessed: Jan. 16, 2020. [Online]. Available: https://emedicine.medscape.com/article/964662-overview#a4

[12] P. Offit, "A Look at Each Vaccine: Hepatitis B Vaccine." Accessed: Jan. 25, 2023. [Online]. Available: https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-details/vaccine-hepatitis-b-vaccine

[13] M. Y. W. Zaki *et al.*, "Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma," *Cancers*, vol. 14, no. 5, p. 1255, Feb. 2022, doi: 10.3390/cancers14051255.

[14] C. Osiowy, "From infancy and beyond… ensuring a lifetime of hepatitis B virus (HBV) vaccine-induced immunity," *Hum. Vaccines Immunother.*, vol. 14, no. 8, pp. 2093–2097, May 2018, doi: 10.1080/21645515.2018.1462428.

[15] World Health Organization, "Hepatitis B." Accessed: Apr. 25, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

[16] S. A. Plotkin, P. A. Offit, W. A. Orenstein, and K. M. Edwards, *Plotkin's vaccines*. Elsevier, 2018.

[17] J. D. Lewis, K. B. Enfield, and C. D. Sifri, "Hepatitis B in healthcare workers: Transmission events and guidance for management," *World J. Hepatol.*, vol. 7, no. 3, pp. 488–497, Mar. 2015, doi: 10.4254/wjh.v7.i3.488.

[18] P. Offit, *Deadly choices: how the anti-vaccine movement threatens us all*. Basic books, 2011.

[19] H. Samant, H. S. Amiri, and G. B. Zibari, "Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management," *J. Gastrointest. Oncol.*, vol. 12, no. Suppl 2, pp. S361–S373, Jul. 2021, doi: 10.21037/jgo.2020.02.08.

[20] H. Zhao, X. Zhou, and Y.-H. Zhou, "Hepatitis B vaccine development and implementation," *Hum. Vaccines Immunother.*, vol. 16, no. 7, pp. 1533–1544, doi: 10.1080/21645515.2020.1732166.

[21] F. Mahmood *et al.*, "HBV Vaccines: Advances and Development," *Vaccines*, vol. 11, no. 12, p. 1862, Dec. 2023, doi: 10.3390/vaccines11121862.

[22] T. Vesikari *et al.*, "Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial," *JAMA Netw. Open*, vol. 4, no. 10, p. e2128652, Oct. 2021, doi: 10.1001/jamanetworkopen.2021.28652.

[23] T. Vesikari, J. M. Langley, V. Popovic, and F. Diaz-Mitoma, "PreHevbrio: the first approved 3-antigen hepatitis B vaccine," *Expert Rev. Vaccines*, vol. 22, no. 1, pp. 1041–1054, Dec. 2023, doi: 10.1080/14760584.2023.2274482.

[24] D.-S. Chen, "Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B," *J. Hepatol.*, vol. 50, no. 4, pp. 805–816, Apr. 2009, doi: 10.1016/j.jhep.2009.01.002.

[25] The College of Physicians of Philadelphia, "Hepatitis A and Hepatitis B." Accessed: Jan. 16, 2020. [Online]. Available: https://www.historyofvaccines.org/content/articles/hepatitis-and-hepatitis-b

[26] N. Šinkovec, M. G. Vitek, V. Učakar, and A. T. Skaza, "Cepljenje proti hepatitisu B – obravnava „neodzivnikov"," 2018. [Online]. Available: https://zzp.si/wp-content/uploads/2018/08/Hepatitis-B-neodzivniki-2018_3a-koncna.pdf

[27] N. Khetsuriani, L. Mosina, P. Van Damme, A. Mozalevskis, S. Datta, and R. A. Tohme, "Progress Toward Hepatitis B Control — World Health Organization

European Region, 2016–2019," *Morb. Mortal. Wkly. Rep.*, vol. 70, no. 30, pp. 1029–1035, Jul. 2021, doi: 10.15585/mmwr.mm7030a1.

[28] Nacionalni Inštitut za javno zdravje, "Program cepljenja in zaščite z zdravili za leto 2019." 2019. [Online]. Available: https://www.nijz.si/sites/www.nijz.si/files/uploaded/rs_-2019-026-01204-obp001-0000.pdf

[29] Slovensko zdravniško društvo, Združenje za pediatrijo, "Hepatitis B." Accessed: Sep. 09, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje/hepatitis-b

[30] Sanofi Pasteur, "Hexacima, Summary of product characteristics." Accessed: Dec. 17, 2021. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/hexacima-epar-product-information_sl.pdf

[31] M. J. Alter, "Epidemiology of hepatitis B in Europe and worldwide," *J. Hepatol.*, vol. 39, pp. 64–69, Jan. 2003, doi: 10.1016/S0168-8278(03)00141-7.

[32] M. Mendy *et al.*, "Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B Vaccination in Two Gambian Villages: No Need for a Booster Dose," *PLOS ONE*, vol. 8, no. 3, p. e58029, Mar. 2013, doi: 10.1371/journal.pone.0058029.

[33] Y. Poovorawan, S. Sanpavat, S. Chumdermpadetsuk, and A. Safary, "Long term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers," *Arch. Dis. Child. - Fetal Neonatal Ed.*, vol. 77, no. 1, pp. F47–F51, Jul. 1997, doi: 10.1136/fn.77.1.F47.

[34] P. Van Damme, "Long-term Protection After Hepatitis B Vaccine," *J. Infect. Dis.*, vol. 214, no. 1, pp. 1–3, Jul. 2016, doi: 10.1093/infdis/jiv750.

[35] A. Rahmani, A. Montecucco, B. Kusznir Vitturi, N. Debarbieri, G. Dini, and P. Durando, "Long-Term Effectiveness of Hepatitis B Vaccination in the Protection of Healthcare Students in Highly Developed Countries: A Systematic Review and Meta-Analysis," *Vaccines*, vol. 10, no. 11, Art. no. 11, Nov. 2022, doi: 10.3390/vaccines10111841.

[36] J. Qiu *et al.*, "Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses," *Expert Rev. Vaccines*, vol. 23, no. 1, pp. 69–81, Dec. 2024, doi: 10.1080/14760584.2023.2289566.

[37] M. Bakker, E. M. Bunge, C. Marano, M. de Ridder, and L. De Moerlooze, "Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review," *Expert Rev. Vaccines*, vol. 15, no. 7, pp. 829–851, Jul. 2016, doi: 10.1586/14760584.2016.1150182.

[38] W. Szmuness, C. E. Stevens, E. A. Zang, E. J. Harley, and A. Kellner, "A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report," *Hepatol. Baltim. Md*, vol. 1, no. 5, pp. 377–385, 1981, doi: 10.1002/hep.1840010502.

[39] C. van den Ende, C. Marano, A. van Ahee, E. M. Bunge, and L. De Moerlooze, "The immunogenicity of GSK's recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience," *Expert Rev. Vaccines*, vol. 16, no. 8, pp. 789–809, Aug. 2017, doi: 10.1080/14760584.2017.1338569.

[40] C. Van Den Ende, C. Marano, A. Van Ahee, E. M. Bunge, and L. De Moerlooze, "The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience," *Expert Rev. Vaccines*, vol. 16, no. 8, pp. 811–832, Aug. 2017, doi: 10.1080/14760584.2017.1338568.

[41] World Health Organization, "Hepatitis B vaccination and multiple sclerosis (MS)." Accessed: May 25, 2022. [Online]. Available: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/hepatitis-b-vaccines/multiple-sclerosis

[42] P. Duclos, "Safety of immunization and adverse events following vaccination against hepatitis B," *J. Hepatol.*, vol. 39, pp. 83–88, Jan. 2003, doi: 10.1016/S0168-8278(03)00153-3.

[43] J. B. Classen, "Clustering of Cases of IDDM 2 to 4 Years after Hepatitis B Immunization is Consistent with Clustering after Infections and Progression to IDDM in Autoantibody Positive Individuals [Abstract]," *Open Pediatr. Med. J.*, vol. 2, no. 1, Feb. 2008, doi: 10.2174/1874309900802010001.

[44] World Health Organization, "Introduction of hepatitis B vaccine into childhood immunization services." 2001. [Online]. Available: https://iris.who.int/bitstream/handle/10665/66957/WHO_V-B_01.31_eng.pdf?sequence=1

26

Literatura

[1] K. Rižner, "Resnica o kovidu-19," Karin Rižner. Accessed: Sep. 14, 2024. [Online]. Available: https://karinrizner.si/resnica-o-kovidu-19/

[2] E. C. Holmes *et al.*, "The origins of SARS-CoV-2: A critical review," *Cell*, vol. 184, no. 19, pp. 4848–4856, Sep. 2021, doi: 10.1016/j.cell.2021.08.017.

[3] A. Crits-Christoph *et al.*, "Genetic tracing of market wildlife and viruses at the epicenter of the COVID-19 pandemic," *Cell*, vol. 187, no. 19, pp. 5468-5482.e11, Sep. 2024, doi: 10.1016/j.cell.2024.08.010.

[4] Centers for Disease Control and Prevention, "Similarities and Differences between Flu and COVID-19." Accessed: Aug. 18, 2024. [Online]. Available: https://www.cdc.gov/flu/about/flu-vs-covid19.html?CDC_AAref_Val=https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm

[5] P. L. D. Ruiz *et al.*, "Pandemic influenza and subsequent risk of type 1 diabetes: a nationwide cohort study," *Diabetologia*, vol. 61, no. 9, pp. 1996–2004, 2018, doi: 10.1007/s00125-018-4662-7.

[6] Y. Nishioka *et al.*, "Association between influenza and the incidence rate of new-onset type 1 diabetes in Japan," *J. Diabetes Investig.*, vol. 12, no. 10, pp. 1797–1804, Oct. 2021, doi: 10.1111/jdi.13540.

[7] C. Debuysschere, M. P. Nekoua, E. K. Alidjinou, and D. Hober, "The relationship between SARS-CoV-2 infection and type 1 diabetes mellitus," *Nat. Rev. Endocrinol.*, vol. 20, no. 10, pp. 588–599, Oct. 2024, doi: 10.1038/s41574-024-01004-9.

[8] L. Yang *et al.*, "Human vascularized macrophage-islet organoids to model immune-mediated pancreatic β cell pyroptosis upon viral infection," *Cell Stem Cell*, pp. S1934-5909(24)00293–5, Aug. 2024, doi: 10.1016/j.stem.2024.08.007.

[9] Centers for Disease Control and Prevention, "Multisystem Inflammatory Syndrome (MIS), About MIS." Accessed: Aug. 18, 2024. [Online]. Available: https://www.cdc.gov/mis/index.html

[10] Centers for Disease Control and Prevention, "Covid-19, Long COVID Basics." Accessed: Aug. 18, 2024. [Online]. Available: https://www.cdc.gov/coronavirus/2019--ncov/long-term-effects/index.html

[11] Centers for Disease Control and Prevention, "Covid-19, Signs and Symptoms of Long COVID." Accessed: Nov. 21, 2024. [Online]. Available: https://www.cdc.gov/covid/long-term-effects/long-covid-signs-symptoms.html

[12] S. Lopez-Leon *et al.*, "More than 50 long-term effects of COVID-19: a systematic review and meta-analysis," *Sci. Rep.*, vol. 11, no. 1, Art. no. 1, Aug. 2021, doi: 10.1038/s41598-021-95565-8.

[13] Y. Jiang *et al.*, "Parallel electrophysiological abnormalities due to COVID-19 infection and to Alzheimer's disease and related dementia," *Alzheimers Dement. J. Alzheimers Assoc.*, Aug. 2024, doi: 10.1002/alz.14089.

[14] P. Gautret *et al.*, "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial," *Int. J. Antimicrob. Agents*, vol. 56, no. 1, p. 105949, Jul. 2020, doi: 10.1016/j.ijantimicag.2020.105949.

[15] P. Gautret *et al.*, "Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study," *Travel Med. Infect. Dis.*, vol. 34, p. 101663, Apr. 2020, doi: 10.1016/j.tmaid.2020.101663.

[16] P. Gautret *et al.*, "Retraction notice to 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial' [International Journal of Antimicrobial Agents 56 (2020), 105949]," *Int. J. Antimicrob. Agents*, p. 107416, Dec. 2024, doi: 10.1016/j.ijantimicag.2024.107416.

[17] B. Singh, H. Ryan, T. Kredo, M. Chaplin, and T. Fletcher, "Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?," *Cochrane Database Syst. Rev.*, 2021, doi: 10.1002/14651858.CD013587.pub2.

[18] M. Popp *et al.*, "Ivermectin for preventing and treating COVID-19," *Cochrane Database Syst. Rev.*, 2022, doi: 10.1002/14651858.CD015017.pub3.

[19] V. Bergengruen, "How 'America's Frontline Doctors' Sold Access to Ivermectin," Time. Accessed: Nov. 19, 2022. [Online]. Available: https://time.com/6092368/americas-frontline-doctors-covid-19-misinformation/

[20] M. Lee, "Network of Right-Wing Health Care Providers Is Making Millions Off Hydroxychloroquine and Ivermectin, Hacked Data Reveals," The Intercept. Accessed: Nov. 19, 2022. [Online]. Available: https://theintercept.com/2021/09/28/covid-telehealth-hydroxychloroquine-ivermectin-hacked/

[21] A. Hurt, "Anti-Vax Doctor Simone Gold Sued by Organization She Founded," Medscape. Accessed: Nov. 19, 2022. [Online]. Available: https://www.medscape.com/viewarticle/983869

[22] Centers for Disease Control and Prevention, "Types of COVID-19 Treatments." Accessed: Nov. 19, 2022. [Online]. Available: https://www.cdc.gov/covid/treatment/index.html

[23] E. Dolgin, "The tangled history of mRNA vaccines," *Nature*, vol. 597, no. 7876, pp. 318–324, Sep. 2021, doi: 10.1038/d41586-021-02483-w.

[24] National Institutes of Health, National Human Genome Research Institute, "Messenger RNA (mRNA)." Accessed: Nov. 21, 2022. [Online]. Available: https://www.genome.gov/genetics-glossary/messenger-rna

[25] A. Akbarzadeh *et al.*, "Liposome: classification, preparation, and applications," *Nanoscale Res. Lett.*, vol. 8, no. 1, p. 102, 2013, doi: 10.1186/1556-276X-8-102.

[26] National Institutes of Health, National Human Genome Research Institute, "Understanding COVID-19 mRNA Vaccines." Accessed: Feb. 12, 2025. [Online]. Available: https://www.genome.gov/about-genomics/fact-sheets/Understanding-COVID-19-mRNA-Vaccines

[27] U. Kalinke *et al.*, "Clinical development and approval of COVID-19 vaccines," *Expert Rev. Vaccines*, pp. 1–11, doi: 10.1080/14760584.2022.2042257.

[28] European Medicines Agency, "COVID-19 vaccines: development, evaluation, approval and monitoring." Accessed: Nov. 23, 2022. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-development-evaluation-approval-monitoring

[29] L. R. Baden *et al.*, "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine," *N. Engl. J. Med.*, vol. 384, no. 5, pp. 403–416, Feb. 2021, doi: 10.1056/NEJMoa2035389.

[30] F. P. Polack *et al.*, "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine," *N. Engl. J. Med.*, vol. 383, no. 27, pp. 2603–2615, Dec. 2020, doi: 10.1056/NEJMoa2034577.

[31] J. Sadoff *et al.*, "Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19," *N. Engl. J. Med.*, vol. 384, no. 23, pp. 2187–2201, Jun. 2021, doi: 10.1056/NEJMoa2101544.

[32] A. R. Falsey *et al.*, "Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine," *N. Engl. J. Med.*, vol. 385, no. 25, pp. 2348–2360, Dec. 2021, doi: 10.1056/NEJMoa2105290.

[33] C. Macmillan, "Emergency Use Authorization Vs. Full FDA Approval: What's the Difference?," Yale Medicine. Accessed: Nov. 25, 2022. [Online]. Available: https://www.yalemedicine.org/news/what-does-eua-mean

[34] European Medicines Agency, "Conditional marketing authorisation." Accessed: May 14, 2023. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation

[35] U.S. Food and Drug Administration, "Emergency Use Authorization for Vaccines Explained." Accessed: Nov. 23, 2022. [Online]. Available: https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained

[36] European Medicines Agency, "COVID-19 vaccines: key facts," European Medicines Agency. Accessed: Nov. 23, 2022. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-key-facts

[37] European Medicines Agency, "COVID-19 medicines." Accessed: Nov. 23, 2022. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised

[38] European Medicines Agency, "COVID-19 Vaccine (inactivated, adjuvanted) Valneva." Accessed: Sep. 17, 2024. [Online]. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivated-adjuvanted-valneva

[39] European Medicines Agency, "Vaxzevria (previously COVID-19 Vaccine AstraZeneca)." Accessed: Sep. 17, 2024. [Online]. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria

[40] European Medicines Agency, "VidPrevtyn Beta." Accessed: Sep. 17, 2024. [Online]. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/vidprevtyn-beta

[41] European Medicines Agency, "Jcovden (previously COVID-19 Vaccine Janssen)."

Accessed: Sep. 17, 2024. [Online]. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/jcovden

[42] British Society for Immunology, "Types of vaccines for COVID-19." Accessed: Nov. 23, 2022. [Online]. Available: https://www.immunology.org/public-information/vaccine-resources/covid-19/covid-19-vaccine-infographics/types-covid19-vaccines

[43] R. Vanaparthy, G. Mohan, D. Vasireddy, and P. Atluri, "Review of COVID-19 viral vector-based vaccines and COVID-19 variants," *Infez. Med.*, vol. 29, no. 3, pp. 328–338, Sep. 2021, doi: 10.53854/liim-2903-3.

[44] S. A. Mendonça, R. Lorincz, P. Boucher, and D. T. Curiel, "Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic," *NPJ Vaccines*, vol. 6, no. 1, pp. 1–14, Aug. 2021, doi: 10.1038/s41541-021-00356-x.

[45] E. Waltz, "How nasal-spray vaccines could change the pandemic," *Nature*, vol. 609, no. 7926, pp. 240–242, Sep. 2022, doi: 10.1038/d41586-022-02824-3.

[46] H. Bastian, "Intranasal & Co: A Very Big Month for Mucosal Covid Vaccines," Absolutely Maybe. Accessed: Nov. 26, 2022. [Online]. Available: https://absolutelymaybe.plos.org/2022/09/29/intranasal-co-a-very-big-month-for-mucosal-covid-vaccines/

[47] M. Xing *et al.*, "An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza," *NPJ Vaccines*, vol. 9, no. 1, pp. 1–14, Mar. 2024, doi: 10.1038/s41541-024-00857-5.

[48] Institute for Health Metrics and Evaluation, "COVID-19 vaccine efficacy summary," Institute for Health Metrics and Evaluation. Accessed: Nov. 24, 2022. [Online]. Available: https://www.healthdata.org/covid/covid-19-vaccine-efficacy-summary

[49] Slovensko zdravniško društvo, Združenje za pediatrijo, "Covid-19." Accessed: Sep. 19, 2024. [Online]. Available: https://www.cepljenje.info/bolezni-in-cepiva-zanje/covid-19

[50] D. R. Feikin *et al.*, "Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression," *The Lancet*, vol. 399, no. 10328, pp. 924–944, Mar. 2022, doi: 10.1016/S0140-6736(22)00152-0.

[51] O. J. Watson, G. Barnsley, J. Toor, A. B. Hogan, P. Winskill, and A. C. Ghani, "Global impact of the first year of COVID-19 vaccination: a mathematical modelling study," *Lancet Infect. Dis.*, vol. 22, no. 9, pp. 1293–1302, Sep. 2022, doi: 10.1016/S1473-3099(22)00320-6.

[52] E. Mathieu *et al.*, "Coronavirus Pandemic (COVID-19)," *Our World Data*, Mar. 2020, Accessed: Nov. 24, 2022. [Online]. Available: https://ourworldindata.org/covid-vaccinations

[53] Centers for Disease Control and Prevention, "Coronavirus Disease 2019 (COVID-19) Vaccine Safety." Accessed: Aug. 24, 2024. [Online]. Available: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html

[54] W. N. Whiteley *et al.*, "Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England," *PLoS Med.*, vol. 19, no. 2, p. e1003926, Feb. 2022, doi: 10.1371/journal.pmed.1003926.

[55] R. Bellanti and S. Rinaldi, "Guillain-Barré syndrome: a comprehensive review," *Eur. J. Neurol.*, vol. 31, no. 8, p. e16365, May 2024, doi: 10.1111/ene.16365.

[56] European Medicines Agency, "Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 13 January 2022," 2022. Accessed: Apr. 17, 2023. [Online]. Available: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-january-2022

[57] C. G. Simone and P. D. Emmady, "Transverse Myelitis," in *StatPearls*, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Jan. 31, 2024. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK559302/

[58] National Institute of Neurological Disorders and Stroke, "Transverse Myelitis." Accessed: Mar. 31, 2024. [Online]. Available: https://www.ninds.nih.gov/health-information/disorders/transverse-myelitis

[59] Centers for Disease Control and Prevention, "Vaccine Safety Systems, About V--safe." Accessed: Sep. 17, 2024. [Online]. Available: https://www.cdc.gov/vaccine--safety-systems/v-safe/index.html

[60] A. M. Hause *et al.*, "COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022," *Morb. Mortal. Wkly. Rep.*, vol. 71, no. 35, pp. 1115–1120, Sep. 2022, doi: 10.15585/mmwr.mm7135a3.

[61] A. M. Hause *et al.*, "Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years," *Pediatrics*, vol. 150, no. 2, p. e2022057313, Aug. 2022, doi: 10.1542/peds.2022-057313.

[62] A. M. Hause *et al.*, "Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022," *Morb. Mortal. Wkly. Rep.*, vol. 71, no. 44, pp. 1401–1406, Nov. 2022, doi: 10.15585/mmwr.mm7144a3.

[63] K. Faksova *et al.*, "COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals," *Vaccine*, Feb. 2024, doi: 10.1016/j.vaccine.2024.01.100.

[64] J. A. Frontera *et al.*, "Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System," *Ann. Neurol.*, vol. 91, no. 6, pp. 756–771, 2022, doi: 10.1002/ana.26339.

[65] S. Ip *et al.*, "Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England," *Nat. Commun.*, vol. 15, p. 6085, Jul. 2024, doi: 10.1038/s41467-024-49634-x.

[66] K. Kocher *et al.*, "Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual," *Lancet Infect. Dis.*, vol. 24, no. 5, pp. e272–e274, May 2024, doi: 10.1016/S1473-3099(24)00134-8.

[67] J. Kemei *et al.*, "A scoping review of COVID-19 online mis/disinformation in Black communities," *J. Glob. Health*, vol. 12, p. 05026, Jul. 2022, doi: 10.7189/jogh.12.05026.

[68] Iniciativa slovenskih zdravnikov, "Ivermektin - podpora prizadevanjem prof. Zwittra." Accessed: Nov. 25, 2022. [Online]. Available: https://www.slovenskizdravniki.si/ivermektin-podpora-prizadevanjem-prof-zwittra/

[69] Zdravniška zbornica Slovenije, "Ograditev od »Iniciative slovenskih zdravnikov«," Zdravniška zbornica. Accessed: Nov. 25, 2022. [Online]. Available: https://www.zdravniskazbornica.si/informacije-publikacije-in-analize/obvestila/2021/11/19/ograditev-od-iniciative-slovenskih-zdravnikov

[70] Center for Countering Digital Hate, "The Disinformation Dozen." 2021. Accessed: Oct. 07, 2022. [Online]. Available: https://counterhate.com/wp-content/uploads/2022/05/210324-The-Disinformation-Dozen.pdf

[71] BioNTech, "Comirnaty, Summary of product characteristics." Accessed: Oct. 18, 2024. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf

[72] Moderna, "Spikevax, Summary of product characteristics." Accessed: Oct. 18, 2024. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/spikevax-epar-product-information_en.pdf

[73] Centers for Disease Control and Prevention, "Myths and Facts about COVID-19 Vaccines." Accessed: Sep. 26, 2024. [Online]. Available: https://www.cdc.gov/covid/vaccines/myths-facts.html?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/facts.html

[74] G. D. Kelen and L. Maragakis, "COVID-19 Vaccines: Myth Versus Fact." Accessed: Nov. 25, 2022. [Online]. Available: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/covid-19-vaccines-myth-versus-fact

[75] Centers for Disease Control and Prevention, "COVID-19 Vaccines for People Who Would Like to Have a Baby." Accessed: Oct. 22, 2024. [Online]. Available: https://www.cdc.gov/covid/vaccines/planning-for-pregnancy.html?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/planning-for-pregnancy.html

[76] Centers for Disease Control and Prevention, "Pregnant and Recently Pregnant People." Accessed: Nov. 25, 2022. [Online]. Available: https://archive.cdc.gov/#/details?url=https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnant-people.html

[77] A. Fox, "Can mRNA vaccines affect my genetic code?" Accessed: May 23, 2023. [Online]. Available: https://www.uwa.edu.au/news/Article/2021/June/Can-mRNA-vaccines-affect-my-genetic-code

[78] P. A. Offit and C. A. Moser, "News & Views: 3 Questions You Will Get About the New mRNA Vaccines." Accessed: May 23, 2023. [Online]. Available: https://www.chop.edu/news/news-views-3-questions-you-will-get-about-new-mrna-vaccines

[79] U.S. Food and Drug Administration, "How Gene Therapy Can Cure or Treat Diseases." Accessed: Nov. 26, 2022. [Online]. Available: https://www.fda.gov/consumers/consumer-updates/how-gene-therapy-can-cure-or-treat-diseases

[80] E. Landhuis, "The Definition of Gene Therapy Has Changed," *Nature*, Oct. 2021, doi: 10.1038/d41586-021-02736-8.

[81] W. Jones, "Twice as Many Vaccine Deaths as Covid Deaths in U.S. Households, Poll Finds," The Daily Sceptic. Accessed: Nov. 26, 2022. [Online]. Available: https://

dailysceptic.org/2022/07/07/twice-as-many-vaccine-deaths-as-covid-deaths-in-u--s-households-poll-finds/

[82] World Health Organization, "WHO COVID-19 dashboard." Accessed: Nov. 26, 2022. [Online]. Available: https://covid19.who.int

[83] N. Bai, "COVID-19 Vaccine Fact Vs. Fiction: An Expert Weighs in on Common Fears." Accessed: Nov. 25, 2022. [Online]. Available: https://www.ucsf.edu/news/2021/01/419691/covid-19-vaccine-fact-vs-fiction-expert-weighs-common--fears

[84] X. Yang *et al.*, "COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis," *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.*, vol. 139, pp. 21–27, Feb. 2024, doi: 10.1016/j.ijid.2023.11.029.

[85] F. P. Havers *et al.*, "COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022," *JAMA Intern. Med.*, vol. 182, no. 10, pp. 1071–1081, Oct. 2022, doi: 10.1001/jamainternmed.2022.4299.

[86] A. M. Cavanaugh, K. B. Spicer, D. Thoroughman, C. Glick, and K. Winter, "Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021," *MMWR Morb. Mortal. Wkly. Rep.*, vol. 70, 2021, doi: 10.15585/mmwr.mm7032e1.

[87] Z. Wang *et al.*, "Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection," *Nature*, vol. 595, no. 7867, Art. no. 7867, Jul. 2021, doi: 10.1038/s41586-021-03696-9.

[88] Y. Yu *et al.*, "mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants," *Sci. Rep.*, vol. 12, no. 1, Art. no. 1, Feb. 2022, doi: 10.1038/s41598-022-06629-2.

[89] S. Havervall *et al.*, "Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers," *JAMA*, vol. 325, no. 19, pp. 2015–2016, May 2021, doi: 10.1001/jama.2021.5612.

[90] S. Lopez-Leon *et al.*, "Long-COVID in children and adolescents: a systematic review and meta-analyses," *Sci. Rep.*, vol. 12, no. 1, Art. no. 1, Jun. 2022, doi: 10.1038/s41598-022-13495-5.

[91] A. C. Sick-Samuels and A. Messina, "COVID Vaccine: What Parents Need to Know." Accessed: Nov. 26, 2022. [Online]. Available: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/covid19-vaccine-what-parents-need--to-know

[92] M. E. Singer, I. B. Taub, and D. C. Kaelber, "Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis," *MedRxiv Prepr. Serv. Health Sci.*, p. 2021.07.23.21260998, Mar. 2022, doi: 10.1101/2021.07.23.21260998.

27

Literatura

[1] D. Gorski, "Contrary to antivaccine claims, childhood immunization schedules are evidence-based," Respectful Insolence. Accessed: Jan. 10, 2020. [Online]. Available: https://respectfulinsolence.com/2016/03/07/contrary-to-antivaccine-claims-childhood-immunization-schedules-are-evidence-based/

[2] K. M. Edwards, Y. Maldonado, C. Byington L, T. Jefferson, and V. Demicheli, "Is the timing of recommended childhood vaccines evidence based?," *Br. Med. J.*, 2016.

[3] Centers for Disease Control and Prevention, "Developing Safe and Effective Vaccines." Accessed: Oct. 04, 2024. [Online]. Available: https://www.cdc.gov/vaccines--children/about/developing-safe-effective-vaccines.html

[4] J. C. Smith, "The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP)," *Vaccine*, vol. 28, pp. A68–A75, Apr. 2010, doi: 10.1016/j.vaccine.2010.02.037.

[5] Centers for Disease Control and Prevention, "Advisory Committee on Immunization Practices (ACIP), ACIP Work Groups." Accessed: Feb. 14, 2024. [Online]. Available: https://www.cdc.gov/vaccines/acip/workgroups.html

[6] European Vaccination Information Portal, "Vaccination schedules in the EU/EEA." Accessed: Oct. 04, 2024. [Online]. Available: https://vaccination-info.europa.eu/en/about-vaccines/when-vaccinate/vaccination-schedules-eueea

[7] A. Kraigher, A. Ihan, and T. Avčin, *Cepljenje in cepiva - dobre prakse varnega cepljenja: univerzitetni učbenik za študente medicinske in zdravstvene fakultete*. Ljubljana: Sekcija za preventivno medicino SZD : Sekcija za klinično mikrobiologijo in bolnišnične okužbe SZD : Inštitut za varovanje zdravja RS, 2011.

[8] Centers for Disease Control and Prevention, "Vaccine Safety, Multiple Vaccines at Once." Accessed: Aug. 08, 2024. [Online]. Available: https://www.cdc.gov/vaccinesafety/concerns/multiple-vaccines-immunity.html

[9] P. A. Offit *et al.*, "Addressing Parents' Concerns: Do Multiple Vaccines Overwhelm or Weaken the Infant's Immune System?," *Pediatrics*, vol. 109, no. 1, pp. 124–129, Jan. 2002, doi: 10.1542/peds.109.1.124.

[10] F. DeStefano, C. S. Price, and E. S. Weintraub, "Increasing Exposure to Antibody-Stimulating Proteins and Polysaccharides in Vaccines Is Not Associated with Risk of Autism," *J. Pediatr.*, vol. 163, no. 2, pp. 561–567, Aug. 2013, doi: 10.1016/j.jpeds.2013.02.001.

[11] Committee on the Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule; Board on Population Health and Public Health Practice; Institute of Medicine, *Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies*. Washington, D.C.: National Academies Press (US), 2013. Accessed: Jan. 12, 2020. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK206948/

[12] P . A. Offit and C. A. Moser, "The Problem With Dr Bob's Alternative Vaccine Schedule," *Pediatrics*, vol. 123, no. 1, pp. e164–e169, Jan. 2009, doi: 10.1542/peds.2008-2189.
[13] T. Haelle, "Sears and Gordon: Should Misleading Vaccine Advice Have Professional Consequences?," Forbes. Accessed: Jan. 13, 2020. [Online]. Available: https://www.forbes.com/sites/tarahaelle/2015/02/03/sears-and-gordon-should-misleading-vaccine-advice-have-professional-consequences/
[14] J. Gordon, "Vaccination Schedule," Jay Gordon, MD FAAP. Accessed: Jan. 13, 2020. [Online]. Available: http://drjaygordon.com/vaccinations/schedule.html
[15] Oregon Medical Board, State of Oregon, "Order of emergency suspension." Accessed: Feb. 14, 2023. [Online]. Available: https://omb.oregon.gov/clients/ormb/OrderDocuments/e579dd35-7e1b-471f-a69a-3a800317ed4c.pdf?fbclid=IwAR1cbKpfMEANt401rRTXRUxMbv_EDZGaKUTw32-jFkuCnr3KfgOwQ2Vowjw
[16] A. Grignolio, *Kdo se boji cepiv?*, 1st ed. *cf, 2018.
[17] R. Monahan, "Pediatrician Paul Thomas Has 15,000 Patients—and He Tells Them the Measles Vaccine Might Cause Autism," Willamette Week. Accessed: Jan. 13, 2020. [Online]. Available: https://www.wweek.com/news/2019/03/20/pediatrician--paul-thomas-has-15000-patients-and-he-tells-them-the-measles-vaccine-might--cause-autism/
[18] A. F. Dempsey, S. Schaffer, D. Singer, A. Butchart, M. Davis, and G. L. Freed, "Alternative Vaccination Schedule Preferences Among Parents of Young Children," *Pediatrics*, vol. 128, no. 5, pp. 848–856, Nov. 2011, doi: 10.1542/peds.2011-0400.
[19] A. L. Hargreaves *et al.*, "Adherence to Timely Vaccinations in the United States," *Pediatrics*, vol. 145, no. 3, p. e20190783, Mar. 2020, doi: 10.1542/peds.2019-0783.
[20] K. H. Nguyen, R. Zhao, C. Mullins, L. Corlin, P. Beninger, and R. A. Bednarczyk, "Trends in vaccination schedules and up-to-date status of children 19-35 months, United States, 2015-2020," *Vaccine*, vol. 41, no. 2, pp. 467–475, Jan. 2023, doi: 10.1016/j.vaccine.2022.11.023.
[21] M. Wheeler and A. M. Buttenheim, "Parental vaccine concerns, information source, and choice of alternative immunization schedules," *Hum. Vaccines Immunother.*, vol. 9, no. 8, pp. 1782–1789, Aug. 2013, doi: 10.4161/hv.25959.
[22] J. Gordon, "Jay Gordon - About." Accessed: Oct. 03, 2024. [Online]. Available: https://www.drjaygordon.com/jay-gordon-about
[23] B. Sears, "Dr Bob's Story." Accessed: Oct. 03, 2024. [Online]. Available: https://drbobsears.com/about-dr-bob-sears/bio/
[24] The Institute for Functional Medicine, "Paul Thomas, MD, FAAP." Accessed: Oct. 03, 2024. [Online]. Available: https://www.ifm.org/about/profile/paul-thomas-md--faap/
[25] V. Iannelli, "What Is the Evidence for Alternative Vaccine Schedules?" Accessed: Jan. 13, 2020. [Online]. Available: https://vaxopedia.org/2018/03/27/what-is-the--evidence-for-alternative-vaccine-schedules/
[26] K. M. Edwards and J. M. Hackell, "Countering Vaccine Hesitancy," *Pediatrics*, vol. 138, no. 3, p. e20162146, Sep. 2016, doi: 10.1542/peds.2016-2146.

[27] P. Boghani, "Dr. Robert W. Sears: Why Partial Vaccinations May Be an Answer." Accessed: Feb. 14, 2023. [Online]. Available: https://www.pbs.org/wgbh/frontline/article/robert-w-sears-why-partial-vaccinations-may-be-an-answer/

[28] S. J. Hambidge *et al.*, "Timely versus delayed early childhood vaccination and seizures," *Pediatrics*, vol. 133, no. 6, pp. e1492-1499, Jun. 2014, doi: 10.1542/peds.2013-3429.

[29] Slovensko zdravniško društvo, Združenje za pediatrijo, "Obvezno cepljenje v Sloveniji." Accessed: Oct. 02, 2024. [Online]. Available: https://www.cepljenje.info/cepljenje-v-sloveniji/obvezno-cepljenje-v-sloveniji

[30] TerraNuova.it, "Vaccinazioni: l'appello di oltre 100 medici." Accessed: Jan. 24, 2020. [Online]. Available: http://www.terranuova.it/News/Genitori-e-figli/Vaccinazioni-l-appello-di-oltre-100-medici

28

Literatura

[1] Naravna imunost, "Poti do imunosti," Naravna imunost. Accessed: Jul. 16, 2018. [Online]. Available: https://www.naravnaimunost.si/poti-do-imunosti/

[2] R. Poličnik and S. Perčič, "Prehrana in zdravje." 2022. Accessed: Jul. 08, 2022. [Online]. Available: https://nijz.si/wp-content/uploads/2022/07/prehrana_skozi_zivljenje.cleaned.pdf

[3] L. B. Palevsky, "The holistic pediatric services." Accessed: May 08, 2019. [Online]. Available: https://www.northportwellnesscenter.com/practitioner/lawrence-palevsky/services

[4] A. Tyrrel, "Choosing A Holistic Pediatrician: Key Factors To Consider For Your Child's Well-being." Accessed: Oct. 07, 2024. [Online]. Available: https://www.drashleypediatrics.com/holistic-pediatrician/choosing-a-holistic-pediatrician%3A--key-factors-to-consider-for-your-child%E2%80%99s-well-being

[5] R. Murdoch, "Here are some concerns about vaccines." Accessed: May 08, 2019. [Online]. Available: https://www.naturalfamilyphysicians.com/general-5

[6] G. Soldner, "What is our global attitude to vaccinating?," Goetheanum. Accessed: Jan. 31, 2023. [Online]. Available: https://goetheanum.ch/en/news/wie-stellen-wir--uns-weltweit-zum-thema-impfen

[7] S. H. van Wees, K. Abunnaja, and S. Mounier-Jack, "Understanding and explaining the link between Anthroposophy and vaccine hesitancy: A systematic review," In Review, 2023. doi: 10.21203/rs.3.rs-2208907/v1.

[8] Vlada Republike Slovenije, "Zakon o zdravilstvu (ZZdrav)." Accessed: May 30, 2019. [Online]. Available: https://pisrs.si/pregledPredpisa?id=ZAKO4283

[9] Vlada Republike Slovenije, "Zakon o spremembah in dopolnitvah Zakona o zdravilstvu," pisrs. Accessed: Feb. 21, 2023. [Online]. Available: https://pisrs.si/pregledPredpisa?id=ZAKO5649

[10] Vlada Republike Slovenije, "Pravilnik o opredelitvi zdravilskih sistemov in zdravilskih metod ter o postopku evidentiranja, priznavanja in nadzora zdravilskih sistemov in zdravilskih metod, ki se uvajajo v zdravilsko dejavnost." 2008. Accessed: Feb. 21, 2023. [Online]. Available: https://pisrs.si/pregledPredpisa?id=PRAV8810

[11] Vlada Republike Slovenije, "Pravilnik o preizkusu iz zdravstvenih vsebin za zdravilce, ki nimajo zdravstvene izobrazbe." Accessed: May 30, 2019. [Online]. Available: https://pisrs.si/pregledPredpisa?id=PRAV8813

[12] Republika Slovenija, Ministrstvo za javno upravo, "Licenca za opravljanje zdravilske dejavnosti." Accessed: Feb. 21, 2023. [Online]. Available: https://spot.gov.si/sl/dejavnosti-in-poklici/dovoljenja/licenca-za-opravljanje-zdravilske-dejavnosti/

[13] Republika Slovenija, Ministrstvo za javno upravo, "Dovoljenje Zdravilske zbornice / Ministrstva za zdravje." Accessed: Feb. 21, 2023. [Online]. Available: https://spot.

gov.si/sl/dejavnosti-in-poklici/dovoljenja/dovoljenje-zdravilske-zbornice-ministrstva-za-zdravje/
[14] Vlada Republike Slovenije, "Zakon o spremembah in dopolnitvah Zakona o zdravstveni dejavnosti." Accessed: Feb. 24, 2023. [Online]. Available: https://pisrs.si/pregledPredpisa?id=ZAKO7305
[15] Vlada Republike Slovenije, "Zakon o spremembah in dopolnitvah Zakona o zdravniški službi," pisrs. Accessed: Feb. 24, 2023. [Online]. Available: http://pisrs.si
[16] Društvo Za dušo, "120-urni mednarodno priznan ajurvedski tečaj." Accessed: Feb. 21, 2023. [Online]. Available: https://www.zaduso.si/120-urni-mednarodno-priznan-ajurvedski-tecaj/
[17] Slovensko homeopatsko društvo, "Homeopatija v Sloveniji." [Online]. Available: https://www.shd.si/default.asp?mid=sl&pid=Homeopatija-v-Sloveniji
[18] Slovensko homeopatsko društvo, "Izhodišča zakona so objavljena." Accessed: Feb. 24, 2023. [Online]. Available: https://www.shd.si/default.asp?mid=sl&pid=novice_podrobno&katid=21&novicaid=417
[19] E. Ernst, "Edzard Ernst, About." Accessed: May 08, 2019. [Online]. Available: https://edzardernst.com/about/
[20] E. Ernst, *A Scientist in Wonderland, a memoir of searching for truth and finding truble*. Imprint Academic, 2015.
[21] E. Ernst, *Trick or treatment*. Transworld Publishers, 2009.
[22] ABC Homeopathy, "Formalinum." Accessed: May 08, 2019. [Online]. Available: https://abchomeopathy.com/r.php/Forma
[23] ABC Homeopathy, "Aldehyde." Accessed: May 08, 2019. [Online]. Available: https://abchomeopathy.com/r.php/ALD
[24] ABC Homeopathy, "Mercurius Vivus." Accessed: May 08, 2019. [Online]. Available: https://abchomeopathy.com/r.php/Merc
[25] ABC Homeopathy, "Alumina." Accessed: May 08, 2019. [Online]. Available: https://abchomeopathy.com/r.php/Alum#..
[26] ABC Homeopathy, "Borax." Accessed: May 08, 2019. [Online]. Available: https://abchomeopathy.com/r.php/Bor
[27] M. Norland and P. Fraser, "Proving: Latex Condom (Latex Vulcani)." 2001. Accessed: Jul. 06, 2022. [Online]. Available: https://www.schoolofhealth.com/docs/SOH/Provings/Proving_of_Latex_Condom_BLK_FINAL.pdf
[28] ABC Homeopathy, "Strychninum." Accessed: May 08, 2019. [Online]. Available: https://abchomeopathy.com/r.php/Stry
[29] ABC Homeopathy, "Gun Powder." Accessed: May 08, 2019. [Online]. Available: https://abchomeopathy.com/r.php/Gun
[30] ABC Homeopathy, "Sulphuricum Acidum." Accessed: May 08, 2019. [Online]. Available: https://abchomeopathy.com/r.php/Sul-ac
[31] ABC Homeopathy, "Lac Felinum." Accessed: May 08, 2019. [Online]. Available: https://abchomeopathy.com/r.php/Lac-f
[32] K. Dam, "Berlin Wall." Accessed: Feb. 01, 2023. [Online]. Available: http://www.interhomeopathy.org/berlin_wall

[33] S. Novella, "Homeopathic X-rays," NeuroLogica Blog. Accessed: Feb. 23, 2020. [Online]. Available: https://theness.com/neurologicablog/index.php/homeopathic-x-rays/
[34] J.-A. Huenecke, "Lux foraminis nigris Homeopathic Proving," The Field Provings. Accessed: Feb. 01, 2023. [Online]. Available: https://www.thefieldprovings.org/lux-foraminis-nigris-proving
[35] R. T. Mathie, J. Frye, and P. Fisher, "Homeopathic Oscillococcinum® for preventing and treating influenza and influenza-like illness," *Cochrane Database Syst. Rev.*, vol. 2015, no. 1, p. CD001957, Jan. 2015, doi: 10.1002/14651858.CD001957.pub6.
[36] European Committee for Homeopathy, "Provings," The European Committee for Homeopathy. Accessed: Feb. 23, 2020. [Online]. Available: https://homeopathyeurope.org/research/provings/
[37] Slovensko homeopatsko društvo, "O homeopatiji." Accessed: May 08, 2019. [Online]. Available: http://shd.si/default.asp?mid=sl&pid=O-homeopatiji
[38] The European Committee for Homeopathy, "The current regulatory status of homeopathic medicine in Europe," The European Committee for Homeopathy. Accessed: May 30, 2019. [Online]. Available: https://homeopathyeurope.org/regulatory-status/
[39] European Parliament and European Council, *Directive 2001/83/EC of the European parliament and of the Council on the Community code relating to medicinal products for human use*. 2001. Accessed: Sep. 10, 2022. [Online]. Available: https://eur-lex.europa.eu/legal-content/SL/TXT/HTML/?uri=CELEX:32001L0083&from=SL
[40] Medicines and Healthcare products Regulatory Agency, "Blue Guide: advertising and promotion of medicines in UK; Appendix 2: Homeopathic Medicines: Guidance on advertising." 2014. Accessed: Apr. 11, 2020. [Online]. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/824550/Appendix_2_-_Blue_Guide.pdf
[41] M. Robbins, "MPs' damning verdict: Homeopathy is useless and unethical," *The Guardian*, Feb. 22, 2010. Accessed: Apr. 11, 2020. [Online]. Available: https://www.theguardian.com/science/blog/2010/feb/22/mps-verdict-homeopathy-useless-unethical
[42] European Medicines Agency, "Report on EMEA workshop on homeopathic medicinal products," 2007. Accessed: Oct. 10, 2023. [Online]. Available: https://www.ema.europa.eu/en/documents/report/report-emea-workshop-homeopathic-medicinal-products_en.pdf
[43] J. Slatnar and T. Trebušak, "Mastitisi in njihovi povzročitelji pri kravah molznicah." Accessed: Feb. 01, 2023. [Online]. Available: https://lj.kgzs.si/Portals/1/A-Splet2021/Mastitis%20koncni-%20tehnoloski%20list%2014102021%20%281%29.pdf
[44] D. Keller and A. Sundrum, "Comparative effectiveness of individualised homeopathy and antibiotics in the treatment of bovine clinical mastitis: randomised controlled trial," *Vet. Rec.*, vol. 182, no. 14, p. 407, 07 2018, doi: 10.1136/vr.104555.
[45] A. L. Bodey, C. J. Almond, and M. A. Holmes, "Double-blinded randomised placebo-controlled clinical trial of individualised homeopathic treatment of hyperthyroid cats," *Vet. Rec.*, vol. 180, no. 15, p. 377, Apr. 2017, doi: 10.1136/vr.104007.

[46] K. Linde *et al.*, "Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials," *The Lancet*, vol. 350, no. 9081, pp. 834–843, Sep. 1997, doi: 10.1016/S0140-6736(97)02293-9.

[47] K. Linde, M. Scholz, G. Ramirez, N. Clausius, D. Melchart, and W. B. Jonas, "Impact of study quality on outcome in placebo-controlled trials of homeopathy," *J. Clin. Epidemiol.*, vol. 52, no. 7, pp. 631–636, Jul. 1999, doi: 10.1016/s0895-4356(99)00048-7.

[48] A. Shang *et al.*, "Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy," *Lancet Lond. Engl.*, vol. 366, no. 9487, pp. 726–732, Sep. 2005, doi: 10.1016/S0140-6736(05)67177-2.

[49] K. Hawke, D. King, M. L. van Driel, and T. M. McGuire, "Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children," *Cochrane Database Syst. Rev.*, vol. 12, no. 12, 2022, doi: 10.1002/14651858.CD005974.pub6.

[50] Slovensko homeopatsko društvo, "Metaanalize in homeopatija." Accessed: May 10, 2019. [Online]. Available: http://shd.si/default.asp?mid=sl&pid={1e9d8bdf-e0b8-4b57-be9e-c4a0a51821f1}

[51] R. Bausell Barker, *Snake oil science*. Oxford University Press, 2007.

[52] M. Loeb *et al.*, "A randomized, blinded, placebo-controlled trial comparing antibody responses to homeopathic and conventional vaccines in university students," *Vaccine*, vol. 36, no. 48, pp. 7423–7429, 19 2018, doi: 10.1016/j.vaccine.2018.08.082.

[53] M. Gilbert, "Homeopathy Support For Measles And Chickenpox," College of Natural Health & Homeopathy. Accessed: Feb. 01, 2023. [Online]. Available: https://cnhh.ac.nz/homeopathy-support-for-measles-and-chickenpox/

[54] The European Committee for Homeopathy, "Benefits of Homeopathy." Accessed: Apr. 11, 2020. [Online]. Available: https://homeopathyeurope.org/homeopathy-in-practice/benefits-of-homeopathy/

[55] S. Kaplan, "Hundreds of Babies Harmed by Homeopathic Remedies, Families Say," Scientific American. Accessed: May 10, 2019. [Online]. Available: https://www.scientificamerican.com/article/hundreds-of-babies-harmed-by-homeopathic-remedies-families-say/

[56] E. Ernst, "Homeopaths should carry public health warnings!" Accessed: May 10, 2019. [Online]. Available: https://edzardernst.com/2019/05/homeopaths-should-carry-public-health-warnings/

[57] British Homeopathic Association, "First aid for your holidays." Accessed: May 10, 2019. [Online]. Available: https://www.britishhomeopathic.org/charity/how-we-can-help/articles/conditions/f/the-travelling-homeopath/

[58] Centers for Disease Control and Prevention, "A Cautionary Tale: The Risks of Unproven Antimalarials." Accessed: May 10, 2019. [Online]. Available: https://stacks.cdc.gov/view/cdc/104132

[59] P. Delaunay, E. Cua, P. Lucas, and P. Marty, "Homoeopathy may not be effective in preventing malaria," *Br. Med. J.*, vol. 321, no. 7271, p. 1288, Nov. 2000.

[60] S. Wiesener, T. Falkenberg, G. Hegyi, J. Hök, P. R. di Sarsina, and V. Fønnebø, "Legal

status and regulation of CAM in Europe," 2012, Accessed: May 13, 2019. [Online]. Available: https://cam-europe.eu/wp-content/uploads/2018/09/CAMbrella-WP2--part_1final.pdf

[61] World Health Organization, "Acupuncture: Review and analysis of reports on controlled clinical trials." Accessed: Feb. 01, 2023. [Online]. Available: https://chiro.org/acupuncture/FULL/Acupuncture_WHO_2003.pdf

[62] D. Colquhoun, "NICE rejects acupuncture for low back pain," DC's Improbable Science. Accessed: May 11, 2019. [Online]. Available: http://www.dcscience.net/2016/03/24/nice-rejects-acupuncture-for-low-back-pain/

[63] D. Colquhoun and S. Novella, "Acupuncture is a theatrical placebo: the end of a myth," DC's Improbable Science. Accessed: May 11, 2019. [Online]. Available: http://www.dcscience.net/2013/05/30/acupuncture-is-a-theatrical-placebo-the--end-of-a-myth/

[64] Relief Acupuncture, "WHO Approved list." Accessed: Feb. 01, 2023. [Online]. Available: https://www.reliefacupuncturepa.com/who-approved-list

[65] K. Kirschner, R. Mandell, J. Knowlton, M. J. Romeo, and L. Conboy, "Acupuncture in Uganda: A Research Letter on the Integration of Acupuncture With Conventional Biomedical Treatments," *Glob. Adv. Health Med.*, vol. 3, no. 4, pp. 61–63, Jul. 2014, doi: 10.7453/gahmj.2014.010.

[66] S. Xu *et al.*, "Adverse Events of Acupuncture: A Systematic Review of Case Reports," *Evid.-Based Complement. Altern. Med. ECAM*, vol. 2013, 2013, doi: 10.1155/2013/581203.

[67] E. Ernst, "Acupuncture – a treatment to die for?," *J. R. Soc. Med.*, vol. 103, no. 10, pp. 384–385, Oct. 2010, doi: 10.1258/jrsm.2010.100181.

[68] S. Won Lee, "A Needle Penetrating the Stomach Cavity after Acupuncture," *Clin. Endosc.*, vol. 47, no. 3, pp. 258–261, 2014, doi: 10.5946/ce.2014.47.3.258.

[69] J. Wheway, T. B. Agbabiaka, and E. Ernst, "Patient safety incidents from acupuncture treatments: A review of reports to the National Patient Safety Agency," *Int. J. Risk Saf. Med.*, vol. 24, no. 3, pp. 163–169, Jan. 2012, doi: 10.3233/JRS-2012-0569.

[70] D. Adams, F. Cheng, H. Jou, S. Aung, Y. Yasui, and S. Vohra, "The safety of pediatric acupuncture: a systematic review," *Pediatrics*, vol. 128, no. 6, pp. e1575-1587, Dec. 2011, doi: 10.1542/peds.2011-1091.

[71] L. Cahlíková *et al.*, "Pharmacognosy and Its Role in the System of Profile Disciplines in Pharmacy," *Nat. Prod. Commun.*, vol. 15, no. 9, p. 1934578X20945450, Sep. 2020, doi: 10.1177/1934578X20945450.

[72] Association of Naturopathic Practitioners, "Naturopathic herbal medicine." Accessed: May 12, 2019. [Online]. Available: https://theanp.co.uk/herbal-medicine

[73] N. Gilbert, "Regulations: Herbal medicine rule book," *Nature*, vol. 480, no. 7378, pp. S98–S99, Dec. 2011, doi: 10.1038/480S98a.

[74] European Medicines Agency, "Herbal medicinal products." Accessed: Oct. 07, 2024. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory-overview/herbal-medicinal-products

[75] European Medicines Agency, "Q&A on non-European traditional herbal medicinal products." 2023. Accessed: Oct. 15, 2023. [Online]. Available: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-european-union-framework-traditional-herbal-medicinal-products-including-those-non-european-tradition_en.pdf

[76] T. Wegener, B. Deitelhoff, and A. Silber-Mankowsky, "Drug safety aspects of herbal medicinal products," *Wien. Med. Wochenschr.*, vol. 165, no. 11–12, pp. 243–250, Jun. 2015, doi: 10.1007/s10354-015-0370-9.

[77] European Medicines Agency, "Implementation of the pharmacovigilance legislation." Accessed: Oct. 07, 2024. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory-overview/pharmacovigilance-overview/legal-framework-pharmacovigilance/implementation-pharmacovigilance-legislation

[78] Y. Xiong *et al.*, "Market access for Chinese herbal medicinal products in Europe--A ten-year review of relevant products, policies, and challenges," *Phytomedicine Int. J. Phytother. Phytopharm.*, vol. 103, p. 154237, Aug. 2022, doi: 10.1016/j.phymed.2022.154237.

[79] G. Onder and R. Liperoti, "Herbal Medications," *JAMA*, vol. 315, no. 10, p. 1068, Mar. 2016, doi: 10.1001/jama.2015.19388.

[80] D. Colquhoun, "Herbs get the push: no statutory regulation for western herbalists or Traditional Chinese Medicine – DC's Improbable Science." Accessed: May 15, 2019. [Online]. Available: http://www.dcscience.net/2015/03/30/herbs-get-the-push-no-statutory-regulation-for-western-herbalists-or-traditional-chinese-medicine/

[81] L. Schneider, "Deliferate misteaks by Tradional Chinese Medicine," For Better Science. Accessed: Apr. 10, 2020. [Online]. Available: https://forbetterscience.com/2020/01/16/deliferate-misteaks-by-tradional-chinese-medicine/

[82] National Health Service, "Herbal medicines." Accessed: Feb. 06, 2023. [Online]. Available: https://www.nhs.uk/conditions/herbal-medicines/

[83] M. Sakurai, "Perspective: Herbal dangers," *Nature*, vol. 480, no. 7378, Art. no. 7378, Dec. 2011, doi: 10.1038/480S97a.

[84] M. L. Coghlan *et al.*, "Combined DNA, toxicological and heavy metal analyses provides an auditing toolkit to improve pharmacovigilance of traditional Chinese medicine (TCM)," *Sci. Rep.*, vol. 5, p. 17475, Dec. 2015, doi: 10.1038/srep17475.

[85] K. F. M. Opuni *et al.*, "Contamination of herbal medicinal products in low-and-middle-income countries: A systematic review," *Heliyon*, vol. 9, no. 9, p. e19370, Aug. 2023, doi: 10.1016/j.heliyon.2023.e19370.

[86] R. W. Byard, I. Musgrave, G. Maker, and M. Bunce, "What risks do herbal products pose to the Australian community?," *Med. J. Aust.*, vol. 206, no. 2, pp. 86–90, 2017, doi: 10.5694/mja16.00614.

[87] B. Klier *et al.*, "Pesticide residues in herbal drugs: Evaluation of a database," *J. Appl. Res. Med. Aromat. Plants*, vol. 15, p. 100223, Dec. 2019, doi: 10.1016/j.jarmap.2019.100223.

[88] H. Albert, B. Klier, M. Knödler, and B. Steinhoff, "Findings on the heavy metal content in herbal drugs and essential oils - an update," *Pharmeuropa Bio Sci. Notes*, vol. 2018, pp. 62–111, 2018.

[89] B. Steinhoff, "Pyrrolizidine Alkaloid Contamination in Medicinal Plants: Regulatory Requirements and Their Impact on Production and Quality Control of Herbal Medicinal Products," *Planta Med.*, vol. 88, pp. 125–129, May 2021, doi: 10.1055/a-1494-3623.

[90] Javna agencija Republike Slovenije za zdravila in medicinske pripomočke, "Pirolizidinski alkaloidi v (tradicionalnih) zdravilih rastlinskega izvora." 2016. Accessed: Oct. 07, 2024. [Online]. Available: https://nijz.si/wp-content/uploads/2022/12/DB_objava_2016_06_16_pirolozidinski.pdf

[91] European Medicines Agency, "Public statement on contamination of herbal medicinal products/traditional herbal medicinal products with pyrrolizidine alkaloids." 2016. Accessed: Oct. 07, 2024. [Online]. Available: https://www.ema.europa.eu/en/documents/public-statement/public-statement-contamination-herbal-medicinal-productstraditional-herbal-medicinal-products-pyrrolizidine-alkaloids_en.pdf

[92] European Medicines Agency, "Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) including recommendations regarding contamination of herbal medicinal products with PAs." Accessed: Oct. 08, 2024. [Online]. Available: https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf

[93] S. Novella, "Herbal Products and Pregnancy," Science-Based Medicine. Accessed: Jun. 08, 2020. [Online]. Available: https://sciencebasedmedicine.org/herbal-products-and-pregnancy/

[94] T. Worth, "Ayurveda: Does it really work?" Accessed: Oct. 09, 2024. [Online]. Available: https://www.webmd.com/balance/ayurvedic-treatments

[95] D. Niranjan, "Blood Purification Therapy - Raktamokshana." Accessed: Oct. 09, 2024. [Online]. Available: https://www.ayurindus.com/raktamokshana/

[96] M. Rosenberg, "Anchoring ayurveda in European health system: Barriers and opportunities," *J. Res. Ayurvedic Sci.*, vol. 7, no. Suppl 1, pp. 82–85, 2023, doi: 10.4103/jras.jras_89_23.

[97] H. Hall, "Neti pots – Ancient Ayurvedic Treatment Validated by Scientific Evidence," Science-Based Medicine. Accessed: May 13, 2019. [Online]. Available: https://sciencebasedmedicine.org/neti-pots-ncient-ayurvedic-treatment-validated-by--scientific-evidence/

[98] V. Agarwal, A. Abhijnhan, and P. Raviraj, "Ayurvedic medicine for schizophrenia," *Cochrane Database Syst. Rev.*, 2007, doi: 10.1002/14651858.CD006867.

[99] National Center for Complementary and Integrative Health, "Ayurvedic Medicine:

In Depth," NCCIH. Accessed: May 13, 2019. [Online]. Available: https://nccih.nih.gov/health/ayurveda/introduction.htm

[100] D. Gyawali, R. Vohra, D. Orme-Johnson, S. Ramaratnam, and R. H. Schneider, "A Systematic Review and Meta-Analysis of Ayurvedic Herbal Preparations for Hypercholesterolemia," *Medicina (Mex.)*, vol. 57, no. 6, Art. no. 6, Jun. 2021, doi: 10.3390/medicina57060546.

[101] S. Mittal, "The inefficacy of AYUSH-64, the anti-malarial Ayurvedic drug developed by Ministry of AYUSH," Alt News. Accessed: Apr. 11, 2020. [Online]. Available: https://www.altnews.in/the-inefficacy-of-ayush-64-the-anti-malarial-ayurvedic-drug-developed-by-ministry-of-ayush/

[102] Government of India, Ministry of Ayush, "Ministry, About us." Accessed: Feb. 09, 2023. [Online]. Available: https://ayush.gov.in/index.html#!/aboutus

[103] G. S. Seethapathy, A.-C. Raclariu-Manolica, J. A. Anmarkrud, H. Wangensteen, and H. J. de Boer, "DNA Metabarcoding Authentication of Ayurvedic Herbal Products on the European Market Raises Concerns of Quality and Fidelity," *Front. Plant Sci.*, vol. 10, p. 68, 2019, doi: 10.3389/fpls.2019.00068.

[104] M. A. Mikulski, M. D. Wichman, D. L. Simmons, A. N. Pham, V. Clottey, and L. J. Fuortes, "Toxic metals in ayurvedic preparations from a public health lead poisoning cluster investigation," *Int. J. Occup. Environ. Health*, vol. 23, no. 3, pp. 187–192, Jul. 2017, doi: 10.1080/10773525.2018.1447880.

[105] R. B. Saper *et al.*, "Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the Internet," *JAMA J. Am. Med. Assoc.*, vol. 300, no. 8, pp. 915–923, Aug. 2008, doi: 10.1001/jama.300.8.915.

[106] A. Bhalla and A. K. Pannu, "Are Ayurvedic medications store house of heavy metals?," *Toxicol. Res.*, vol. 11, no. 1, pp. 179–183, Jan. 2022, doi: 10.1093/toxres/tfab124.

[107] L. Breeher, M. A. Mikulski, T. Czeczok, K. Leinenkugel, and L. J. Fuortes, "A cluster of lead poisoning among consumers of Ayurvedic medicine," *Int. J. Occup. Environ. Health*, vol. 21, no. 4, pp. 303–307, Oct. 2015, doi: 10.1179/2049396715Y.0000000009.

[108] R. Gair, "Heavy metal poisoning from Ayurvedic medicines," *Br. Columbia Med. J.*, vol. 50, no. 2, p. 105, 2008.

[109] M. Rosenberg, "Ayurveda in Europe – Status and perspectives," *Int. J. Ayurveda Res.*, vol. 3, no. 1, p. 39, 2022, doi: 10.4103/ijar.ijar_8_22.

[110] R. A. Cooper and H. J. McKee, "Chiropractic in the United States: Trends and Issues," *Milbank Q.*, vol. 81, no. 1, pp. 107–138, Mar. 2003, doi: 10.1111/1468-0009.00040.

[111] G. Goncalves, C. Le Scanff, and C. Leboeuf-Yde, "Effect of chiropractic treatment on primary or early secondary prevention: a systematic review with a pedagogic approach," *Chiropr. Man. Ther.*, vol. 26, no. 1, p. 10, Apr. 2018, doi: 10.1186/s12998-018-0179-x.

[112] R. Brown, "The Status of Chiropractic in Europe: a position paper," European Chiropractors' Union, 2013. Accessed: Mar. 29, 2022. [Online]. Available:

https://chiro.org/Graphics_Box_LINKS/FULL/The_Status_of_Chiropractic_in_Europe_A_Position_Paper.pdf

[113] E. Ernst and P. H. Canter, "A systematic review of systematic reviews of spinal manipulation," *J. R. Soc. Med.*, vol. 99, no. 4, pp. 192–196, Apr. 2006, doi: 10.1258/jrsm.99.4.192.

[114] B. F. Walker, S. D. French, W. Grant, and S. Green, "Combined chiropractic interventions for low-back pain," *Cochrane Database Syst. Rev.*, 2010, doi: 10.1002/14651858.CD005427.pub2.

[115] S. M. Rubinstein, M. van Middelkoop, W. J. J. Assendelft, M. R. de Boer, and M. W. van Tulder, "Spinal manipulative therapy for chronic low-back pain," *Cochrane Database Syst. Rev.*, 2011, doi: 10.1002/14651858.CD008112.pub2.

[116] S. Berger, "How safe are the vigorous neck manipulations done by chiropractors?," Washington Post. Accessed: May 15, 2019. [Online]. Available: https://www.washingtonpost.com/national/health-science/how-safe-are-the-vigorous-neck-manipulations-done-by-chiropractors/2014/01/06/26870726-5cf7-11e3-bc56-c6ca94801fac_story.html

[117] E. Ernst, "Adverse effects of spinal manipulation: a systematic review," *J. R. Soc. Med.*, vol. 100, no. 7, pp. 330–338, Jul. 2007, doi: 10.1258/jrsm.100.7.330.

[118] M. Laycock, "Man died after going to chiropractor for aching leg, inquest hears," York Press. Accessed: Nov. 28, 2019. [Online]. Available: https://www.yorkpress.co.uk/news/18028898.john-lawler-suffered-broken-neck-chiropractor-treatment-inquest-told/

[119] E. Ernst, "Death by chiropractic neck manipulation? More details on the Lawler case." Accessed: Nov. 28, 2019. [Online]. Available: https://edzardernst.com/2019/11/death-by-chiropractic-neck-manipulation-more-details-on-the-lawler-case/

[120] J. Johnston, "Retired bank manager dies after trip to the chiropractor," Mail Online. Accessed: Nov. 28, 2019. [Online]. Available: https://www.dailymail.co.uk/news/article-7716805/Retired-bank-manager-dies-trip-chiropractor.html

[121] R. C. Turner, B. P. Lucke-Wold, S. Boo, C. L. Rosen, and C. L. Sedney, "The potential dangers of neck manipulation & risk for dissection and devastating stroke: An illustrative case & review of the literature," *Biomed. Res. Rev.*, vol. 2, no. 1, p. 10.15761/BRR.1000110, 2018.

[122] S. Barrett, "Chiropractic's Dirty Secret: Neck Manipulation and Strokes." Accessed: May 15, 2019. [Online]. Available: https://www.quackwatch.org/01QuackeryRelatedTopics/chirostroke.html

[123] J. Bellamy, "Australia's Chiropractic Board bans spinal manipulation for children under two pending evidence review," Science-Based Medicine. Accessed: May 16, 2019. [Online]. Available: https://sciencebasedmedicine.org/australias-chiropractic-board-bans-spinal-manipulation-for-children-under-two-pending-evidence-review/

[124] F. C. Albuquerque *et al.*, "Craniocervical arterial dissections as sequelae of chiropractic manipulation: patterns of injury and management.," *J. Neurosurg.*, vol. 115, no. 6, pp. 1197–1205, 2011, doi: 10.3171/2011.8.JNS111212.

[125] U. Reuter, M. Hämling, I. Kavuk, K. M. Einhäupl, E. Schielke, and for the German vertebral arterydissection study group, "Vertebral artery dissections afterchiropractic neck manipulationin Germany over three years," *J. Neurol.*, vol. 253, no. 6, pp. 724–730, Jun. 2006, doi: 10.1007/s00415-006-0099-x.

[126] M. Furlan-Rus, "Kiropraktikov poseg s hudimi posledicami," Dnevnik. Accessed: May 15, 2019. [Online]. Available: https://www.dnevnik.si/165801

[127] College of Naturopathic Medicine, "What is Naturopathy?" Accessed: May 15, 2019. [Online]. Available: https://www.naturopathy-uk.com/home/home-what--is-naturopathy/

[128] WebMD, "Naturopathic Medicine: What You Need to Know." Accessed: May 15, 2019. [Online]. Available: https://www.webmd.com/balance/guide/what-is-naturopathic-medicine

[129] S. P. Myers and V. Vigar, "The State of the Evidence for Whole-System, Multi--Modality Naturopathic Medicine: A Systematic Scoping Review," *J. Altern. Complement. Med. N. Y. N*, vol. 25, no. 2, pp. 141–168, Feb. 2019, doi: 10.1089/acm.2018.0340.

[130] Australian Government, Department of Health and Aged Care, "The Review of the Australian Government Rebate on Private Health Insurance for Natural Therapies." Australian Government Department of Health and Ageing, 2019. Accessed: May 16, 2019. [Online]. Available: http://www.health.gov.au/internet/main/publishing.nsf/Content/phi-natural-therapies

[131] Australian Government, National Health and Medical Research Council, "Natural Therapies Review." Accessed: Oct. 11, 2024. [Online]. Available: https://www.nhmrc.gov.au/health-advice/public-health/complementary-medicines/natural--therapies-review

[132] I. Lloyd, "Global Naturopathic Regulation," Natural Medicine Journal. Accessed: May 15, 2019. [Online]. Available: https://www.naturalmedicinejournal.com/journal/2018-08/global-naturopathic-regulation

[133] B. M. Hermes, "The Wild West: Tales of a Naturopathic Ethical Review Board," Science-Based Medicine. Accessed: May 16, 2019. [Online]. Available: https://sciencebasedmedicine.org/wild-west-tales-of-a-naturopathic-ethical-review-board/

[134] T. Caulfield and C. Rachul, "Supported by science?: what canadian naturopaths advertise to the public," *Allergy Asthma Clin. Immunol. Off. J. Can. Soc. Allergy Clin. Immunol.*, vol. 7, no. 1, p. 14, Sep. 2011, doi: 10.1186/1710-1492-7-14.

[135] B. M. Hermes, "When naturopaths treat autism, children suffer." Accessed: May 16, 2019. [Online]. Available: https://www.kevinmd.com/blog/2016/10/naturopaths-treat-autism-children-suffer.html

[136] Združenje naturopatov Slovenije, "Program kongresa 2019." Accessed: May 16, 2019. [Online]. Available: https://naturopatija.org/program-kongresa/

[137] D. Highland, "Man accused of killing doctor had sued him over cancer treatments," Lexington Herald Leader. Accessed: Dec. 04, 2024. [Online]. Available: https://www.kentucky.com/news/state/article137725463.html

[138] R. Srivastava, "What do doctors say to 'alternative therapists' when a patient dies? Nothing. We never talk," *The Guardian*, 2015. Accessed: May 16, 2019. [Online]. Available: https://www.theguardian.com/commentisfree/2015/mar/03/what-do--doctors-say-to-alternative-therapists-when-a-patient-dies-nothing-we-never--talk

[139] S. Maude, "Naturopathy under microscope after cancer sufferers speak from under shadow of death," Stuff. Accessed: Mar. 28, 2020. [Online]. Available: https://www.stuff.co.nz/national/health/96110398/naturopathy-under-microscope-after-two-cancer-sufferers-speak-out-under-shadow-of-death

[140] B. M. Hermes, "A toddler dies from meningitis, governments need to block naturopathic pediatrics," Naturopathic Diaries. Accessed: May 16, 2019. [Online]. Available: https://www.naturopathicdiaries.com/restrict-licensed-naturopaths/

[141] D. Gorski, "Death by intravenous 'turmeric': Naturopaths circle the wagons and the chair of the Naturopathic Medical Committee of California looks for dirt on conventional medicine." Accessed: May 18, 2019. [Online]. Available: https://respectfulinsolence.com/2017/04/12/death-by-intravenous-turmeric-naturopaths-circle-the-wagon/

[142] S. Gavura, "The horrible consequences of seeking 'natural' immunity: Naturopathy and Whooping Cough," Science-Based Medicine. Accessed: Jul. 16, 2018. [Online]. Available: https://sciencebasedmedicine.org/the-horrible-consequences-of-seeking-natural-immunity-naturopathy-and-whooping-cough/

[143] Centers for Disease Control and Prevention, "Symptoms of Whooping Cough." Accessed: Sep. 23, 2021. [Online]. Available: https://www.cdc.gov/pertussis/signs--symptoms/?CDC_AAref_Val=https://www.cdc.gov/pertussis/about/complications.html

[144] NDs for Vaccines, "Vaccine position statement." Accessed: Jan. 30, 2020. [Online]. Available: https://ndsforvaccines.com/about-us/vaccine-position-statement/

[145] B. Goldacre, *Bad Science*. Harper Perennial, 2009.

[146] National Institutes of Health, Office of Dietary Supplements, "Dietary Supplements: What You Need to Know." Accessed: Feb. 09, 2023. [Online]. Available: https://ods.od.nih.gov/factsheets/WYNTK-Consumer/

[147] V. Navarro, I. Khan, E. Björnsson, L. B. Seeff, J. Serrano, and J. H. Hoofnagle, "Liver Injury from Herbal and Dietary Supplements," *Hepatol. Baltim. Md*, vol. 65, no. 1, pp. 363–373, Jan. 2017, doi: 10.1002/hep.28813.

[148] S. Zgonik, "Imperij Herte Kosmina: Ne ustavijo je niti kazni za zavajanje," N1. Accessed: Oct. 14, 2024. [Online]. Available: https://n1info.si/poglobljeno/imperij-herte-kosmina-ne-ustavijo-je-niti-kazni-za-zavajanje/

[149] S. Zgonik, "Biostile, misterij dr. Majića in sporno sklicevanje na zdravnike," N1. Accessed: Oct. 14, 2024. [Online]. Available: https://n1info.si/poglobljeno/biostile-misterij-dr-majica-in-sporno-sklicevanje-na-zdravnike/

[150] S. Zgonik, "Zavajajočih 10: Črni seznam slovenskih prodajalcev prehranskih dopolnil," N1. Accessed: Oct. 14, 2024. [Online]. Available: https://n1info.si/poglobljeno/zavajajocih-10-crni-seznam-slovenskih-prodajalcev-prehranskih-dopolnil/

[151] M. J. J. Ronis, K. B. Pedersen, and J. Watt, "Adverse effects of nutraceuticals and dietary supplements," *Annu. Rev. Pharmacol. Toxicol.*, vol. 58, pp. 583–601, Jan. 2018, doi: 10.1146/annurev-pharmtox-010617-052844.

[152] J. Landsman, "Vitamin C outperforms vaccines," NaturalNews. Accessed: Feb. 21, 2020. [Online]. Available: https://www.naturalnews.com/049146_vitamin_C_vaccines_natural_health.html

[153] S. Barrett, "The Dark Side of Linus Pauling's Legacy." Accessed: Feb. 21, 2020. [Online]. Available: https://www.quackwatch.org/01QuackeryRelatedTopics/pauling.html

[154] H. Hemilä and E. Chalker, "Vitamin C for preventing and treating the common cold," *Cochrane Database Syst. Rev.*, 2013, doi: 10.1002/14651858.CD000980.pub4.

[155] H. Hemilä and P. Louhiala, "Vitamin C for preventing and treating pneumonia," *Cochrane Database Syst. Rev.*, 2013, doi: 10.1002/14651858.CD005532.pub3.

[156] H. Hemilä and T. Koivula, "Vitamin C for preventing and treating tetanus," *Cochrane Database Syst. Rev.*, 2013, doi: 10.1002/14651858.CD006665.pub3.

[157] T. Fujii *et al.*, "Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial," *JAMA*, vol. 323, no. 5, pp. 423–431, Feb. 2020, doi: 10.1001/jama.2019.22176.

[158] H. Hemilä, "Vitamin C and Infections," *Nutrients*, vol. 9, no. 4, Mar. 2017, doi: 10.3390/nu9040339.

[159] M. Olczak-Pruc *et al.*, "Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis," *Nutrients*, vol. 14, no. 19, p. 4217, Oct. 2022, doi: 10.3390/nu14194217.

[160] R. Puckett and M. Offringa, "Prophylactic vitamin K for vitamin K deficiency bleeding in neonates," *Cochrane Database Syst. Rev.*, 2000, doi: 10.1002/14651858.CD002776.

[161] L. Hayes, "Beware of 'Standard of Care,'" Age of autism. Accessed: Feb. 22, 2020. [Online]. Available: https://www.ageofautism.com/2016/04/beware-of-standard-of-care.html

[162] N. T. Fear, E. Roman, P. Ansell, J. Simpson, N. Day, and O. B. Eden, "Vitamin K and childhood cancer: a report from the United Kingdom Childhood Cancer Study," *Br. J. Cancer*, vol. 89, no. 7, pp. 1228–1231, Oct. 2003, doi: 10.1038/sj.bjc.6601278.

[163] V. Iannelli, "Does the Vitamin K Shot Contain 100mcg of Aluminum?" Accessed: Feb. 22, 2020. [Online]. Available: https://vaxopedia.org/2018/08/25/does-the-vitamin-k-shot-contain-100mcg-of-aluminum/

[164] U.S. Food and Drug Administration, "FDA warns consumers about the dangerous and potentially life threatening side effects of Miracle Mineral Solution." Accessed: Feb. 09, 2023. [Online]. Available: https://www.fda.gov/news-events/press-announcements/fda-warns-consumers-about-dangerous-and-potentially-life-threatening-side-effects-miracle-mineral

[165] "A word from Jim Humble," Jim Humble. Accessed: Jan. 18, 2025. [Online]. Available: https://jimhumble.co/

[166] Department of Justice, U.S. Attorney's Office, Southern District of Florida, "Leader of 'Genesis II Church of Health and Healing,' Who Sold Toxic Bleach as Fake 'Miracle' Cure for COVID-19 and Other Serious Diseases, Guilty of Conspiracy to Defraud the United States," 2023, Accessed: Oct. 11, 2024. [Online]. Available: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/press-releases/leader-genesis-ii-church-health-and-healing-who-sold-toxic-bleach-fake-miracle-cure-covid-19-and

[167] Založba Ara, "Rešite si zdravje ali celó življenje z MMS-om, ionom klorovega dioksida." Accessed: Nov. 29, 2019. [Online]. Available: https://www.misteriji.si/knjige/knjige-ara-zalozbe/poti-do-zdravja/resite-si-zdravje-ali-celo-zivljenje-z-mms-om-ionom-klorovega-dioksida.html

[168] Centers for Disease Control and Prevention, Agency for Toxic Substances and Disease Registry, "Chlorine Dioxide & Chlorite." Accessed: Feb. 09, 2023. [Online]. Available: https://wwwn.cdc.gov/TSP/ToxFAQs/ToxFAQsDetails.aspx?faqid=581&toxid=108

[169] A. Merlan, "'Don't Call 911': In Private, Fake Autism Experts Gave Dangerous Advice," *VICE*, Oct. 16, 2020. Accessed: Jan. 18, 2025. [Online]. Available: https://www.vice.com/en/article/dont-call-911-in-private-fake-autism-experts-gave-dangerous-advice/

[170] D. Gorski, "Bleaching away what ails you: The Genesis II Church is still selling Miracle Mineral Supplement as a cure-all," Science-Based Medicine. Accessed: Jun. 08, 2019. [Online]. Available: https://sciencebasedmedicine.org/miracle-mineral-supplement-as-a-cure-all/

[171] Jojo's Mum, "A Drop At A Time: Parasite Protocol Round 1: Day 1 ~ Biofilm," A Drop At A Time. Accessed: Jun. 08, 2019. [Online]. Available: http://jojosmmsjourney.blogspot.com/2013/04/parasite-protocol-round-1-day-1-biofilm.html

[172] A. Merlan, "Bleach Peddler Kerri Rivera Appears to Be Back to Peddling Bleach After Police Raid," *VICE*, Apr. 25, 2022. Accessed: Jan. 18, 2025. [Online]. Available: https://www.vice.com/en/article/bleach-peddler-kerri-rivera-appears-to-be-back-to-peddling-bleach-after-police-raid/

[173] F. Ryan, "The fake cures for autism that can prove deadly," *The Guardian*, Jul. 13, 2016. Accessed: Dec. 05, 2024. [Online]. Available: https://www.theguardian.com/society/2016/jul/13/fake-cures-autism-prove-deadly

[174] D. Gorski, "Is medical error really the third most common cause of death in the US?" Accessed: Feb. 23, 2020. [Online]. Available: https://respectfulinsolence.com/2020/02/10/medical-error-third-most-common-cause-of-death/

[175] B. A. Rodwin *et al.*, "Rate of Preventable Mortality in Hospitalized Patients: a Systematic Review and Meta-analysis," *J. Gen. Intern. Med.*, Jan. 2020, doi: 10.1007/s11606-019-05592-5.

[176] J. E. Sunshine, N. Meo, N. J. Kassebaum, M. L. Collison, A. H. Mokdad, and M.

Naghavi, "Association of Adverse Effects of Medical Treatment With Mortality in the United States: A Secondary Analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study," *JAMA Netw. Open*, vol. 2, no. 1, pp. e187041–e187041, Jan. 2019, doi: 10.1001/jamanetworkopen.2018.7041.

[177] D. Gorski, "Do medical errors really kill a quarter of a million people a year in the US? (2019 edition)." Accessed: Feb. 23, 2020. [Online]. Available: https://respectfulinsolence.com/2019/02/13/medical-errors-2019/

[178] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[179] S. Novella, "Conspiracy Thinking And Alternative Medicine," Science-Based Medicine. Accessed: Oct. 16, 2024. [Online]. Available: https://sciencebasedmedicine.org/conspiracy-thinking-and-alternative-medicine/

[180] N. Satija and H. L. Sun, "A major funder of the anti-vaccine movement has made millions selling natural health products," Washington Post. Accessed: Jan. 14, 2020. [Online]. Available: https://www.washingtonpost.com/investigations/2019/10/15/fdc01078-c29c-11e9-b5e4-54aa56d5b7ce_story.html

[181] D. Gorski, "Quack tycoon Joe Mercola abandons an old antivax friend." Accessed: Oct. 15, 2024. [Online]. Available: https://www.respectfulinsolence.com/2024/06/04/quack-tycoon-joe-mercola-abandons-an-old-antivax-friend/

[182] World Health Organization, "Global vaccine market report 2023," Geneva, 2024. Accessed: Jun. 13, 2024. [Online]. Available: https://iris.who.int/bitstream/handle/10665/376909/B09022-eng.pdf?sequence=1

[183] Business Research Insight, "Traditional Chinese Medicine Market Size - Forecast To 2032." Accessed: Oct. 16, 2024. [Online]. Available: https://www.businessresearchinsights.com/market-reports/traditional-chinese-medicine-tcm-market-109110

[184] The Business Research Company, "Homeopathy Market Size, Growth, Trends and Forecast 2024-2033." Accessed: Oct. 16, 2024. [Online]. Available: https://www.thebusinessresearchcompany.com/report/homeopathy-global-market-report

[185] Grand View Research, "Ayurveda Market Size, Share, Trends & Growth Report, 2030." Accessed: Oct. 16, 2024. [Online]. Available: https://www.grandviewresearch.com/industry-analysis/ayurveda-market-report

[186] Global Industry Analysts, Inc., "Chiropractic Care - Global Strategic Business Report." Accessed: Oct. 16, 2024. [Online]. Available: https://www.researchandmarkets.com/reports/5662785/chiropractic-care-global-strategic-business

[187] Grand View Research, "Dietary Supplements Market Size And Share Report, 2030." Accessed: Oct. 16, 2024. [Online]. Available: https://www.grandviewresearch.com/industry-analysis/dietary-supplements-market-report

[188] B. Chappell and A. Tsioulcas, "YouTube, Apple and Facebook Ban Infowars, Which Decries 'Mega Purge,'" *NPR*, Aug. 06, 2018. Accessed: Oct. 19, 2024. [Online]. Available: https://www.npr.org/2018/08/06/636030043/youtube-apple-and-facebook-ban-infowars-which-decries-mega-purge

[189] S. Brown, "Alex Jones's Infowars Media Empire Is Built to Sell Snake-Oil Diet

Supplements," Intelligencer. Accessed: Oct. 19, 2024. [Online]. Available: https://nymag.com/intelligencer/2017/05/how-does-alex-jones-make-money.html
[190] Government of Canada, Health Canada, "Health Canada." Accessed: Feb. 10, 2023. [Online]. Available: https://www.canada.ca/en/health-canada.html
[191] A. Grignolio, *Kdo se boji cepiv?*, 1st ed. *cf, 2018.
[192] M. Enserink and J. Cohen, "Fact-checking Judy Mikovits, the controversial virologist attacking Anthony Fauci in a viral conspiracy video," Science. Accessed: Jun. 08, 2020. [Online]. Available: https://www.sciencemag.org/news/2020/05/fact-checking-judy-mikovits-controversial-virologist-attacking-anthony-fauci-viral
[193] L. Schneider, "Judy Mikovits' Plandemic COVID-portunism," For Better Science. Accessed: Aug. 03, 2020. [Online]. Available: https://forbetterscience.com/2020/06/24/judy-mikovits-plandemic-covid-portunism/
[194] A. Merlan, "The Star of 'Plandemic' Spent Years Flooding the Vaccine Court System with Bad Science," Vice. Accessed: Aug. 04, 2020. [Online]. Available: https://www.vice.com/en_us/article/7kpe3b/the-star-of-plandemic-spent-years-flooding-the-vaccine-court-system-with-bad-science
[195] J. K. Ward, F. Gauna, M. J. Deml, N. MacKendrick, and P. Peretti-Watel, "Diversity of attitudes towards complementary and alternative medicine (CAM) and vaccines: A representative cross-sectional study in France," *Soc. Sci. Med.*, vol. 328, p. 115952, Jul. 2023, doi: 10.1016/j.socscimed.2023.115952.
[196] S. Novella, "Placebo Effect Revisited," Science-Based Medicine. Accessed: Oct. 19, 2024. [Online]. Available: https://sciencebasedmedicine.org/placebo-effect-revisited/

29

Literatura

[1] M. Karamanou, G. Panayiotakopoulos, G. Tsoucalas, A. A. Kousoulis, and G. Androutsos, "From miasmas to germs: a historical approach to theories of infectious disease transmission," *Infez. Med.*, vol. 20, no. 1, pp. 58–62, Mar. 2012.

[2] J.-M. Cavaillon and S. Legout, "Louis Pasteur: Between Myth and Reality," *Biomolecules*, vol. 12, no. 4, p. 596, Apr. 2022, doi: 10.3390/biom12040596.

[3] C. Gainty, "Germ theory denialism is alive and well – and taking the nuance out of scientific debate," *The Conversation*, Jul. 05, 2021. Accessed: Jan. 31, 2025. [Online]. Available: http://theconversation.com/germ-theory-denialism-is-alive-and-well-and-taking-the-nuance-out-of-scientific-debate-163408

[4] Rachel Schraer, London. *The online groups who believe germs don't exist*, (Nov. 06, 2023). Accessed: Jan. 31, 2025. [Online Video]. Available: https://www.youtube.com/watch?v=YGiixnL9FS4

[5] P. E. Tressoldi, "Extraordinary Claims Require Extraordinary Evidence: The Case of Non-Local Perception, a Classical and Bayesian Review of Evidences," *Front. Psychol.*, vol. 2, p. 117, Jun. 2011, doi: 10.3389/fpsyg.2011.00117.

[6] Naravna imunost, "Zakaj zbolimo?," Naravna imunost. Accessed: Jul. 16, 2018. [Online]. Available: https://www.naravnaimunost.si/zakaj-zbolimo/

[7] Naravna imunost, "Prednosti prebolevanja otroških nalezljivih bolezni," Naravna imunost. Accessed: Jul. 16, 2018. [Online]. Available: https://www.naravnaimunost.si/prednosti-prebolevanja/

[8] K. L. Manchester, "Louis Pasteur, fermentation, and a rival," *South Afr. J. Sci.*, vol. 103, no. 9–10, pp. 377–380, Oct. 2007.

[9] D. Gorski, "Germ theory denial: A major strain in 'alt-med' thought," Science-Based Medicine. Accessed: Jan. 31, 2025. [Online]. Available: https://sciencebasedmedicine.org/germ-theory-denialism-a-major-strain-in-alt-med-thought/

[10] Naravna imunost, "Bolezni & cepljenje," Naravna imunost. Accessed: Nov. 30, 2023. [Online]. Available: https://www.naravnaimunost.si/bolezni-cepljenje/

[11] D. W. Cramer *et al.*, "Mumps and ovarian cancer: modern interpretation of an historic association," *Cancer Causes Control CCC*, vol. 21, no. 8, p. 1193, Jun. 2010, doi: 10.1007/s10552-010-9546-1.

[12] National Health Service, "Complications, Mumps." Accessed: Jul. 18, 2021. [Online]. Available: https://www.nhs.uk/conditions/mumps/complications/

[13] E. C. Alvord, U. Jahnke, E. H. Fischer, M. W. Kies, B. F. Driscoll, and D. A. Compston, "The multiple causes of multiple sclerosis: the importance of age of infections in childhood," *J. Child Neurol.*, vol. 2, no. 4, pp. 313–321, Oct. 1987, doi: 10.1177/088307388700200418.

[14] S. O. Shaheen, D. J. P. Barker, C. B. Heyes, A. W. Shiell, P. Aaby, and A. J. Hall, "Measles and atopy in Guinea-Bissau," *The Lancet*, vol. 347, no. 9018, pp. 1792–1796, 1996, doi: 10.1016/s0140-6736(96)91617-7.

[15] T. Rønne, "Measles virus infection without rash in childhood is related to disease in adult life," *Lancet Lond. Engl.*, vol. 1, no. 8419, pp. 1–5, Jan. 1985, doi: 10.1016/s0140-6736(85)90961-4.

[16] E. von Mutius, "Infection: friend or foe in the development of atopy and asthma? The epidemiological evidence," *Eur. Respir. J.*, vol. 18, no. 5, pp. 872–881, Nov. 2001, doi: 10.1183/09031936.01.00268401.

[17] J. Pogačnik, "MZ in NIJZ naj investirata v nakup strokovne literature o cepljenju," Peticija.online. Accessed: Dec. 09, 2019. [Online]. Available: https://www.peticija.online/mz_in_nijz_naj_investirata_v_nakup_strokovne_literature_o_cepljenju

[18] Y. Kubota, H. Iso, A. Tamakoshi, and JACC Study Group, "Association of measles and mumps with cardiovascular disease: The Japan Collaborative Cohort (JACC) study," *Atherosclerosis*, vol. 241, no. 2, pp. 682–686, Aug. 2015, doi: 10.1016/j.atherosclerosis.2015.06.026.

[19] M. J. Mina *et al.*, "Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens," *Science*, vol. 366, no. 6465, pp. 599–606, Nov. 2019, doi: 10.1126/science.aay6485.

[20] V. N. Petrova *et al.*, "Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles," *Sci. Immunol.*, vol. 4, no. 41, p. eaay6125, Nov. 2019, doi: 10.1126/sciimmunol.aay6125.

[21] S. A. Zorina *et al.*, "Infectious Microorganisms Seen as Etiologic Agents in Parkinson's Disease," *Life*, vol. 13, no. 3, p. 805, Mar. 2023, doi: 10.3390/life13030805.

[22] B. Sundaresan, F. Shirafkan, K. Ripperger, and K. Rattay, "The Role of Viral Infections in the Onset of Autoimmune Diseases," *Viruses*, vol. 15, no. 3, p. 782, Mar. 2023, doi: 10.3390/v15030782.

[23] K. Yusuf, V. Sampath, and S. Umar, "Bacterial Infections and Cancer: Exploring This Association And Its Implications for Cancer Patients," *Int. J. Mol. Sci.*, vol. 24, no. 4, p. 3110, Feb. 2023, doi: 10.3390/ijms24043110.

[24] J. T. Schiller and D. R. Lowy, "An Introduction to Virus Infections and Human Cancer," *Recent Results Cancer Res. Fortschritte Krebsforsch. Progres Dans Rech. Sur Cancer*, vol. 217, pp. 1–11, 2021, doi: 10.1007/978-3-030-57362-1_1.

[25] Naravna imunost, "Zgodovina stekline," Naravna imunost. Accessed: Feb. 01, 2020. [Online]. Available: https://www.naravnaimunost.si/zgodovina-stekline/

[26] R. Subramaniam (Mani), "Human Rabies Survivors in India: An Emerging Paradox?," *PLoS Negl. Trop. Dis.*, vol. 10, no. 7, Jul. 2016, doi: 10.1371/journal.pntd.0004774.

[27] World Health Organization, "Rabies." Accessed: Feb. 02, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/rabies

[28] National Health Service, "Rabies." Accessed: Feb. 02, 2020. [Online]. Available: https://www.nhs.uk/conditions/rabies/
[29] Nacionalni Inštitut za javno zdravje, "Steklina." [Online]. Available: https://www.nijz.si/sl/steklina
[30] University of California, *Rabies in a human patient*. Accessed: Feb. 02, 2020. [Online Video]. Available: https://www.youtube.com/watch?v=-moG6JDmJdc
[31] Centers for Disease Control and Prevention, "Rabies in the United States: Protecting Public Health." Accessed: Nov. 24, 2024. [Online]. Available: https://www.cdc.gov/rabies/php/protecting-public-health/index.html
[32] World Health Organization, "Control of Neglected Tropical Diseases, Global burden of dog-transmitted human rabies." Accessed: Feb. 01, 2020. [Online]. Available: http://www.who.int/rabies/epidemiology/en/
[33] A. Tobin, "How rabies attacks the brain, seen in Israel for the first time." Accessed: Feb. 02, 2020. [Online]. Available: https://www.timesofisrael.com/how-rabies-attacks-brain-seen-in-israel-for-1st-time/

30

Literatura

[1] M. Likar, *Cepiva danes in jutri*. Arkadija, 2004.

[2] Vlada Republike Slovenije, *Zakon o nalezljivih boleznih (ZNB)*. 1995. Accessed: May 27, 2019. [Online]. Available: https://pisrs.si/pregledPredpisa?id=ZAKO433

[3] S. Dobrovič, "Svoboda odločanja pri obveznem cepljenju," diplomsko delo, Univerza v Mariboru, Pravna fakulteta, 2015. [Online]. Available: https://dk.um.si/Dokument.php?id=81765

[4] P. Malovrh, "Vloge za opustitev cepljenja zdesetkane," Delo. Accessed: Feb. 15, 2023. [Online]. Available: https://www.delo.si/novice/slovenija/vloge-za-opustitev-cepljenja-zdesetkane/

[5] A. Lončar, "Udarec po denarnici ne prepriča staršev, da bi cepili," Siol. Accessed: Feb. 15, 2023. [Online]. Available: https://siol.net/novice/slovenija/udarec-po-denarnici-ne-preprica-starsev-ki-ne-cepijo-video-497806

[6] R. G. Mungwira *et al.*, "Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries," *PLOS ONE*, vol. 15, no. 5, p. e0233334, maj 2020, doi: 10.1371/journal.pone.0233334.

[7] A. Vojnović Zorman, "Odškodnine za posledice stranskih učinkov ali smrt po cepljenju proti covidu-19," RTVSLO. Accessed: Feb. 16, 2023. [Online]. Available: https://www.rtvslo.si/tv/info/koda/odskodnine-za-posledice-stranskih-ucinkov-ali-smrt-po-cepljenju-proti-covidu-19/603237

[8] Vrhovno sodišče Republike Slovenije, *Sodba II Ips 1253/2008*. 2012. Accessed: Jul. 18, 2018. [Online]. Available: http://www.sodisce.si/znanje/sodna_praksa/vrhovno_sodisce_rs/2012032113046239/#

[9] B. Ferlič Žgajnar, "221 vlog za izplačilo odškodnin zaradi posledic cepljenja proti covidu-19," Delo. Accessed: Oct. 21, 2024. [Online]. Available: https://www.delo.si/novice/slovenija/221-vlog-za-izplacilo-odskodnin

[10] S. Banjanac Lubej, "15 let po cepljenju proti steklini ima dekle 130 diagnoz," RTVSLO. Accessed: May 29, 2019. [Online]. Available: https://www.rtvslo.si/crna-kronika/15-let-po-cepljenju-proti-steklini-ima-dekle-130-diagnoz/294162

[11] M. Furlan-Rus, "»Samo slepec ne vidi, da je krivo cepljenje«," Dnevnik. Accessed: May 29, 2019. [Online]. Available: https://www.dnevnik.si/1042728761

[12] World Health Organization, "Rabies vaccines: WHO position paper – April 2018." 2018. Accessed: Feb. 16, 2023. [Online]. Available: https://iris.who.int/bitstream/handle/10665/272372/WER9316-201-219.pdf?sequence=1

[13] World Health Organization, "Control of neglected tropical diseases, Vaccinations and immunization, Rabies." Accessed: Nov. 25, 2024. [Online]. Available: https://www.who.int/teams/control-of-neglected-tropical-diseases/rabies/vaccinations-and-immunization

[14] W. Huynh, D. J. Cordato, E. Kehdi, L. T. Masters, and C. Dedousis, "Post-vaccination encephalomyelitis: literature review and illustrative case," *J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas.*, vol. 15, no. 12, pp. 1315–1322, Dec. 2008, doi: 10.1016/j.jocn.2008.05.002.

[15] Statistični urad Republike Slovenije, "Osnovni podatki o rojenih, Slovenija, letno." Accessed: Feb. 06, 2025. [Online]. Available: https://pxweb.stat.si:443/SiStatDataSiStatData/pxweb/sl/Data/-/05J1002S.PX/

[16] Slovensko zdravniško društvo, Združenje za pediatrijo, "Koledar splošnih obveznih in priporočenih cepljenj." Accessed: Nov. 04, 2023. [Online]. Available: https://www.cepljenje.info/zivljenjska-obdobja/otroci/2/koledar-splosnih-obveznih-in-priporocenih-cepljenj

[17] S. F. Halabi and S. B. Omer, "A Global Vaccine Injury Compensation System," *JAMA*, vol. 317, no. 5, pp. 471–472, Feb. 2017, doi: 10.1001/jama.2016.19492.

[18] Nacionalni Inštitut za javno zdravje, "Obvezno cepljenje po mnenju Ustavnega sodišča primeren ukrep." Accessed: May 29, 2019. [Online]. Available: https://nijz.si/nalezljive-bolezni/cepljenje/obvezno-cepljenje-po-mnenje-ustavnega-sodisca-primeren-ukrep/

[19] European Vaccination Information Portal, "Mandatory or recommended vaccination." Accessed: Feb. 16, 2023. [Online]. Available: https://vaccination-info.eu/en/vaccination/when-vaccinate/mandatory-or-recommended-vaccination

[20] S. Sheikh *et al.*, "A report on the status of vaccination in Europe," *Vaccine*, vol. 36, no. 33, pp. 4979–4992, Aug. 2018, doi: 10.1016/j.vaccine.2018.06.044.

[21] European Center for Disease Prevention and Control, "Vaccine Scheduler." Accessed: Nov. 25, 2024. [Online]. Available: https://vaccine-schedule.ecdc.europa.eu/

[22] C. Vagnoni, E. Rough, and S. Bunn, "UK Vaccination Policy." 2022. Accessed: Nov. 25, 2024. [Online]. Available: https://commonslibrary.parliament.uk/research-briefings/cbp-9076/

[23] UK Health Security Agency, "Complete routine immunisation schedule from 1 September 2024." Accessed: Nov. 25, 2024. [Online]. Available: https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule/the-complete-routine-immunisation-schedule-from-february-2022

[24] Nacionalni Inštitut za javno zdravje, "Precepljenost predšolskih otrok v Sloveniji v letu 2017, preliminarni podatki," Nacionalni inštitut za javno zdravje, Ljubljana, 2018. Accessed: Nov. 25, 2024. [Online]. Available: https://www.nijz.si/sites/www.nijz.si/files/uploaded/predsolski_otroci_precepljenost_2017_12_03_2018.pdf

[25] World Health Organization and United Nations International Children's Emergency Fund, "Immunization, measles (% of children ages 12-23 months)." Accessed: May 29, 2019. [Online]. Available: https://data.worldbank.org/indicator/SH.IMM.MEAS?locations=BT

[26] Nacionalni Inštitut za javno zdravje, "Precepljenost predšolskih otrok v Sloveniji v letu 2023, preliminarni podatki," Nacionalni inštitut za javno zdravje, Ljubljana, 2024. Accessed: Oct. 21, 2024. [Online]. Available: https://nijz.si/wp-content/

uploads/2024/03/Predsolski-otroci_precepljenost_2023_preliminarno-porocilo_21032024.pdf

[27] NIJZ, "V letu 2020 sprememba pri cepljenju dojenčkov." Accessed: Jan. 16, 2020. [Online]. Available: https://www.nijz.si/sl/v-letu-2020-sprememba-pri-cepljenju--dojenckov

[28] Slovensko zdravniško društvo, Združenje za pediatrijo, "Precepljenost otrok upadla." Accessed: Oct. 22, 2024. [Online]. Available: https://www.cepljenje.info/novice-in-clanki/precepljenost-otrok-upadla

[29] A. Kraigher, B. Voljč, and T. Kamin, *Cepljenje stališča in odnos ključnih javnosti do cepljenja v Sloveniji*. Ljubljana: Nacionalni inštitut za javno zdravje, 2018. Accessed: May 30, 2019. [Online]. Available: http://www.nijz.si/sites/www.nijz.si/files/publikacije-datoteke/monografija_8_07-03-18.pdf

31

Literatura

[1] E. Peterson J., "Hitchens' Razor and the Burden of Proof." Accessed: Oct. 24, 2024. [Online]. Available: https://elizabethjpeterson.com/2021/10/hitchens-razor-and--the-burden-of-proof/

[2] L. Chaitow, *Cepljenje in imunizacija: nevarnosti, zablode in alternative (Dejstva, ki bi jih morali poznati vsi starši)*. Maribor: samozaložba I. Vrhovec, 1998.

[3] J. Gedeon, J. E. Greve, and C. Stein, "Robert F Kennedy Jr sworn in as health secretary after Senate confirmation," *The Guardian*, Feb. 13, 2025. Accessed: Feb. 14, 2025. [Online]. Available: https://www.theguardian.com/us-news/2025/feb/13/rfk--health-secretary-confirmed

[4] C. Idlebrook, "Diabetes, Vaccines, and the Patent Troll," Insulin Nation. Accessed: Mar. 23, 2019. [Online]. Available: https://insulinnation.com/living/diabetes-vaccines-and-the-patent-troll/

[5] E. Check Hayden, "'Patent trolls' target biotechnology firms," *Nature*, vol. 477, no. 7366, pp. 521–521, Sep. 2011, doi: 10.1038/477521a.

[6] B. L. Fisher, "Harris Coulter Was a Brave Visionary." Accessed: Apr. 16, 2024. [Online]. Available: https://www.nvic.org/newsletter/mar-2010/harris-coulter-was-a--brave-visionary

[7] B. L. Fisher, "Biography, Barbara Loe Fisher." Accessed: Apr. 16, 2024. [Online]. Available: https://www.nvic.org/about/staff-volunteers/barbara-loe-fisher

[8] University of British Columbia, Faculty of Medicine, "Shaw, Christopher." Accessed: May 20, 2024. [Online]. Available: https://neuroscience.ubc.ca/shaw-christopher/

[9] M. Simpson, "Christopher Shaw and Lucija Tomljenovic, oft-retracted anti-vaccine shills." Accessed: May 24, 2024. [Online]. Available: https://www.skepticalraptor.com/skepticalraptorblog.php/christopher-shaw-and-lucija-tomljenovic-anti-vaccine/

[10] L. Tomljenovic and L. B. McHenry, "A reactogenic 'placebo' and the ethics of informed consent in Gardasil HPV vaccine clinical trials: A case study from Denmark," *Int. J. Risk Saf. Med.*, vol. 35, no. 2, pp. 159–180, 2024, doi: 10.3233/JRS-230032.

[11] Children's Health Defense, "Science Department Staff," Children's Health Defense. Accessed: Dec. 05, 2024. [Online]. Available: https://childrenshealthdefense.org/science-about-us/

[12] A. P. Han, "Journal to retract paper called 'anti-vaccine pseudoscience,'" Retraction Watch. Accessed: May 20, 2024. [Online]. Available: https://retractionwatch.com/2017/10/09/journal-retract-paper-called-anti-vaccine-pseudoscience/

[13] B. Mole, "Study claims vaccines-autism link; scientists find fake data, have rage stroke," Ars Technica. Accessed: Jul. 21, 2018. [Online]. Available: https://arstechnica.com/science/2017/10/study-claims-vaccines-autism-link-scientists-find-fake-data--have-rage-stroke/

[14] World Health Organization, "Aluminium adjuvants," *Wkly. Epidemiol. Rec.*, vol. 87, no. 30, pp. 277–288, 2012.
[15] Children's Medical Safety Research Institute (CMSRI), "Scientific Advisory Board." Accessed: Apr. 04, 2019. [Online]. Available: https://web.archive.org/web/20180620232340/https://www.cmsri.org/about/scientific-advisory-board/
[16] T. Blackwell, "Medical journal yanks study that questions safety of HPV vaccine," *National Post*, 2016. Accessed: May 24, 2024. [Online]. Available: https://nationalpost.com/health/medical-journal-yanks-study-that-questions-safety-of-hpv-vaccine
[17] J. Kucinich, "Dem MegaDonor Pulls Funding From Anti-Vax Group, Regrets Involvement," *The Daily Beast*, Jun. 20, 2019. Accessed: May 22, 2024. [Online]. Available: https://www.thedailybeast.com/dem-megadonor-pulls-funding-from-anti-vax-group-blames-wife-for-initial-involvement
[18] L. VanLeer, "Library Guide to Academic Publishing: Journal Article Retraction." Accessed: May 20, 2024. [Online]. Available: https://academicguides.waldenu.edu/library/academicpublishing/retraction
[19] Elsevier Author Services, "Paper Retraction: Meaning and Main Reasons." Accessed: May 20, 2024. [Online]. Available: https://scientific-publishing.webshop.elsevier.com/research-process/paper-retraction-meaning-and-main-reasons/
[20] V. Stern, "Retracted letter about vaccine safety made potentially 'slanderous' claims," Retraction Watch. Accessed: Sep. 28, 2021. [Online]. Available: https://retractionwatch.com/2018/02/21/retracted-letter-about-vaccine-safety-made-potentially-slanderous-claims/
[21] J. Boulier, "Gherardi: a media story (2 or 3 embarrassing truths about his research)," Rougeole Epidémiologie. Accessed: Apr. 03, 2019. [Online]. Available: http://rougeole-epidemiologie.overblog.com/2017/10/gherardi-a-media-story-2-or-3-embarrassing-truths-about-his-research.html
[22] V. Iannelli, "Who Is Chris Exley?" Accessed: Apr. 03, 2019. [Online]. Available: https://vaxopedia.org/2018/06/06/who-is-chris-exley/
[23] M. Mold, D. Umar, A. King, and C. Exley, "Aluminium in brain tissue in autism," *J. Trace Elem. Med. Biol. Organ Soc. Miner. Trace Elem. GMS*, vol. 46, pp. 76–82, Mar. 2018, doi: 10.1016/j.jtemb.2017.11.012.
[24] A. Al-Ahmad, "Does the latest paper from Exley show a link between ASD and aluminum?" Accessed: Apr. 03, 2019. [Online]. Available: https://scientistabe.wordpress.com/2017/11/27/neurosciences-aluminum-does-the-latest-paper-from-exley-show-a-link-between-asd-and-aluminum/
[25] S. Das and J. Leake, "Funding halted for Professor Chris Exley, who links vaccines to autism," 2019. Accessed: May 23, 2024. [Online]. Available: https://www.thetimes.com/uk/science/article/funding-halted-for-professor-chris-exley-linking-vaccines-to-autism-8xvwp0g8p
[26] Elsevier, "Series Editor, Yehuda Shoenfeld," www.elsevier.com. Accessed: Oct. 22, 2024. [Online]. Available: https://www.elsevier.com/books-and-journals/book-series/yehuda-shoenfeld

[27] R. Inbar *et al.*, "WITHDRAWN: Behavioral abnormalities in young female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil," *Vaccine*, Jan. 2016, doi: 10.1016/j.vaccine.2015.12.067.

[28] V. Iannelli, "Who is Dr. Yehuda Shoenfeld." Accessed: Jul. 22, 2018. [Online]. Available: https://vaxopedia.org/2017/09/20/who-is-dr-yehuda-shoenfeld/

[29] K. Kupferschmidt, "Top Israeli immunologist accused of promoting antivaccine views," Science. Accessed: Dec. 01, 2019. [Online]. Available: https://www.sciencemag.org/news/2019/11/top-israeli-immunologist-accused-promoting-antivaccine-views

[30] M. Carey, "Looking back at two decades of Geier," Left Brain Right Brain. Accessed: Jul. 22, 2018. [Online]. Available: https://leftbrainrightbrain.co.uk/2013/10/20/looking-back-at-two-decades-of-geier/

[31] Maryland State Board of Physicians, "Order for Summary Suspension of License to Practice Medicine." Accessed: Feb. 05, 2020. [Online]. Available: https://www.mbp.state.md.us/bpqapp/Orders/D2425004.271.PDF

[32] H. V. Ratajczak, "Theoretical aspects of autism: causes--a review," *J. Immunotoxicol.*, vol. 8, no. 1, pp. 68–79, Mar. 2011, doi: 10.3109/1547691X.2010.545086.

[33] M. Carey, "Sloppy science – a perfect example of how the anti-vaccine crowd will listen to anything," Left Brain Right Brain. Accessed: Mar. 24, 2019. [Online]. Available: https://leftbrainrightbrain.co.uk/2011/02/11/sloppy-science-a-perfect-example-of-how-the-anti-vaccine-crowd-will-listen-to-anything/

[34] M. Černič, *Ideološki konstrukti o cepljenju*, 1st ed. Vega, 2014.

[35] Journal of Autism and Developmental Disorders, "Retraction Note: Autism Tsunami: The Impact of Rising Prevalence on the Societal Cost of Autism in the United States," *J. Autism Dev. Disord.*, vol. 53, no. 8, p. 3315, 2023, doi: 10.1007/s10803-023-06016-4.

[36] O. Dyer, "Measles outbreak in Somali American community follows anti-vaccine talks," *BMJ*, vol. 357, p. j2378, May 2017, doi: 10.1136/bmj.j2378.

[37] Genetic Literacy Project, "Russell Blaylock: Neurosurgeon turned Newsmax conspiracy theorist and pseudoscience peddler." Accessed: Sep. 27, 2021. [Online]. Available: https://geneticliteracyproject.org/glp-facts/russell-blaylock/

[38] J. Schwarcz, "Seems neurosurgeons are not immune to neuroses," McGill University, Office for Science and Society. Accessed: Sep. 27, 2021. [Online]. Available: https://www.mcgill.ca/oss/article/controversial-science-health-news-supplements/seems-neurosurgeons-are-not-immune-neuroses

[39] S. Basser, "Anti-immunisation scare: The inconvenient facts," *The Skeptic*, vol. 17, no. 1, 1997. Accessed: Nov. 27, 2024. [Online]. Available: https://www.skeptics.com.au/wp-content/uploads/magazine/The%20Skeptic%20Volume%2017%20(1997)%20No%201.pdf

[40] Massachusetts Institute of Technology, Computer Science & Artificial Intelligence Laboratory, "Stephanie Seneff." Accessed: Nov. 27, 2024. [Online]. Available: https://www.csail.mit.edu/person/stephanie-seneff

[41] J. Barrière *et al.*, "Letter to Editor 'Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs':

Important concerns on the validity of this article," *Food Chem. Toxicol.*, vol. 178, p. 113897, Aug. 2023, doi: 10.1016/j.fct.2023.113897.

[42] F. Teoh, "Joe Rogan interview with Peter McCullough contains multiple false and unsubstantiated claims about the COVID-19 pandemic and vaccines," Health Feedback. Accessed: Nov. 27, 2024. [Online]. Available: https://healthfeedback.org/claimreview/joe-rogan-interview-with-peter-mccullough-contains-multiple-false-and-unsubstantiated-claims-about-the-covid-19-pandemic-and-vaccines/

[43] A. Grignolio, *Kdo se boji cepiv?*, 1st ed. *cf, 2018.

[44] "Avtizem povezan s pomanjkanjem koristnih bakterij v črevesju," Planet lepote. Accessed: Mar. 22, 2020. [Online]. Available: https://www.planet-lepote.com/avtizem-povezan-s-pomanjkanjem-koristnih-bakterij-v-crevesju

[45] J. Jarry, "Dr. Peter McCullough's Libertarian Medical Train Makes a Pit Stop in East Palestine," Office for Science and Society. Accessed: Nov. 27, 2024. [Online]. Available: https://www.mcgill.ca/oss/article/covid-19-medical-critical-thinking/dr-peter-mcculloughs-libertarian-medical-train-makes-pit-stop-east-palestine

[46] The Wellness Company, "Ultimate Spike Detox," The Wellness Company. Accessed: Nov. 27, 2024. [Online]. Available: https://www.twc.health/products/ultimate-spike-detox

[47] E. J. Dickson, "A Guide to 17 Anti-Vaccination Celebrities," Rolling Stone. Accessed: Jan. 31, 2020. [Online]. Available: https://www.rollingstone.com/culture/culture-features/celebrities-anti-vaxxers-jessica-biel-847779/

[48] Alenka Vindiš, "O meni." Accessed: Jan. 31, 2020. [Online]. Available: https://www.alenkavindis.si/o-meni/

[49] Ž. Porobija, "Sladoljev i Gajski: nitko i ništa osim za novinare u Hrvatskoj." Accessed: Jan. 31, 2020. [Online]. Available: https://www.autograf.hr/sladoljev-i-gajski-nitko-i-nista-osim-za-novinare-u-hrvatskoj/

[50] D. R. Grimes, "On the Viability of Conspiratorial Beliefs," *PLOS ONE*, vol. 11, no. 1, p. e0147905, Jan. 2016, doi: 10.1371/journal.pone.0147905.

[51] N. P. Taylor, "GSK dumps universal flu vaccine after interim data readout," FierceBiotech. Accessed: Jun. 09, 2019. [Online]. Available: https://www.fiercebiotech.com/biotech/gsk-dumps-universal-flu-vaccine-after-interim-data-readout


[52] R. Kwok, "Vaccines: The real issues in vaccine safety," *Nature*, vol. 473, no. 7348, pp. 436–438, May 2011, doi: 10.1038/473436a.

[53] The Nightingale Collaboration, "Results," Nightingale Collaboration. Accessed: Aug. 10, 2018. [Online]. Available: http://www.nightingale-collaboration.org/results.html

[54] J. Bellamy, "FDA blacklists cesium chloride, ineffective and dangerous naturopathic cancer treatment," Science-Based Medicine. Accessed: Aug. 10, 2018. [Online]. Available: https://sciencebasedmedicine.org/fda-blacklists-cesium-chloride-ineffective-and-dangerous-naturopathic-cancer-treatment/

[55] F. Man, "10 hypocrisies/double standards of the anti-vaccine movement," The Logic of Science. Accessed: Jun. 09, 2019. [Online]. Available: https://thelogicofscience.com/2015/07/13/10-hypocrisiesdouble-standards-of-the-anti-vaccine-movement/


[56] U. Šorn, *So cepiva prava izbira?* Grafika Gracer, 2022.



Ali držijo trditve nasprotnikov cepljenja, da so cepiva škodljiva in nepotrebna?

Besedilo, napisano na podlagi 1400 virov, na temeljit, a obenem razumljiv način odgovarja na vprašanja, kot so:

- Ali nam prikrivajo resnico o cepivih in avtizmu?
- Ali cepiva dovolj testirajo preden dobijo dovoljenje za promet?
- Kako jih izdelujejo?
- Ali so sestavine cepiv strupene in nevarne?
- Ali cepiva povzročajo številne hude neželene učinke?
- Ali je prebolevanje nalezljivih bolezni manj nevarno od cepljenja?
- Ali so sistemi poročanja o neželenih učinkih po cepljenju nezanesljivi?
- Ali je cepljenje proti HPV smiselno?
- Kako so razvijali cepiva proti covidu-19 in ali so jih dovolj testirali?
- Kako je s cepljenjem v Sloveniji?
- Ali so alternativne metode zdravljenja učinkovite in varne?



9 789619 695401

37,90 €